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Abstract 
Background: Inflammatory Bowel Disease (IBD) is a complex chronic condition affecting the 
gastrointestinal (GI) system and is sub-classified into Crohn’s Disease (CD) and Ulcerative Colitis 
(UC). Patients with IBD can present with a multitude of symptoms, making the diagnosis 
challenging and frequently resulting in delays. 
Aim & objective: The aim of this research was to better understand the extent of, and reasons for, 
diagnostic delay in IBD. The first objective was to establish the extent of which the diagnosis of IBD 
is typically delayed and any characteristics which may be related to this. The second objective was 
to explore the individual experience of delay, including possible contributing factors for delay as 
well as any impact of delay on the patient. 
Methods: Two distinct methods were used. A systematic review was conducted to identify articles 
that reported a time-period of diagnostic delay of IBD.  A narrative synthesis was then used to 
present the extent of IBD and explore consultation and healthcare factors for delay, which is 
defined below. Secondly, interviews were conducted with participants who self-reported a delay in 
IBD diagnosis, in order to explore this delay from their perspective. Participants were asked their 
opinions on factors which may have contributed to their delay and any consequences of this delay. 
Misdiagnoses they had been given before their IBD diagnosis was also discussed. Thematic analysis 
was applied to this dataset. 
Results: For the systematic review, 7570 articles were sourced from the search following de-
duplication. 5127 and 2143 articles were excluded following title and abstract review respectively. 
Of the remaining 284 articles for full-text review, 35 met the inclusion criteria. The median values 
of diagnostic delay were between 2 and 5.3 months for IBD, 2 to 26.4 months for CD and 2 to 12 
months for UC. Consultation delays, defined as the time between the onset of patient symptoms 
and them seeking medical advice, ranged from 1 to 8.6 months in CD and 0.7 to 1.9 months in UC. 
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Healthcare delays, the time between patients seeking medical advice to receiving a diagnosis, were 
0.7 to 20.8 months and 0.2 to 1.1 months for CD and UC respectively. From interviews with sixteen 
participants, irritable bowel syndrome (IBS), gastroenteritis and mental health conditions were 
commonly reported misdiagnoses. Participants cited a perceived insignificance of symptoms, fear 
and embarrassment as reasons why they delayed seeking medical advice. Patient-reported reasons 
for healthcare delays included GP reluctance to refer to secondary care and prolonged, ineffective 
management. Participants described experiencing issues with waiting lists for appointments and 
delayed diagnostic procedures. Some participants felt their delay had negatively impacted on their 
diagnosis, including a need for stronger medication or surgery. 
Discussion: The overall diagnostic delay of IBD is extensive but varies considerably. Delay seems to 
be worse in CD than UC, particularly regarding healthcare delays. This is also supported by the 
interview findings.  
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1. Introduction 
This thesis explores the extent to which the diagnosis of Inflammatory Bowel Disease (IBD), a 
chronic inflammatory condition affecting the gastrointestinal (GI) tract, can be delayed. Although 
there has been a considerable research effort into exploring the delays in diagnosis of IBD, this 
thesis aims to collate this data and build upon these findings in the form of a systematic review and 
novel qualitative research, in order to establish the extent of delay as described in the literature 
and investigate personal accounts of delay as experienced by people with IBD.  
IBD is a relapsing-remitting condition characterised by chronic inflammation of the GI tract, 
meaning that symptom severity changes over time and therefore can give rise to acute 
exacerbations of symptoms. These are known as flares (Bernstein, 2015). Although there is no cure, 
management is largely aimed at reducing inflammation. The two most prevalent forms of IBD are 
Crohn’s Disease (CD) and Ulcerative Colitis (UC). Whilst both are characterised by inflammation, 
the spectrum of symptoms, pathophysiology and distribution of disease differs considerably 
between CD and UC (Rosen, Dhawan, & Saeed, 2015). These conditions are discussed in more 
detail below and in the next chapter.  
This chapter provides an introduction to IBD as well as the rationale for conducting research into 
delays in diagnosis. The aims of this research have been described along with the specific 
objectives. 
 
1.1 An overview of inflammatory bowel disease 
The aetiology of IBD is incompletely understood, though it is thought that a combination of genetic 
and environmental factors increase the risk of developing the condition (Khor, Gardet, & Xavier, 
2011). 
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Typically, CD causes weight loss, diarrhoea, oral ulcers and perianal disease whereas patients with 
UC mostly experience rectal bleeding, abdominal pain and diarrhoea (Ghosh & Mitchell, 2007). 
There is significant overlap of clinical features between the two diseases and patients may not 
always present with clear, identifiable symptoms. Extra-intestinal manifestations (EIM) of IBD are 
symptoms that can occur before or after the diagnosis that are not limited to the GI tract. EIM 
include arthritis, dermatological conditions such as erythema nodosum, primary sclerosing 
cholangitis and uveitis (Vavricka et al., 2015). Again, these manifestations may conceal the true 
diagnosis of IBD. 
As with many chronic conditions, IBD has the potential to negatively impact on an individual’s 
quality of life (Ghosh & Mitchell, 2007). In addition, IBD is associated with higher levels of stress 
and depression (Zhang et al., 2016) 
 
1.2 Diagnostic delay in inflammatory bowel disease 
The diagnosis of IBD can be challenging, as presenting symptoms can be varied and readily 
mistaken for another condition. For example, people with IBD may experience a wide combination 
of symptoms including a change in bowel habit, abdominal pain and rectal bleeding, which could 
also be consistent with more prevalent disorders such as irritable bowel syndrome (IBS), 
gastroenteritis and haemorrhoids. EIM may also complicate an individuals’ presentation. 
Additionally, in countries with a higher incidence of tuberculosis, IBD may be mistaken for 
abdominal tuberculosis which can prolong diagnostic delays (Das et al., 2009). Diagnostic delays 
can also impede effective management. 
Diagnostic delay is defined as a delay in receiving a diagnosis of health conditions from the time 
when symptoms for that condition begin, until a final diagnosis for that condition is provided by a 
healthcare professional (D.-W. Lee et al., 2017). 
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 Rationale for this research 
IBD has largely been considered a problem in high income countries, with approximately 2.5-3 
million Europeans having the condition (Burisch, Jess, Martinato & Lakatos, 2013). However, 
research has also established an increasing incidence of IBD in areas previously considered less 
affected (Ray, 2016; Thia, Loftus, Sandborn, & Yang, 2008). As the global burden of IBD increases, it 
is important that people experiencing symptoms suggestive of IBD are investigated promptly and 
appropriately; and following diagnosis, are managed optimally. 
IBD also exerts a marked socioeconomic burden, particularly as it largely affects the working-age 
population who, with severe disease, may be unable to work or require more frequent absence 
from work (Michael et al., 2014). Additionally, the healthcare costs of IBD are significant. For 
example, in a cohort study conducted by Bassi, Dodd, Williamson and Bodger which included 479 
IBD patients at a university hospital in the Northwest of England, the total cost of care over the six 
month study period for this cohort was £757,433. Exacerbations led to a two- to three-fold 
increase in costs for outpatient care and over twenty-fold increase in hospitalised patients, 
compared to the cost of managing inactive IBD (Bassi, Dodd, Williamson, & Bodger, 2004).  
There is evidence that diagnostic delays in IBD have a negative impact on the clinical course of 
disease. For instance, a retrospective study carried out by Lee et al. found that a delayed diagnosis 
of CD and UC was associated with an increased risk of intestinal surgery due to poorly-controlled 
disease (OR= 6.81; 95% CI= 1.12-41.4) (D.-W. Lee et al., 2017). A cohort study of CD patients in 
Korea also demonstrated a link between diagnostic delay of over eighteen months and worsening 
clinical outcomes, as there was an increased risk of intestinal stenosis (HR= 1.43; 95% CI= 1.07-
1.93) internal fistulae (HR= 1.62; CI= 1.12-2.33) and perianal fistulae (HR= 1.38; 95% CI= 1.06-1.80) 
(Mo Moon C. et al., 2015). The increased need for surgery following a delayed diagnosis is likely to 
represent increased disease severity. 
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By conducting a systematic review, a benchmark value for diagnostic delay can be sought from 
existing literature, along with the identification of any important characteristics that may 
contribute to delay. This will clarify the impact of a delayed IBD diagnosis. Furthermore, specific 
individual reasons for diagnostic delay can be explored from the perspective of patients themselves 
through interviews, uncovering areas of improvement to reduce delay. 
 
 The aims of this thesis 
The aim of this thesis was to explore the extent of, and reasons for, diagnostic delay of IBD at both 
a population- and patient-level. The specific objectives were: 
1. To provide a benchmark time-period of diagnostic delay, from IBD symptom onset to IBD 
diagnosis, through the completion of a systematic review 
2. To explore possible reasons for, and consequences of, diagnostic delay from the 
perspective of individuals who have experienced a delay in IBD diagnosis, through 
participant interviews 
Combining a systematic review and qualitative study was seen to be the most effective means to 
address these research objectives. The use of two research methods to answer the research aims 
was influenced by a pragmatic methodology that has been adopted within this research. This 
pragmatic methodology is commonly used in mixed methods studies as it allows the freedom to 
choose different methods that are suited to the research objectives. Pragmatism is considered to 
be outcome orientated, meaning that methods are chosen based on whether they are most suited 
to answer the research aims (Morgan, 2007). This is in opposition to other methodologies with 
certain philosophical underpinnings where the choice of research methodology is dictated by the 
methods themselves (A. Brierley, 2017). Pragmatism was demonstrated in the decision to conduct 
a systematic review and qualitative research. The systematic review provides a comprehensive and 
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objective insight into diagnostic delay due to the structured method by which it was performed. On 
the other hand, the qualitative research in this thesis explores possible factors influencing delay 
and consequences of delay, from the perspective of individuals who have experienced this delay 
first-hand. 
This thesis comprises a convergent mixed method design, whereby the results from the systematic 
review and qualitative research are analysed individually and subsequently combined to allow 
exploration of the research aims through joint interpretation (Fetters, Curry, & Creswell, 2013; 
Creswell & Plano Clark, 2011). This mixed method approach was beneficial, as the merging of 
results from two different methods strengthened the findings for diagnostic delay whilst being 
manageable within the time constraints of the MPhil, as the systematic review and qualitative 
research were conducted in parallel. 
 
 A summary of thesis chapters 
The structure of the thesis is as follows. Chapter 2 provides a summary of IBD, including proposed 
risks, disease presentation, diagnosis and management as well as outlining delays in diagnosis. The 
methodology and results of the systematic review conducted within this thesis are self-contained 
within Chapter 3. Chapter 4 outlines the methodology of the qualitative research conducted, 
including justification of the decisions made during the research process. The results of the 
qualitative research are presented in Chapter 5. Chapter 6 provides an overall discussion of the 
findings, including their implications for clinical practice; as well as the author’s reflections from 
completing this MPhil. 
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2 Background 
Further to the information provided in the introduction, this chapter provides a more detailed 
overview of Inflammatory Bowel Disease (IBD), including the epidemiology, putative risk factors, 
diagnosis and management. An overview of some existing literature on delayed IBD diagnosis is 
also provided, though this is explored in greater detail within the systematic review in Chapter 3.  
 
 An overview of the digestive tract 
2.1.1 Anatomy of the gastrointestinal system 
The digestive system is made up of the gastrointestinal (GI) or alimentary tract along with 
accessory organs of digestion, including the salivary glands, liver and pancreas. The GI tract is 
formed by the mouth, pharynx, oesophagus, stomach, small bowel, large bowel (or colon), rectum 
and anus. Digestion, absorption and excretion are the main functions of the GI tract, along with 
playing a role in immunity (Reed & Wickham, 2009). 
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2.1.2 Function of the gastrointestinal system 
The functions of the GI tract are carried out by specific actions of each organ. For instance, both 
mechanical and chemical breakdown of food occurs throughout the GI tract, from the chewing 
food in the mouth and the release of stomach acid, for example. This acidic environment of the 
stomach stimulates protein digestion. Food is transported along the GI tract by muscles lining the 
tract from oesophagus to rectum performing co-ordinated contractions called peristalsis 
(Greenwood-Van Meerveld, Johnson, & Grundy, 2017).  
Figure 2.1.1- The organs of the gastrointestinal system, reprinted with permission from Pixabay 
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Absorption of nutrients, including amino acids and sugars, from broken-down food occurs in the 
small bowel. Key vitamins absorbed in the small bowel include folate and Vitamin B12 (Kozyraki & 
Cases, 2013). The small bowel, approximately 24 feet, consists of the duodenum, jejunum and 
ileum. The colon is subdivided into caecum, ascending colon, transverse colon, descending colon 
and rectum. The main action of the large bowel is the absorption of water as well as certain 
vitamins (Vitamin K and B1). Faeces is solid when it enters the sigmoid colon and it is then stored in 
the rectum- the last 8 inches of the large bowel, until it is excreted through the anus by voluntary 
relaxation of the anal sphincters (Reed & Wickham, 2009). 
Salivary glands aid digestion by releasing chemicals that initiate digestion of food, particularly 
starch by the amylase enzyme. The liver produces bile that is stored in the gallbladder, which aids 
the absorption of fat molecules in the small intestine. Bile is reabsorbed in the terminal ileum or 
excreted out of the body in faeces (Camilleri, 2014).  Detoxification of absorbed products of 
digestion is another important function of the liver (Reed & Wickham, 2009). The role of the 
pancreas in digestion is twofold, firstly- the release of pancreatic enzymes initiates digestion of 
food within the small bowel, and secondly the release of hormones such as insulin and glucagon 
maintain homeostasis of blood glucose (Rehfeld, Nylander, & Karnov, 2017) 
 
 Epidemiology of inflammatory bowel disease 
Geographically, the highest incidence rates of IBD arise from Northern Europe and North America. 
In 2010, total incidence rates in Western Europe were 6.3 for Crohn’s Disease (CD) and 9.8 for 
Ulcerative Colitis (UC) per 100,000 person-years. These rates were lower in Eastern Europe, 3.3 and 
4.6 per 100,000 respectively (Burisch, 2014). In Northern Europe, the United Kingdom and 
Scandinavia have the highest incidence of IBD. There are approximately 620,000 people living with 
IBD in the UK (Mikocka-Walus, Power, Rook & Robins, 2018). These regions have consistently had 
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higher rates of IBD whereas places like Latin America, Eastern Europe and Asia have been 
considered to be less affected (Burisch et al., 2013). However, there has been an increase in IBD, 
particularly UC, in these areas over recent years. Potential explanations for this include a move 
towards a more industrialised and ‘Westernised’ society in these regions, as well as improved 
identification of the disease (Loftus, 2004).  
People with IBD are mostly diagnosed between the ages of 20 to 30 years old, although both the 
paediatric and older population can be affected (Duricova et al., 2014). It is estimated that, of 
those with IBD, between 10-15% are diagnosed under 18 years of age (Heyman et al., 2005) This 
demonstrates a considerable disease burden amongst the younger population. 
 
 Crohn’s disease 
CD typically causes non-continuous areas of inflammation anywhere along the GI tract from mouth 
to anus, Figure 2.3.1(a). These discrete areas of disease are known as ‘skip lesions’, as healthy 
bowel is punctuated by sections of inflammation. CD commonly affects the union of the small and 
large bowel, called the terminal ileum and often spares the rectum. At colonoscopy, typical 
appearances include ‘cobblestoning’ appearance may be identified, Figure 2.3.1(b). When 
microscopically examining biopsies, inflammation affects all layers of the bowel wall and discrete 
granulomas may be seen (Mas-Moya & Singhi, 2015). Granulomas form when various immune cells 
cluster together and may be present in other infective or inflammatory conditions. However, when 
present in the biopsy of individuals experiencing IBD-like symptoms, they confirm the diagnosis of 
CD (Molnár, Tiszlavicz, Gyulai, Nagy, & Lonovics, 2005). These colonoscopic and histologic features 
help to differentiate between CD and UC. 
The prototypical symptoms and signs of CD include weight loss, diarrhoea and abdominal pain 
alongside fever, fatigue and poor appetite (Ghosh & Mitchell, 2007; Mowat et al., 2011). Certain 
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complications may occur with CD, either before or after diagnosis. Perianal fistulae are abnormal 
connections between two organs that are usually separate and are commonly associated with CD 
(Kotze et al., 2018). For 10% of people, perianal fistula is the first manifestation. Perianal fistulae 
typically occur from the rectum or anus to the perianal skin, from rectum to vagina called a 
rectovaginal fistula or from the rectum to the bladder, a colovesical fistula. Symptoms may include 
pain, discharge, impaired sexual function, gas in the urine stream or passing gas per vagina, 
depending on the type of fistula (Kotze et al., 2018). 
Strictures may occur in the GI tract which result from ongoing inflammation leading to fibrosis. This 
inflammation and fibrosis disrupts the normal anatomy of the bowel wall and leads to destruction 
of the muscular layers (Chang et al., 2015). Intestinal adhesions are another complication and arise 
when fibrosis connects intra-abdominal organs to each other or to the intra-abdominal wall. 
General symptoms include bloating, abdominal pain and nausea (Tabibian, Swehli, Boyd, Umbreen, 
& Tabibian, 2017). Both strictures and adhesions may lead to bowel obstruction or perforation. In 
this context, patients may present acutely with signs and symptoms consistent with intestinal 
obstruction or bowel perforation and may require urgent surgery. Such symptoms include severe 
abdominal pain, constipation and vomiting, which may contain faecal matter (Hwang & Varma, 
2008; Mas-Moya & Singhi, 2015). As described in section 2.1.2, a number of vitamins are absorbed 
in the terminal ileum, therefore inflammation due to CD in this area can result in vitamin 
deficiencies. Similarly, reduced reabsorption of bile acids by the small bowel, referred to as bile 
acid malabsorption, can lead to a plethora of issues including steatorrhoea (diarrhoea caused by 
increased concentrations of fat within stool), pigment gallstones and kidney stones, Table 2.4.1 
(Lenicek et al., 2011; Vítek, 2014). Regarding Extra-intestinal manifestations (EIM), arthritis, 
erythema nodosum and ankylosing spondyloarthritis are largely associated with CD (Vavricka et al., 
2015; Yi et al., 2012) . Further information on EIM can be found in section 2.6. 
 
 12 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.1- The disease distribution of CD within the GI tract, highlighted in red (a), endoscopic 
features of CD (b) reprinted with permission from Wikimedia Commons 
(https://commons.wikimedia.org/wiki/File:Crohn%27s_Disease_vs._Ulcerative_Colitis.jpg ) and the 
European Crohn’s and Colitis Organisation 
 
 
  Ulcerative colitis 
UC affects the large bowel, causing continuous and uniform inflammation that originates in the 
rectum and progresses through the large bowel, see Figure 2.4.1(a). Although UC is a disease 
confined to the large bowel, ‘backwash ileitis’ can occur from profound inflammation that extends 
into the small bowel. Circumferential and superficial ulceration with friable blood vessels are 
typical findings of UC during colonoscopy, as seen in Figure 2.4.1(b). Histologically, UC causes 
ulcerative inflammation that does not affect all layers of the bowel wall (Mowat et al., 2011). 
Rectal bleeding and diarrhoea are the key symptoms of UC (Ghosh & Mitchell, 2007). Patients may 
also describe urgency and a feeling of incomplete evacuation of stool, known as tenesmus (Mowat 
et al., 2011). The EIM associated with UC are pyoderma gangrenosum and primary sclerosing 
cholangitis (Vavricka et al., 2015). Complications include acute-severe, or fulminant, UC which is 
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characterised by worsening rectal bleeding, diarrhoea, fever and abnormal blood results, such as 
elevated CRP and ESR. The Truelove-Witts criteria is used to identify these acute episodes and 
treatment initially involves intravenous rehydration and corticosteroids, although proctocolectomy 
may be indicated in severe colitis which is unresponsive to medical management (Lasch et al., 
2016). Diagnosis and management of acute-severe UC are discussed in sections 2.8.5 and 2.10.2 
respectively. Toxic megacolon is a rare but potentially life-threatening complication. It can be 
caused by pseudomembranous colitis (infectious colitis caused by Clostridium difficile infection), 
ischaemia and UC, although CD patients with ileocolic disease may be at increased risk. It is 
characterised by dilation of the large bowel due to deep inflammation which weakens the 
contractility of the muscles in the bowel wall (Table 2.4.1) (Autenrieth & Baumgart, 2012). The 
management of toxic megacolon is discussed under surgical management of IBD in Section 2.11.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.1- disease distribution of UC, highlighted in red (a), endoscopic features of UC 
(b), reprinted from Gastroenterology Consultants of Augusta and ‘Endoscopic approach in 
ulcerative colitis’, reprinted with permission from Wikimedia Commons 
(https://commons.wikimedia.org/wiki/File:Crohn%27s_Disease_vs._Ulcerative_Colitis.jpg) 
and Yamada et al., 2018; BMC Gastroenterology 
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Table 2.4.1- The key differences between Crohn’s Disease and Ulcerative Colitis 
 
 
 
 Indeterminate colitis 
In approximately 10% of patients in whom a diagnosis of IBD has been confirmed, a diagnosis of CD 
or UC cannot be made based on standard investigations like endoscopy or histology. Such people 
are diagnosed with Indeterminate Colitis (IC) or IBD-unclassified. This group of individuals is poorly-
defined, as a certain proportion are later diagnosed with either UC or CD though many will remain 
IC. There is currently no diagnostic test that will confirm a diagnosis of IC and it is considered a 
diagnosis of exclusion, as a diagnosing IC is based upon ruling out other conditions like CD or UC. IC 
patients tend to be managed similarly to UC patients; however for those who undergo a colectomy, 
they have an increased risk of complications than UC patients, but less than CD patients (Tremaine, 
2011). 
 
 Extra-intestinal manifestations 
EIM are signs and symptoms of IBD that are external to the GI tract. Approximately 25-40% of 
patients display EIM as part of their CD or UC (Levine & Burakoff, 2011). The most common system 
 CD UC 
Key symptoms Diarrhoea, abdominal pain, 
perianal disease, weight loss 
Rectal bleeding, tenesmus, 
abdominal pain, bloating 
Location of disease Mouth to anus, discontinuous 
areas of inflammation 
Large bowel only, with potential 
for ‘backwash ileitis’ 
Diagnostic findings Macroscopic- cobblestone 
Microscopic- granulomas 
Macroscopic- continuous 
ulceration 
Microscopic- ulceration, friable 
vessels 
Complications Bowel stenosis, adhesions  
obstruction 
Abscess, perianal disease, bile 
acid malabsorption 
Dilation of large bowel  toxic 
megacolon 
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affected by EIM is the musculoskeletal system, where arthritis can occur in the sacroiliac joints, 
spine and peripheral joints, frequently referred to as IBD related arthropathy. Osteoporosis can 
also arise due to steroid use, intestinal malabsorption and inflammatory-mediated bony 
destruction and can increase the risk of fracture (Targownik, Bernstein, & Leslie, 2013). A variety of 
skin manifestations are also associated with IBD, of which erythema nodosum and pyoderma 
gangrenosum are key examples. Erythema nodosum is the most common, presenting as deep, 
tender lesions often overlying the shins due to inflammation in subcutaneous fat. Pyoderma 
gangrenosum begins as a pustule or papule which breaks down into an ulcer, often coated with pus 
or necrotic debris (Levine & Burakoff, 2011). 
The hepatobillary system can also be affected in IBD. For example, primary sclerosing cholangitis is 
particularly associated with UC and causes stricturing of the bile ducts, which transport bile from 
the liver into the gallbladder for storage or into the small intestine via the pancreas. It may be 
asymptomatic, identified only through abnormal liver function blood tests, though patients may 
present with jaundice. Primary sclerosing cholangitis is an independent risk factor for 
cholangiocarcinoma, which is cancer of the biliary system, or colorectal cancer (Karlsen, Folseraas, 
Thorburn, & Vesterhus, 2017; Levine & Burakoff, 2011). Ocular symptoms occur in 0.3 to 5% of all 
IBD patients, often in association with peripheral arthritis and erythema nodosum. Conditions 
include episcleritis, causing redness, irritation and burning and scleritis, which can impair vision as 
well as causing redness and pain. Often, the severity of EIMs mirrors the severity of the IBD and the 
mainstay of most treatment is to reduce IBD disease activity (Levine & Burakoff, 2011). Table 2.6.1 
provides an overview of the EIMs of IBD. 
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Table 2.6.1- The extra-intestinal manifestations of inflammatory bowel disease 
 
 
 Aetiology of inflammatory bowel disease 
Many risk factors have been linked to IBD, though the causes are incompletely understood.  The 
general consensus is that genetically susceptible individuals are affected by as-yet unconfirmed 
environmental exposures. This section discusses the proposed explanations behind IBD. 
 
 Genetic risk 
A link between genetics and IBD has been demonstrated.  For instance, monozygotic twin studies 
have demonstrated concordance rates of 10-15% in UC and 30-35% in CD (Khor et al., 2011). 
However, genetics have also been implicated in UC through a systematic review carried out by 
Childers et al. (2014). They found that UC patients diagnosed before the age of eighteen had a 
stronger family history of IBD than those diagnosed after eighteen and they were likely to be 
Body system Extra-Intestinal Manifestation 
Musculoskeletal Arthritis (spine, sacroiliac joints, peripheral joints), ankylosing 
spondylitis, tendonitis, clubbing, osteoporosis, fracture 
Skin Erythema nodosum, pyoderma gangrenosum, psoriasis, aphthous 
stomatitis, Sweet syndrome, metastatic CD 
Hepatopancreatobiliary Primary sclerosing cholangitis, pigment gallstones  
Eye Episcleritis, scleritis, uveitis 
Renal Renal stones, obstructive uropathy, urinary fistulae 
 17 
 
diagnosed at a younger age than their affected family members were when they were diagnosed 
(Childers et al., 2014). 
The CARD 15 gene, which codes for the NOD2 immune receptor, was the first gene identified in the 
development of CD in the white population. NOD2 receptors are found within cells and their 
function is to maintain homeostasis between intestinal bacteria and the intestinal wall by 
stimulating Paneth cells, a type of immune cell, to release proteins, called alpha-defensins, as an 
innate immune response (Baumgart & Carding, 2007). Mutations in the CARD15 gene causes a 
reduction in NOD2 receptors which leads to the release of pro-inflammatory cytokines which are 
chemicals that generate an immune response which damages the intestinal lining (Yamamoto-
Furusho et al., 2018). 
The Genome-Wide Association Studies (GWAS) have identified 99 genetic risk loci for IBD, including 
28 genes associated with both CD and UC. GWAS has identified genetic variations which alter 
certain immune signalling chemicals and pathways that lead to the inflammation of IBD, including 
JAK2 and IL-10 (Khor et al., 2011; Verstockt, Smith, & Lee, 2018). 
 
 Tobacco smoking 
Cigarette smoking is a known risk factor for CD, with ex-smokers also at increased risk (Lunney et 
al., 2012). Surprisingly, smoking has been shown to be protective for the development of UC, with 
people developing UC typically being non- or ex- smokers. Additionally, smokers who do develop 
UC are more likely to display milder disease than their non-smoking counterparts (Lunney et al., 
2012). The mechanism by which smoking or nicotine confers protection in UC is unknown, but has 
been linked to changes in inflammatory and immune signalling, permeability of the GI tract and 
blood vessels. In light of the apparent differences smoking has on UC and CD, it is unlikely to be 
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caused by immune changes alone as if this were the case, both CD and UC should improve 
following smoking (Thomas, Rhodes, Green, & Richardson, 2000). 
 
 Diet and lifestyle 
As IBD has consistently affected Western countries, a link between the Western diet and IBD has 
been proposed. Evidence supporting this includes a systematic review undertaken by Forbes et al., 
which identified literature citing a connection between diet and IBD. For instance, there appears to 
be an increased risk of developing CD with increased consumption of saturated fats and meat. UC 
has been linked to poly-unsaturated fatty acids, omega-6 fatty acids and meat. A diet high in fibre 
and fruit appears to decrease the risk of CD, but not UC (Forbes et al., 2017). Khalili et al. propose 
that a diet high in sugar and unsaturated fats may cause abnormalities in the microbes of the GI 
tract and alter the barrier function which could contribute to IBD (Khalili et al., 2018).   
An association between improved hygiene standards since 1980 and CD has been postulated, for 
example access to clean water and smaller family sizes causing a reduction in overcrowding. This 
decreased exposure to microbes, like bacteria, during childhood may impede the development of 
the immune system, causing an excessive immune response at times of microbe exposure. This is 
known as the ‘hygiene hypothesis’ and has been linked to many autoimmune and allergic diseases 
such as IBD and asthma (Castiglione et al., 2012; Stiemsma et al., 2015). 
 
 Additional risk and protective factors 
Other proposed risk factors for IBD include GI infections, not being breastfeed, oral contraceptive 
pill and antibiotic use, but evidence around these factors remains limited (Loftus, 2004; Ponder & 
Long, 2013).  
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Undergoing an appendectomy has been found to confer some protection against the development 
of UC (Loftus, 2004). 
 
 Diagnosis of inflammatory bowel disease 
 History 
In patients presenting with certain GI symptoms, such as diarrhoea, tenesmus, weight loss, rectal 
bleeding and nocturnal defaecation, IBD is an important differential diagnosis. Assessing the cause 
of any symptoms involves taking a comprehensive history from the patient, performing an 
appropriate examination and arranging appropriate investigations. The patient history should 
explore symptoms, family history, recent travel history and affected contacts to predict an 
infective, endocrine or autoimmune origin to symptoms. A typical history of possible IBD may 
involve symptoms of diarrhoea, rectal bleeding and weight loss for many weeks (Abreu & Harpaz, 
2007). 
 
 Clinical examination 
A thorough examination should be performed, including a general assessment of health to identify 
possibly signs of anaemia or the EIM of IBD. Examining the oral cavity, abdomen and perineum 
should be done as part of the examination of the GI system (Abreu & Harpaz, 2007). Angular 
stomatitis (erythema and maceration of the skin adjacent to the angle of the mouth), perianal 
disease and any abdominal pain or mass may indicate IBD. Perianal complications are present in 
over 50% of Crohn’s disease patients, therefore the perineum should be inspected and a digital 
rectal examination should be performed to identify pain and blood or pus on the glove. As 40% of 
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IBD patients have EIMs including uveitis and erythema nodosum, examination of eyes, skin and 
musculoskeletal system should be performed (Huang, Chandra, & Shih, 2012; Harper et al., 1987). 
  
 Initial investigations 
Many investigations are used in combination to diagnose IBD. Though colonoscopy and biopsy are 
used to confirm the diagnosis of IBD, other investigations should be performed to identify patients 
with features suggestive of IBD before they undergo this invasive test. Routine blood tests should 
be performed in primary care, including a Full Blood Count to identify anaemia and elevated white 
blood cells, which suggests infection or inflammation (Bochner, 2000). Markers of inflammation 
like C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and ferritin should be tested 
for. In addition to being an acute phase protein indicative of inflammation, ferritin levels also 
identify anaemia, which is common in IBD due to reduced uptake of iron within the duodenum and 
jejunum and GI bleeding (Schmidt et al., 2016). A screening test to exclude Coeliac disease should 
also be performed. Stool culture and microscopy with Clostridium difficile toxin assay can identify 
an infective cause of symptoms (Abreu & Harpaz, 2007).  
Although CRP and ESR are important tests to identify inflammation, the faecal calprotectin level 
identifies  inflammation specifically within the GI tract. Calprotectin is a protein found within white 
bloods cells called neutrophils, which infiltrate the gastrointestinal tract during inflammatory 
conditions like IBD and are passed in faeces where concentrations can be measured (Banerjee et 
al., 2015). Therefore, a normal faecal calprotectin level excludes IBD as GI inflammation is absent 
(Carter, Lobo, & Travis, 2004). Consequently, the National Institute of Health and Care Excellence 
(NICE) recommends the use for faecal calprotectin in patients to differentiate between 
inflammatory and non-inflammatory causes of symptoms, in both a primary and secondary care 
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setting (NICE, 2013). This test was first introduced for use by UK gastroenterologists in 2013 and 
has since been available in primary care. 
 
 Secondary care referral 
A suspected diagnosis of IBD should result in a referral to appropriate secondary care services, 
either an adult or paediatric consultant gastroenterologists where a macroscopic and histological 
diagnosis can be made through sigmoidoscopy or colonoscopy and biopsy (NICE 2015). Specialists 
may perform or repeat investigations done in primary care. Patients under NHS healthcare may be 
referred to secondary care under different pathways. For instance, in suspected IBD patients 
should have a specialist appointment within four weeks. Alternatively, patients may fulfil the 
criteria for the two-week wait referral (NICE, 2015). This referral system was first introduced in 
2000 and guides primary care to urgently refer patients displaying certain criteria, like being 40 
years and over with abdominal pain and weight-loss or 60 years and above with iron deficiency 
anaemia, as colorectal cancer must be ruled out (NICE 2015). As there is overlap with the 
symptoms of IBD and those of cancer, it is possible that some individuals are diagnosed via this 
referral pathway.  
In order to assess the extent of disease in IBD, the boundaries of inflammation should be identified 
by an endoscopic procedure like oesophagogastroscopy, sigmoidoscopy or colonoscopy. Endoscopy 
involves the introduction of a thin tube into the GI tract, either via the mouth or anus, which has a 
camera on the end to allow the operator to observe the inner layer of the GI tract. Biopsies can be 
taken by inserting biopsy forceps through the endoscope to sample the tissue. Sigmoidoscopy is a 
useful investigative procedure for UC; however there is a risk of missing a diagnosis of CD as there 
may be further inflammation beyond the limit of the sigmoidoscope (Langan, Gotsch, Krafczyk, & 
Skillinge, 2007). As such, a colonoscopy may be performed which can diagnose both UC and CD. 
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Proctoscopy is a procedure which can be performed in an outpatient appointment, though it only 
offers a limited view of the anus and rectum. CD affecting the upper GI tract can be seen on 
oesophagogastroscopy. Figure 2.7 outlines the sections of bowel that can be observed using 
different endoscopic techniques. 
Additional imaging may be required to identify small bowel or ileocolonic CD, such as an MRI scan 
of the abdomen or wireless capsule endoscopy (a swallowed video capsule). Perianal disease can 
be assessed by MRI scan. A laparoscopic approach to diagnosis may be required, albeit it very 
rarely, especially when there is a possibility of intestinal tuberculosis, which as previously discussed 
is particularly relevant in areas of the world where tuberculosis is endemic (Mowat et al., 2011). 
 
Figure 2.8.1- The endoscopic procedures used to diagnose IBD: oesophagogastroscopy (red), 
colonoscopy (orange), sigmoidoscopy (green) and proctoscopy (purple), reprinted with permission 
from National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health 
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 Diagnostic criteria for inflammatory bowel disease 
As outlined in Section 2.8.3, there are a wide range of investigations that can be carried out to 
determine the presence of IBD but there is no gold-standard test. Consequently, clinicians use 
clinical presentation, endoscopic and histological findings to diagnose IBD, which have been 
collated within criteria that can be used to aid the diagnosis of IBD.  
The Lennard-Jones criteria is the most well-known criteria used to diagnose CD. It focuses on the 
histological appearance of colonic biopsies, splitting the characteristics of CD into ‘major’ 
(granuloma) and ‘minor’ (fibrosis, macroscopic discontinuation of disease, transmural 
inflammation) items. A confirmed or probable diagnosis of CD is made by the presence or absence 
of these items, seen in Table 2.9.1 (Reinisch et al., 2016). 
Table 2.9.1- The Lennard-Jones criteria, adapted from Reinisch (2016) 
 
The European Crohn’s and Colitis Organisation (ECCO) have generated some guidelines for 
diagnosing IBD. These guidelines acknowledge that a single reference standard does not exist for 
CD or UC and recommends factors that clinicians should consider when diagnosing individuals with 
IBD, including the patient’s presenting symptoms as well as the results of any investigations. The 
criteria for diagnosis is based on clinical presentation, endoscopic, cross-sectional imaging, 
 Lennard-Jones Criteria 
Major Item Granuloma (aggregation of immune cells) 
Minor Item Transmural inflammation (inflammation spanning all layers of 
the bowel wall) 
Macroscopic discontinuity of disease (‘skip lesions’) 
Fibrosis (damaged bowel wall from chronic inflammation) 
Lymphoid aggregates (collection of white blood cells) 
Discontinuous inflammation on histology 
‘Established CD’ 
‘Probable CD’ 
‘Non-CD’ 
1 major + 1 minor/ 3 minor 
2 minor 
1 major/ 1 minor / none 
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histological and biochemical investigations, which is also reflected within current NICE guidelines 
(Maaser et al., 2018; NICE 2015). Examples of the guidance included aid the clinician to consider 
other diagnoses and select the most appropriate investigations to confirm or refute IBD. For 
example, in order to exclude GI infections, symptoms should be present for over six weeks and 
stool specimens should be obtained. Regarding colonoscopic diagnosis, ileocolonoscopies with 
biopsies of inflamed tissue from at least two locations in the colon should be completed; 
continuous inflammation with rectal involvement may indicate UC whereas CD should be 
suspected when discontinuous lesions, strictures and fistulae are present. The endoscopic and 
histologic differences between CD and UC can be found in Table 2.4.1. 
Research has been carried out that compares the clinical efficacy of the Lennard-Jones and ECCO 
criteria. This study, conducted by Reinisch et al. found that there are limitations with the Lennard-
Jones criteria, as when it was applied to 328 patients with long-standing, confirmed CD who had 
been diagnosed with the ECCO criteria, 49% (n= 162) would not have been identified as having CD 
at the time of their diagnosis, demonstrating some weaknesses in this diagnostic criteria (Reinisch 
et al., 2016). 
There are also criteria that can assess the severity of IBD once diagnosed. For example, the 
Truelove and Witts Severity Index for UC uses characteristics like stool frequency per day and blood 
in stool alongside the presence of fever, anaemia and raised ESR to determine disease severity 
(Table 2.9.2) (Sehgal & Koltun, 2010). Similarly, the Montreal classification measures the behaviour 
of the disease, for example, stricturing disease, which is the narrowing or stenosis of the bowel; or 
penetrating disease, where perforations have occurred; and location along the GI tract (Table 
2.9.3) (Sehgal & Koltun, 2010). The Mayo score is another means of assessing the severity of UC, 
combining disease severity with endoscopic findings and the physician’s global assessment (Table 
2.9.4). Disease severity is established by stool frequency and the presence or absence of rectal 
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bleeding. Within each category, a maximum of three points can be scored. A higher score indicates 
increased severity (Paine, 2014; Schroeder, Tremaine, & Ilstrup, 1987). 
Table 2.9.2- The Truelove Witts criteria, used to assess disease severity of UC, adapted from Kedia, 
Ahuja and Tandon (2014) 
Key: ESR; Erythrocyte Sedimentation Rate, CRP; C-Reactive Protein, bpm; beats per minute, g; gram, dL; 
decilitre, mm; millimetre, h; hour. 
Table 2.9.3- The Montreal Classification, used to assess the severity of both CD and UC, adapted 
from Satsangi, Silverberg, Vermeire and Colombel (2006) 
 
 Mild Moderate Severe 
    
Number of bloody stools per day <4 4 - 6 >6 
Pulse <90 bpm ≤90 bpm >90 bpm 
Temperature <37.5°C ≤37.8°C >37.8°C 
Haemaglobin >11.5g/dL ≥10.5g/dL <10.5g/dL 
ESR <20mm/h ≤30mm/h >30mm/h 
CRP Normal ≤30mg/dL >30mg/dL 
 Montreal Classification 
Crohn’s Disease 
Age of diagnosis A1- <16 yrs 
A2- 17 – 40 yrs 
A3- >40 yrs 
Location L1- ileal 
L2- colonic 
L3- ileocolonic 
L4- isolated upper disease 
Behaviour B1- non-stricturing/non-penetrating 
B2- stricturing 
B3- penetrating 
P- perianal disease 
Ulcerative Colitis 
Extent E1- ulcerative proctitis (distal to rectosigmoid junction) 
E2- left-sided UC (distal to splenic flexure) 
E3- extensive UC (proximal to splenic flexure) 
Severity S0- clinical remission/asymptomatic 
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Table 2.9.4- The Mayo Score, used to assess disease severity of UC, adapted from Tremaine and 
Ilstrup (1987) 
 
 
 Differential diagnoses of inflammatory bowel disease 
There are certain conditions that must be considered by the clinician when faced with a patient 
describing similar GI symptoms to those discussed previously. Through examination and careful 
selection of investigative tests, the correct diagnosis may be established. The following conditions 
are some of the differential diagnoses of IBD. 
Irritable bowel syndrome (IBS) is a common functional condition affecting the GI tract. It is 
characterised by abdominal pain and bloating, alongside a change in frequency and form of bowel 
habit. Whilst not fully established, IBS has been linked to a disorder of the brain-gut 
communication between the central nervous system and nervous system of the GI tract, called the 
enteric nervous system. The diagnosis is largely symptom-focussed. Management involves 
 
 
Stool frequency  0- Normal number for this patient 
1- 1 to 2 more than normal 
2- 3 to 4 more stools than normal 
3- 5 more stools than normal 
 
Rectal bleeding 0- No blood seen 
1- Streaks of blood with stool less than half 
the time 
2- Obvious blood with stool most of the time 
3- Blood alone passes 
Findings on endoscopy 0- Normal/inactive disease 
1- Mild disease (erythema, decreased 
vascular pattern, mild friability) 
2- Moderate disease (marked erythema, lack 
of vascular pattern, friability, erosion) 
3- Severe (spontaneous bleeding, ulcerations) 
Physician’s global assessment 0- Normal 
1- Mild disease 
2- Moderate disease 
3- Severe disease 
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alleviating symptoms through dietary modification, antispasmodics and other pharmacological 
management for diarrhoea or constipation. IBS differs from IBD in that patients frequently 
experience relief in their symptoms after defaecation and they would have normal colonoscopic 
findings and faecal calprotectin levels (Weaver et al., 2017). 
The symptoms and signs of IBD also overlap with colorectal cancer, including rectal bleeding, 
weight loss, abdominal mass and anaemia. Patients with CD or colorectal cancer can develop 
strictures. As clinical presentation is similar, differentiating IBD from colorectal cancer involves 
endoscopic and histological assessment of the bowel, as anaemia and elevated CRP may be present 
in cancer and IBD (Holm et al., 2018). A tumour may be visible by endoscopy and a biopsy would 
reveal cancerous cells (Hamilton, Round, Sharp, & Peters, 2005). Colorectal cancer is more 
prevalent in the older population, meaning increased vigilance is needed in older people presenting 
with these symptoms to identify the cause (Ahnen et al., 2014).  
As the GI tract is in contact with the external environment, there is potential for infection. In the 
developed world, viruses are mostly responsible for gastroenteritis, with bacteria contributing to a 
small proportion of gastroenteritis (Oude Munnink & van der Hoek, 2016). Common viral causes of 
gastroenteritis include norovirus and rotavirus, whilst Salmonella, Campylobacter and Shigella are 
bacterial causes (Oude Munnink & van der Hoek, 2016; Singh et al., 2015). Gastroenteritis leads to 
diarrhoea, vomiting, fever and abdominal pain. Generally, these symptoms are acute-onset and 
resolve over a few days; however, microbes such as Giardia lamblia can cause protracted 
symptoms. Diagnosis is achieved by conducting a food and travel history and arranging blood tests 
and stool culture if symptoms persist. Management involves rehydration and, rarely, antibiotics (Al 
Jassas et al., 2018). Gastroenteritis differs from IBD in the length of symptoms, as it is an acute 
condition that tends to resolve quickly and with no further complication. On the other hand, 
symptoms of IBD are more chronic with episodes of worsening of symptoms, or ‘flares’. 
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Nevertheless, following an episode of gastroenteritis, symptoms can outlast the initial infectious 
insult resulting in post-infectious irritable bowel syndrome (Gwee, 2010). 
Diverticular disease is another differential diagnosis and is more common in the older population. 
It is thought that up to 50% of individuals have colonic diverticula, which are small outpouchings of 
the colon. It is thought to arise from high pressures within the bowel from constipation and small 
stool volumes. Diverticular disease can be asymptomatic, though rectal bleeding, abdominal pain 
and fever may occur due to diverticulitis (Weizman & Nguyen, 2011). Complications include rectal 
haemorrhage, abscess formation or the development of fistulae which is similar to complications of 
IBD. Increasing dietary fibre is the mainstay of treatment, alongside oral antibiotics or intravenous 
treatment in uncomplicated or complicated diverticulitis (Weizman & Nguyen, 2011) In older 
people with this clinical presentation, diverticular disease would be most common, although IBD is 
an important differential to exclude. 
Haemorrhoids are a common condition affecting the anorectal region of the GI tract. They arise 
from venous dilation following deterioration of the supportive network in anal cushions, which has 
been linked to constipation, straining and pregnancy. Painless rectal bleeding is the most common 
manifestation, with perianal itching occurring due to prolapsed haemorrhoids. Diagnosis is clinical 
and management consists of dietary changes or surgical intervention (Lohsiriwat, 2012). IBD may 
be misdiagnosed as haemorrhoids due to rectal bleeding. However, if a patient presents with 
multiple GI symptoms, an alternative diagnosis should be considered. 
 
 Management of inflammatory bowel disease 
Managing IBD requires expert multidisciplinary team involvement to educate and support patients. 
Depending on the clinical need of the patient, gastroenterologists, colorectal surgeons, 
hepatologists, dieticians and physiotherapists may be involved in their care (Ricci, Lanzarotto, & 
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Lanzini, 2008). The IBD patient must be considered holistically, including the impact of the 
condition on nutrition, growth and mental wellbeing. Treatment options differ depending on the 
extent of disease and whether the patient is in remission or has active inflammation (Bernstein, 
2015). 
All patients diagnosed with IBD in the UK should be cared for by a specialist IBD team (Lee & 
Melmed, 2017). This should comprise of a named gastroenterologist, IBD nurse specialists, 
colorectal surgeons, pathologist and dietician. Patients are able to contact their team with any 
issues, for example relapsing symptoms and hospital admissions. This ensures continuity of care 
and allows prompt management of flares. As previously described in section 2.3, IBD can cause 
weight loss and CD in particularly is associated with nutrient deficiency, so dietetic care is 
important. As part of their treatment, patients with IBD are able to access a range of specialist 
services, including rheumatology, dermatology, ophthalmology and psychology (Mowat et al., 
2011). 
 
 Medical management 
The aim of medical management of IBD is to weaken the aberrant immune and inflammatory 
responses occurring in the GI tract. There are different management options for active disease, 
commonly known as a ‘flare’, or to maintain remission (Bernstein, 2015). If the patient is 
experiencing a flare, corticosteroids and thiopurines may be used to induce remission. Steroids are 
not used to maintain remission due to the wealth of adverse effects they may cause, including 
weight gain, diabetes, hypertension and osteoporosis (Waljee et al., 2017). Instead, 
aminosalicylates, thiopurines and anti-Tumour Necrosis Factor Alpha (TNFα) therapy can be used. 
Anti-TNFα therapy, also known as ‘biological therapy’, has been shown to reduce inflammation and 
promote healing of damaged bowel. Side effects of the immunosuppressive agents to treat IBD 
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include fever and an increased risk of infections, including TB (Mowat et al., 2011). Medical 
treatment of perianal disease involves the use of thiopurines, biological therapy and antibiotics, 
commonly metronidazole and ciprofloxacin (Klag, Goetz, Stange, & Wehkamp, 2015). There is a 
role for antibiotics in the management of IBD. The use of probiotic therapy is also being explored, 
though evidence of any clinical effectiveness is largely inconclusive (Guandalini & Sansotta, 2019). 
A further novel procedure in the management of IBD is faecal microbiota transplantation. 
However, a systematic review conducted by Colman and Rubin containing eighteen included 
papers found variable results and more research is needed in this field (Colman & Rubin, 2014). 
Complications of IBD may also require management, including iron replacement therapy by using 
oral ferrous sulphate, ferrous fumarate or intravenous iron, although side effects may include GI 
intolerance with oral tablets and intravenous treatment can be costly and inconvenient for 
patients. Oral ferric maltol may be a useful alternative, as a placebo-controlled trial demonstrated 
improvements in haemoglobin as well as being well-tolerated by participants (Schmidt et al., 2016). 
Additional complications of IBD which may require treatment include vitamin deficiencies which 
may require intramuscular injections and bile salt malabsorption, which can be managed using 
colesevelam hydrochloride (NICE, 2013). 
 
 Surgical management 
A significant role for the surgical management of IBD exists, both in elective and urgent scenarios. 
For CD, surgical intervention involves resecting diseased bowel and is reserved for failed medical 
management, stricturing or fistulating disease and perforation. The same patient may require 
multiple resections due to recurrence of the disease in another area of bowel and it is difficult to 
predict individuals at increased risk of this (Hwang & Varma, 2008). For instance, in a population-
based retrospective cohort study of 1936 patients with CD, the cumulative rate of intestinal re-
resection was 33% at 5 years and 44% at 10 years after the initial resection (Bernell, Lapidus, & 
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Hellers, 2000). Furthermore, factors could increase the likelihood of post-operative recurrence of 
CD include patient smoking, location and behaviour of disease, disease duration before first 
surgery and prior resections (Gklavas, Dellaportas, & Papaconstantinou, 2017). 
Surgical management of perianal disease in CD is frequently needed, in particular anal fissures and 
fistula-in-ano. Surgical management of anal fissures can be effective, though the potential effect on 
bowel continence means surgery should be a last resort. Deciding a surgical management plan for 
anal fistulae can be complex due to the importance of preserving continence and whether or not to 
divert faeces from the affected area through a temporary ostomy to aid the resolution of perianal 
disease (Hwang & Varma, 2008). Initial management may involve the use of seton thread, which is 
passed into the fistula tract to maintain patency and allow drainage which reduces inflammation 
(Adegbola et al., 2018). Further surgical management depends on whether the fistula infiltrates the 
anal sphincter, as there is a risk of causing faecal incontinence. Surgical management of ‘low’ 
fistulae, which are fistulae that do not affect the anal sphincters, involves fistulotomy. The fistula is 
divided and opened to allow healing. For ‘high’ fistulae that do affect the anal sphincters, 
sphincter-saving treatment includes the use of fibrin glue to induce blood clot formation in the 
fistula track or inserting a fistula plug made of porcine small intestinal mucosa to encourage cell 
growth within the fistula (Adegbola et al., 2018). 
Urgent surgical management of UC is largely indicated for severe, intractable colitis which can be 
identified using the Truelove-Witts criteria as described in section 2.9. Features include fever, 
numerous bloody stools and signs of haemodynamic instability or the presence of toxic megacolon. 
Toxic megacolon was discussed in section 2.4. In refractory colitis, a total proctocolectomy with 
end ileostomy is a common procedure as the diseased bowel is removed and the complications of 
anastomoses and pelvic dissection are avoided (Hwang & Varma, 2008).  
With regards to elective surgery, the risk of malignancy is the most common indication, a 
cumulative risk which according to a 2001 meta-analysis increases from 2% at 10 years to 18% at 
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30 years following UC diagnosis (Eaden, Abrams, & Mayberry, 2001). A restorative proctocolectomy 
with ileal pouch-anal anastomosis is the procedure of choice, as it removes the diseased bowel 
whilst maintaining a normal defecation pathway, though sometimes a second operation to close 
the diverting loop ileostomy is needed in the future. Pouchitis is a long-term complication of the 
ileal-pouch anastomosis and can cause perineal pain and cramping. This can be managed with 
antibiotics like metronidazole and ciprofloxacin, though a small number of people may need pouch 
excision. Anti-diarrhoeal medications may be indicated in people with altered bowel function, 
including increased frequency of defecation and episodes of incontinence (Hwang & Varma, 2008). 
 
 Impact of inflammatory bowel disease  
The impact of IBD on an individual’s life can be profound. A review of twenty-three studies 
focussing on living with IBD identified key themes raised by participants as problems they faced as 
a result of their IBD, including living in fear of complications, experiencing fatigue and living in 
secrecy due to a lack of public awareness about the condition (Fourie, Jackson, & Aveyard, 2018). 
The over-arching conclusion from a 2012 meta-analysis was that people with IBD try to ‘push’ to 
live a normal life, by controlling the aspects of life that they could, but are ‘pulled’ back by their IBD 
due to fears surrounding incontinence, social isolation and difficulties managing fatigue (Kemp, 
Griffiths, & Lovell, 2012). Such issues are also evidenced in a survey undertaken by Ghosh and 
Mitchell (2007), participants described their symptoms of IBD as having a large impact on work and 
leisure activities. Of the 3025 participants in the study with CD, 348 had weekly symptom flare-ups, 
along with 162 of the 2333 UC participants. Additional examples of the concerns expressed by the 
participants related to bowel incontinence, sexual relationships and feeling disadvantaged at work 
(Ghosh & Mitchell, 2007). Similarly, in interviews and focus groups conducted by Hall, Rubin, 
Dougall, Hungin and Neely, participants described feeling like their bodies were ‘under attack’ from 
a disease affecting all aspects of their lives as they had concerns regarding the availability of toilets, 
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incontinence and feeling unhygienic. Attempts to maintain normality around others was also 
raised, as participants felt reluctant to discuss their condition for fear of worrying or burdening 
others and being an embarrassment (Hall, Rubin, Dougall, Hungin, & Neely, 2005).  
As discussed in Chapter 1, IBD can have financial implications. McMullan et al. interviewed twenty-
eight participants with UC and some expressed concerns about their ability to continue working. 
They recounted needing to change employment, wake earlier to allow additional time to manage 
symptoms and reduce hours because of fatigue, which then placed a financial burden on 
themselves and their families (McMullan et al., 2017). Furthermore, the management of IBD can 
also affect patient quality of life, as a study conducted in the USA found that quality of life 
decreased with the presence of side effects, which were more common in patients taking multiple 
medications, particularly steroids (Cross, Lapshin, & Finkelstein, 2008). In a study by Kemp et al., 
participant satisfaction with their IBD management appears mixed, with some stating that regular 
follow-up visits were an unnecessary burden when their condition was in remission. When asked 
their opinion about self-management for their condition, those with more severe disease were 
reluctant to make medical decisions without consulting a medical professional first. In addition, 
participants were asked about integrated IBD care with their specialist and their GP. Many were 
more comfortable to discuss their condition with a specialist, particularly when their GP admitted 
they were not as knowledgeable about IBD, though GP-led care with specialist IBD team 
involvement was considered acceptable (Kemp, Griffiths, Campbell, & Lovell, 2013). Finally, the 
mental health impact of IBD has also been explored, as anxiety amongst IBD patients appears to be 
common and is largely linked to the episodic nature of the disease and availability of toilets, which 
is problematic for participants even in remission. On occasion, some participants described 
avoiding excessive anxiety by not leaving the house, which contributes to low mood and social 
isolation. Low mood was also linked to stigma surrounding the condition and lack of knowledge 
amongst peers (Jordan, Ohlsen, Hayee, & Chalder, 2018). Whilst there is a wealth of qualitative 
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research investigating the individual impact of IBD on the patient, there is an absence of that 
examining delays in IBD diagnosis, highlighting the novelty of the research conducted in this thesis. 
 
 Diagnostic delay in inflammatory bowel disease 
As outlined in Chapter 1, despite the appreciation that there are delays in the diagnosis of IBD, 
there is no clear consensus regarding the absolute length of delay. The median diagnostic delays 
reported in existing literature is varied, ranging from two months to over twelve months for both 
CD and UC (Basaranoglu et al., 2015; Langholz, Munkholm, Nielsen, Kreiner, & Binder, 1991a; 
Pellino et al., 2015). In addition, a certain proportion of patients within some studies have reported 
experiencing prolonged diagnostic delays upwards of two decades (Burisch, 2014; Yang et al., 
2000). The changes in diagnostic delay in IBD over time have been reported by some studies 
although findings are conflicting, so collating the delay values from all existing literature may 
provide a clearer insight into whether diagnostic delays have changed over time (Cantoro et al., 
2017; Romberg-Camps et al., 2009). 
Besides a lack of clarity around the extent of this delay, it is unknown what characteristics can 
influence it. Examples may include variance in presenting symptoms, clinical competence, 
geographical location and certain participant demographics like age (Burisch, 2014; Harper, 
McAuliffe, & Beeken, 1986; Novacek et al., 2019). Such characteristics of delay can be considered 
patient- or healthcare-related based on the level at which the delay occurs, which is explored 
further in Chapter 3. The impact that delays in diagnosis can have on the clinical course of IBD have 
been demonstrated in various research, where delays were associated with increased surgery rates 
and likelihood of complicated disease, as discussed in section 1.3 (Li et al., 2015; Moon et al., 
2015). 
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 Chapter summary 
This chapter demonstrates the complexity of IBD, particularly the range of presenting symptoms, 
presence of EIMs and challenges in diagnosis. In order to make a diagnosis of IBD, clinicians must 
piece together blood test results, radiological and endoscopic findings to reach the diagnosis. The 
delays taken to reach this diagnosis may have a detrimental effect on the person’s IBD, as 
medication and other management options are also delayed. Consequently, complications can 
arise, such as strictures and fistulae in CD, which may require surgery to manage. The extent at 
which the diagnosis of IBD is delayed should be established and combining this with possible 
reasons for delay provides a platform from which future research can be conducted to reduce 
delays and possibly improve clinical outcomes. 
The next chapter explores the extent of diagnostic delay through the completion of a systematic 
review. The methodology followed to conduct the systematic review is outlined, as well as the data 
analysis of the included articles. 
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3. Extent of Diagnostic Delay in Inflammatory Bowel Disease- A 
Systematic Review 
 
A systematic review was conducted to explore the extent of diagnostic delay in Inflammatory 
Bowel Disease (IBD). The methodical approach taken to perform a systematic review allows for a 
thorough and reliable analysis of existing literature in a chosen field to answer a specific research 
question. 
 
 Systematic review overview 
Evidence-based medicine involves basing decisions of patient care on the best clinical evidence, 
which could be evidence into the accuracy of certain investigations, prognostic factors or 
preventative measures (Sackett, 1997). Consequently, a high volume of research exists and the 
rapid rate at which literature is published makes it impossible for healthcare professionals to keep 
abreast of. For example, in Medline alone, over 904636 citations were added in 2018 (US National 
Library of Medicine, 2019). It would be immensely time-consuming for an individual to locate and 
read every piece of literature on a given topic. A systematic review provides an excellent solution 
to this problem as they answer a specific research question by collating the literature and drawing 
overall conclusions. 
The decision was made to conduct a systematic review because it allows the assimilation of all 
existing data on the diagnostic delay of IBD to be presented within one analysis. The risk of bias is 
reduced, because of the defined, structured methodology by which a systematic review is 
completed, for example selecting inclusion and exclusion criteria prior to undertaking the search 
and quality appraising included articles to highlight to the reader the quality of the described study 
design (Katikireddi, Egan, & Petticrew, 2015). Additionally, systematic reviews can be reproduced in 
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the future and the similar results should be found, as the standardised process by which it was 
completed should be described to the reader (Gopalakrishnan & Ganeshkumar, 2013). The ability 
for researchers to update systematic reviews is crucial to allow clinical guidelines to develop over 
time, particularly with advancing medicine. 
 
3.2 Methods 
 Protocol 
 
Completing a protocol before the systematic review is commenced is important as it outlines the 
review and clarifies the aims. The protocol provides an overall structure to the review process. 
Within the protocol, aspects like inclusion and exclusion criteria, databases to search and methods 
of quality appraisal are confirmed. A comprehensive protocol for this systematic review was 
produced to ensure transparency and reproducibility (Moher et al., 2015). To reduce the chance of 
duplicating ongoing or published systematic reviews that answer a similar research question to the 
one devised for this thesis, PROPSERO was searched for similar protocols as well as a scoping 
search in PubMed. Once originality of this review was confirmed, it was registered with PROSPERO- 
an international register for systematic reviews, and can be found at the following: 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=108886 (Reference 
 number- CRD42018108886). 
The protocol was based on the Preferred Reporting Items for Systematic Review and Meta-Analysis 
Protocols (PRISMA-P) (Moher et al., 2015). The protocol was revised with advice from co-author JP 
and a member of the systematic review team at the Research Institute for Primary Care and Health 
Sciences (RI) at Keele University (OB). The protocol is included in Appendix 1. 
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 Inclusion criteria 
 
Selection of articles was dictated by the presence or absence of defined inclusion and exclusion 
criteria outlined within the protocol. The reviewers collaborated to devise the inclusion and 
exclusion criteria, ensuring that everyone understood the criteria to reduce the risk of ambiguity 
during the review process. The research aims provided the foundation of the criteria, which is 
outlined using the PICOS framework in Table 3.2.1 (Methley, Campbell, Chew-Graham, McNally, & 
Cheraghi-Sohi, 2014). Alongside the inclusion or exclusion based on participant characteristics and 
study design, selection based upon publication format was also exercised, as certain publications 
were considered more relevant than others.  
 
3.2.2.1 Primary outcome 
The main outcome of this systematic review was to establish the extent of diagnostic delay for IBD, 
CD and UC. Therefore literature that was included in the systematic review demonstrated a 
quantified time period of delay from the onset of symptoms to diagnosis. It was anticipated that 
delay data for IBD would be reported in median and mean values, as these have been used to 
explore delay in other conditions, including giant cell arteritis (Prior et al., 2017).  
 
3.2.2.2 Secondary outcomes 
Further outcomes of this systematic review include exploring consultation and healthcare delays; 
defined as the time between the patient experiencing symptoms to seeking medical advice and the 
time between seeking medical advice to receiving a diagnosis. Where possible, comparisons were 
made between diagnostic delay and IBD phenotype, geographical location and age of patients. 
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 Exclusion criteria 
Articles that did not provide a definition of diagnostic delay were excluded, as were those that only 
included diagnostic delay from when participants first presented to their doctor, for example. 
Conditions such as indeterminate colitis (IC), ischaemic colitis and Irritable Bowel Syndrome (IBS) 
were excluded. Although IC is considered IBD, the aim was to include research with a clear IBD 
diagnosis, therefore if a paper only discussed a diagnostic delay of IC it was excluded. Case studies 
or series with less than ten participants were excluded from the review as they poorly represent 
the population of people with IBD. Editorials, conference abstracts, systematic reviews and 
literature reviews were excluded as the aim was to obtain peer-reviewed primary research. 
 
Table 3.2.1- The inclusion and exclusion criteria, presented using the PICOS framework 
 
 
 Inclusion Criteria Exclusion Criteria 
Population Confirmed diagnosis of IBD, CD or 
UC 
No diagnosis of IBD 
Diagnosis of other forms of colitis 
(ischaemic, eosinophilic, 
microscopic) 
Intervention N/A N/A 
Comparator N/A N/A 
Outcome Defined time period of delay from 
symptom onset to diagnosis 
No time period of delay 
Study Design Cross-sectional study 
Cohort study 
Case-control study 
Case study/ case-series with <10 
participants 
Animal studies 
Publication 
Type 
Full-text, peer-reviewed literature Conference abstracts 
Editorial/author comments 
Systematic review 
Literature review 
Articles not in English that cannot 
be translated 
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 Databases 
The following databases were searched- Medline and EMBASE were searched from inception 
(1974) to 2018 as well as Cumulative Index to Nursing and Cumulative Index to Nursing and Allied 
Health Literature (CINAHL). The platform used to search Medline and EMBASE was Ovid and 
CINAHL was accessed using Healthcare Databases Advanced Search. 
Medline is an American-based database containing a large volume of literature from health, 
biomedical and life sciences. EMBASE contains articles with a biomedical or pharmaceutical 
background. As IBD is considered a condition with multidisciplinary management, using CINAHL 
was deemed worthwhile as the focus of its articles are on nursing or allied health professionals. 
Using these databases ensured the completion of a comprehensive systematic review by gathering 
relevant biomedical literature. The EMBASE search was carried out on the 16th October 2018 and 
both the CINAHL and Medline searches on 18th October 2018. 
 
 Search strategy 
The search strategy (Appendix 2) was used to identify articles from the databases. Search terms 
were formulated with assistance from the supervisory team (JP, BS and AF) and the systematic 
review team at the RI (NC). Search terms for ‘diagnostic delay’ were based on previous systematic 
reviews that explored the diagnostic delay of cancer and giant cell arteritis alongside new terms 
(Neal et al., 2015; Prior et al., 2017). 
 
 Creating the search terms 
A variety of search terms for IBD and diagnostic delay were devised and Medical Subject Headings 
(MeSH) were also used. These are used by databases to categorise articles based on topic and they 
 42 
 
can be ‘exploded’ to expand the search to include terms associated with the MeSH word. For 
instance, when the MeSH term ‘inflammatory bowel disease’ is ‘exploded’, ‘Crohn’s Disease’, 
‘experimental inflammatory bowel disease’ and ‘ulcerative colitis’ terms are also searched for. The 
MeSH terms used in the strategy included ‘inflammatory bowel diseases’, ‘colitis’, ‘delayed 
diagnosis’ and ‘early diagnosis’. ‘Early diagnosis’ was included to identify articles that may make 
reference to a delayed diagnosis in research of an early diagnosis. 
Alongside MeSH terms, free text search terms were used to search article titles, abstracts and 
keywords, which outline the desired subject of the search. Searching titles, abstracts and keywords 
was achieved by using the function “.ti,ab,kw” at the end of each search term. The combinations of 
terms used to search for IBD include ‘inflammatory bowel disease*’, ‘crohn*’, ‘ibd’ and ‘inflam* 
colitis*’. To do a thorough search for diagnostic delay examples of the terms used are ‘diagnos* 
adj3 delay*’, (late* OR earl*) adj3 refer*’ and ‘delay* adj3 consult*’, based upon the 
aforementioned systematic reviews. The adj3 function searched for articles where the selected 
words appeared within two words of one another. 
 
 Combining the search terms 
Joining together the search terms for IBD and diagnostic delay was done using Boolean functions 
(Bramer, de Jonge, Rethlefsen, Mast, & Kleijnen, 2018). All terms for IBD were linked using the ‘OR’ 
command, to show all articles which reference any term used to describe IBD included in the 
search strategy. This was repeated for diagnostic delay terms. Then, both of these combined 
searches were simultaneously searched using the ‘AND’ command which identifies articles 
associated with both diagnostic delay and IBD. This process was repeated across each database. 
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 Search limits 
There was only one limit imposed on the search, where the Boolean ‘NOT’ function was used to 
reduce the number of animal studies. This was done by searching for ‘exp animals/NOT humans/’ 
and then applying the ‘NOT’ function to this search. 
Search limits were not applied to the other exclusion criteria, for example ischaemic colitis, as any 
papers that contained exclusion criteria were identified and excluded during the review phase.  
 
 Article storage- Mendeley 
Mendeley (version 1.16.1, Mendeley Ltd) was the referencing software used to manage the articles 
sourced from the search strategy. This particular referencing software was chosen because of the 
ability to manage a high volume of articles and the option to store references on a desktop 
program. Citations from the database searches were exported to Mendeley using Research 
Information System file formats. Duplicates were deleted using the inbuilt duplicate program, 
which occurs when citations are imported. Close duplicates were checked manually to ensure 
correct deletion of duplicates. When assessing close duplicates, Mendeley provides a percentage 
confidence when articles are possible duplicates and the interface shows the title, authors and 
abstract simultaneously to facilitate the manual check.  
 
 Article review  
 
Rayyan was used to manage each stage of the review (Ouzzani, Hammady, Fedorowicz and 
Elmagarmid, 2016). A screenshot of the Rayyan interface is presented in Figure 3.2.1. This online 
interface allows each reviewer to access all uploaded articles and work through each review stage, 
indicating which articles should be included or excluded and to also provide the reason for this 
choice. Rayyan also has an inbuilt duplicate program. Other reviewers can be invited to access the 
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articles, which facilitates the multiple reviewer process. In addition, there is the option to blind the 
decisions made by other reviewers when the review stage is ongoing and un-blind to allow the 
resolution of conflict between reviewers. Data from the review can be collected, including the 
number of articles that were included and excluded and at what point in the review process, for 
example title or abstract. The data from this feature is included in the PRISMA flowchart (Figure 
3.3.1). 
A simultaneous title and abstract review was conducted by EC and JP, who reviewed 50% each. The 
article title was read first, with the abstract being reviewed if the title was relevant. If excluded, the 
article was labelled with a reason for exclusion, for example ‘review article’ or ‘wrong study design’ 
and at which point this happened- ‘title’ or ‘abstract’.  
Once the initial review was completed, a second review of the included and excluded abstracts was 
carried out, with EC and JP reviewing all abstracts. In the event of conflict, the reviewers met to 
decide whether these articles should be included or excluded. 
The full-text review was conducted by four reviewers (EC, JP, BS, AF), with EC reviewing 100% of 
the articles and JP, BS and AF second-reviewing approximately one third of the articles each. Again, 
EC and JP resolved any conflicts.
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Figure 3.2.1- A screenshot of the Rayyan QCRI literature management website, retrieved from Rayyan QCRI 
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 Paediatric papers 
In light of the large volume of literature identified by this review and the time constraints in which 
to complete it, the decision was made to exclude paediatric papers from the systematic review. 
Although paediatric IBD is an important issue, the scope of the review was restricted to the adult 
IBD population to ensure the volume of findings were extracted thoroughly and an accurate 
benchmark for adult IBD could be found. However, with regards to dissemination of research 
findings, a systematic review of these paediatric articles will form a separate publication. 
 
 Foreign language papers 
Twenty-seven papers included in the search were non-English language. Staff and students at the 
RI were emailed to generate help with reviewing and extracting data from these papers. Of these 
twenty-seven papers, fifteen were adult IBD papers. Languages included Italian, French, German 
and Spanish. An abbreviated data extraction form was distributed to volunteers so that the 
reviewers could establish whether the article met the inclusion criteria. Data was extracted from 
included articles by the same volunteer. Of the fifteen papers, three were included in the review. In 
addition to assistance from volunteer reviewers, Google translate was used on the three included 
papers to adequately complete the data extraction and quality appraisal. 
 
 Data extraction 
In order to ensure the extraction of the important data from the articles, a data extraction form 
was developed and trialled (Appendix 3). Following a discussion with supervisors and alterations to 
the document, both JP and EC completed the data extraction. JP extracted the data from 4 papers 
and reviewed 38% of the data extraction completed by EC to identify any errors or omitted data. 
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Key data included in the extraction form was participant demographics, study design and mean or 
median values for diagnostic delay. 
 
 Converting delay data 
To allow comparisons of delay between studies, the decision was made to present all data on delay 
in months, as the majority of papers displayed median data in this format. The data presented in 
years tended to be overall ranges of delay, so using a smaller unit of time was beneficial for data 
interpretation of median and mean values. Conversion was done by multiplying delay data in years 
by twelve and dividing data in days by thirty. Thirty was chosen as it is the mean length of each 
month. 
 
 Quality appraisal 
The quality appraisal of the literature is an essential component to the systematic review process 
when forming conclusions about the findings. When conducting research, there are many 
opportunities for bias to be introduced, particularly with the selection process, data processing and 
reporting of results (Pannucci & Wilkins, 2010). As such, the quality appraisal of literature is an 
essential component to the systematic review process when forming conclusions about the 
findings. The Newcastle-Ottawa Scale (NOS), which was developed for appraising cohort and case-
control studies, was used (Wells et al., 2014). It has also been adapted for use on cross-sectional 
studies (Herzog et al., 2013). There are differences in the scoring system between the cohort and 
cross-sectional NOS, which is discussed further in section 3.3.2. It is a commonly used and reliable 
method of appraisal (Luchini, Stubbs, Solmi, & Veronese, 2017). The NOS for both cohort and cross-
sectional studies is divided into three categories- selection, comparability, and outcome. Within 
each of these categories, there are statements or questions to be answered by the appraiser. Each 
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statement is ordered by quality, and the statements deemed high quality by the authors of the 
NOS are awarded star(s), according to the scale. 
Both EC and JP independently appraised the included literature and combined results, which was 
reviewed by EC to resolve any conflict. The NOS frameworks for cohort and cross-sectional studies 
were used and have been included in Appendix 4 and Appendix 5 respectively. 
 
3.2.15.1 Quality appraisal of the cohort studies 
The first domain appraises the risk of selection bias, which is when differences in outcome occur 
within the selected sample and the overall population, commonly due to inappropriate selection 
and participant attrition (Hernan, Hernandez-Diaz, & Robins, 2004). In the NOS, there are four 
items that comprise the selection category and the two items used in the appraisal of the articles in 
this systematic review were the “representativeness of the exposed cohort” and “ascertainment of 
exposure”, which was having a diagnosis of IBD. There were two items that were excluded, which 
were “selection of the non-exposed cohort” as there was only 1 article including a group of 
participants that did not have IBD, and “demonstration that the outcome of interest was not 
present at start of study”; all participants recruited for studies had a prior diagnosis of IBD so 
information on diagnostic delay was already available. The second domain, comparability, was 
excluded from the appraisal of these articles, as “comparability of cohorts on the basis of the 
design or analysis”, where the study controlled for age, gender and other factors was not 
important when assessing diagnostic delay. Additionally, many of these articles were large 
population cohort studies collecting data from all people with IBD in a specific area and did not 
recruit controls. Outcome was the final domain used in the quality appraisal process, made up of 
three items. The only item used in this category was “assessment of outcome”, which relates to 
where the information regarding diagnostic delay was sourced. The other two items were “was 
follow-up long enough for outcomes to occur?” and “adequacy of follow up of cohorts”. As 
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previously outlined, data on diagnostic delay was provided before study commencement so 
integrity of follow-up was not important. 
 
3.2.15.2 Quality appraisal of the cross-sectional studies 
As above, the first category of the NOS for cross-sectional studies aims to identify selection bias. 
This was done by using three of the four items in the selection category, which were 
“representativeness of the sample”, “sample size” and “ascertainment of exposure (risk factor” 
were used in the appraisal process. An item assessing comparability of respondents and non-
respondents was omitted, as non-respondents were not discussed in any cross-sectional study in 
this systematic review. The first item assessed whether the sample size was representative of the 
population, whether the sample size was justified, comparability between respondent and non-
respondent characteristics and how the exposure of IBD was identified. The comparability category 
was omitted from this appraisal, as this was not important when assessing diagnostic delay. The 
only item used to assess outcome was “assessment of the outcome”, as providing diagnostic delay 
data did not require “statistical testing”, which was the other item under outcome.  
 
 Data analysis 
In order to collate the findings from this systematic review, narrative synthesis was used. This 
involved producing a descriptive piece of text to outline the key findings from the review, 
describing to the reader the characteristics within the included articles to strengthen the 
conclusions drawn. 
The guidance of how to complete a narrative synthesis, which had been devised by Popay et al. 
(2006), was followed where appropriate in order to reduce the risk of generating biased or 
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inaccurate conclusions from the data. This risk arises because of an absence of defined 
methodological frameworks that should be followed when completing a narrative synthesis (Popay 
et al., 2006). Using this guidance as a foundation ensured attempts to reduce reporting bias. The 
guidance adopted in this narrative synthesis was to provide a ‘textual description of studies’ 
‘tabulation’ of the included studies, to present key information from each study in ‘groups and 
clusters’ based on IBD phenotype and the presence of healthcare or consultation delay data, as 
well as sub-group analyses to look for any connections between the data. The data provided on 
consultation and healthcare factors for delay was also analysed. 
Where possible, the primary outcome, which is the reported time-period of diagnostic delay, will 
be pooled using meta-analysis methods, which is an analytical method to reach conclusions about 
the pooled data set (Haidich, 2010). If applicable, sensitivity analysis will also be performed. 
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3.3 Results 
Following the database search, 7362, 2781 and 447 articles were sourced from EMBASE, Medline 
and CINAHL respectively. Of these 10,590 articles, 3020 duplicate articles were deleted. This left 
7570 to undergo title and abstract review, with 5127 studies being excluded based on title. The 
abstracts of 2443 articles were reviewed and 2143 of these were excluded. The remaining 300 
studies were included in a full text review. Following the exclusion of ninety-three conference 
abstracts, seven articles where full texts were not sourced and four papers which were not 
translated, the remaining 196 full texts were sourced and reviewed. Thirty-five papers met the 
inclusion criteria and this data was extracted. 
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Records identified through 
database searching: 
EMBASE= 7362 
Medline= 2781 
CINAHL= 447 
7570 titles screened 
independently by EC and JP  
Excluded after title screen= 5127 
Not relevant = 4677 
Wrong study design = 303 
Review article = 103 
Wrong publication type = 25 
Animal study = 19 
  
2443 abstracts screened 
independently by EC and JP 
  
Excluded after abstract screen= 2143 
Wrong outcome= 1158 
Wrong population= 422 
Wrong study design= 323 
Review article= 208 
Wrong publication type= 21 
Animal study= 11 
300 full text articles assessed 
for eligibility 
35 studies included in 
narrative synthesis  
Excluded after full-text screen = 265 
Conference abstracts= 93 
Wrong outcome= 88 
Paediatric papers= 48 
Wrong study design= 21 
No paper= 7 
Unable to translate= 4 
Duplicate data= 4 
7570 records after duplicates 
removed  
Figure 3.3.1- A flow chart demonstrating the screening process of the studies identified from the 
search strategy, based on the inclusion and exclusion criteria. Adapted from ‘Preferred reporting 
items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement’ 
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 Characteristics of included studies 
Thirty-five articles were included in the systematic review (Table 3.3.1). Twenty-nine were cohort 
studies (83%), of which nine were prospective (31%), eighteen were retrospective (62%) and two 
studies (7%) combined both approaches. The remaining six papers (17%) were cross-sectional. 
Publication dates ranged from 1971 to 2019, with eighteen being published from 2010 onwards. 
In total, the number of participants included in the articles comprised within this systematic review 
was 14,524. There was one article that provided information regarding the diagnostic delay of IBD 
but not related specifically to delays in CD or UC (Parente et al., 2015) . The total number of 
participants from this study was 252. The remaining studies did provide information of the 
diagnostic delays of either or both CD and UC. The overall number of CD participants within these 
studies was 9170 and for UC, this number was 7311. 
The studies represent wide variation in geographical area, including seventeen (49%) from 
European and eleven (31%) Asian countries. Five articles (14%) were from North America including 
the USA and Canada; and one (3%) from South America. One article (3%) was from Africa. Two 
articles (6%) originated from the United Kingdom, four (12%) from Italy, three (9%) from the USA 
and two (6%) from Iran. 
The studies were conducted in a range of healthcare settings. The majority of studies were carried 
out in either a secondary (n= 22, 63%) or tertiary care (n= 7, 20%) setting, whilst six (17%) utilised 
population registries. 
Finally, the criteria used to diagnose IBD was provided by most included studies. This largely 
centred around the fulfilment of certain presenting symptoms, radiologic and histologic findings 
(n= 14, 40%). Studies also used the Lennard-Jones criteria (n= 4, 11%) for CD and the Copenhagen 
Diagnostic Criteria for CD (n= 2, 6%) and UC (n=2. 6%). 
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Table 3.3.1- An outline of the characteristics of the included studies in this systematic review 
 
Author and 
Publication Year 
Country Study Design Recruitment 
Period 
Healthcare Setting Diagnostic Criteria for IBD 
Kyle (1971) Scotland Cross-sectional 1955-1969 Not reported CD= history and examination findings, brief use of 
radiology/endoscopy 
Lind 1985) Norway Prospective 
cohort 
1975-1979 Secondary CD= standardised investigational program 
(colonoscopy/gastroscopy. Biopsy, barium enema) 
Foxworthy (1985) USA Prospective 
cohort 
1975-1983 Secondary CD= clinical presentation/course, 
radiologic/histologic/laparotomy appearance 
Harper (1986) USA Cross-sectional 1983-1984 Secondary CD= typical symptoms/findings, 
radiologic/endoscopic/operative features 
Di Simone (1987) France Retrospective 
cohort 
Not reported Not reported UC= not reported 
Lee (1987) England Retrospective 
cohort 
1969-1983 Secondary CD= clinical records, histopathological diagnostic index 
from consultant colleagues 
Sategna-Guidetti 
(1990) 
Italy Retrospective 
cohort 
1965-1988 Secondary CD= classical criteria 
Langholz (1991) Denmark Prospective 
cohort 
1962-1987 Secondary UC= Copenhagen criteria  
Munkholm (1992) Denmark Prospective 
cohort 
1962-1987 Secondary CD= Copenhagen criteria 
Wright (1992) South Africa Prospective 
cohort 
1970-1988 Secondary CD= compatible clinical, radiologic, endoscopic, histologic 
features 
Wengrower (1997) Israel Prospective 
cohort 
Not reported Military recruits CD= clinical, laboratory, radiographic, endoscopic, 
histological features 
Yang (2000) 
 
Korea Retrospective + 
prospective 
cohort 
1986-1977 Secondary UC= diarrhoea, blood/pus in stool, sigmoidoscopy, 
histological/cytological, radiologic/endoscopic features 
Saro Gismera (2003) Spain Retrospective + 
prospective 
cohort 
1954-1977 Secondary CD= Lennard-Jones criteria 
UC= Truelove criteria (severity) 
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Aghazadeh (2004) Iran Retrospective 
cohort 
1992-2002 Secondary CD= Lennard-Jones 
UC= not reported 
Burgmann, (2006) Canada Cross-sectional 2004-2005 Manitoba IBD registry CD= ICD codes 
UC= ICD codes 
Albert (2008) Germany Cross-sectional 2005-2007 Patient organisation CD= not reported 
Romberg-Camps  
(2009) 
Netherlands Prospective 
cohort 
1991-2002 Population registry CD= Lennard-Jones criteria 
UC= continuous mucosal inflammation without 
granuloma, affecting rectum +/ some/ all of the colon in 
continuity with rectum 
Roth (2010) Canada Retrospective 
cohort 
1996-2001 Secondary UC= not reported 
Jain (2012) India Retrospective 
cohort 
2005-2010 Secondary CD= not reported 
UC= not reported 
Vavricka (2012) Switzerland Retrospective 
cohort 
2006-2009 Population registry CD= not reported 
UC= not reported 
Taghavi (2013) Iran Prospective 
cohort 
1989-2009 Population registry CD= Lennard-Jones 
UC= not reported 
Burisch, 2014 Europe Prospective 
cohort 
Jan 2010-Dec 
2010 
Secondary CD= Copenhagen diagnostic criteria 
UC= Copenhagen diagnostic criteria 
Pellino, 2015 Italy Cross-sectional 2000-2009 Secondary CD= accepted ECCO criteria 
Li (2015) China Retrospective 
cohort 
2010-2014 Secondary CD= colonoscopy, enteroscopy, capsule endoscopy, 
histopathology, haematology 
Parente (2015) Brazil Retrospective 
cohort 
2011-2012 Secondary IBD= World Gastroenterology Organisation guidelines 
Moon (2015) Korea Retrospective 
cohort 
2000-2008 Cohort study register CD= clinical, endoscopic, radiologic, histologic findings 
Maconi (2015) Italy Retrospective 
cohort 
2012-2013 Primary and secondary CD= not reported 
Basaranoglu (2015) Turkey Retrospective 
cohort 
1995-2007 Tertiary CD= clinical, radioscopic, endoscopic, histologic findings 
UC= not reported 
Lin (2015) Taiwan Retrospective 
cohort 
1991-2014 Not reported UC= not reported 
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Lee (2017) South Korea Retrospective 
cohort 
2000-2015 Secondary CD= not reported (Montreal classification for disease 
severity at diagnosis) 
UC= not reported (Montreal classification for disease 
severity at diagnosis) 
Cantoro, 2017 Italy Retrospective 
cohort 
1955-2014 Secondary CD= not reported (Montreal classification for disease 
severity at diagnosis) 
UC=  not reported (Montreal classification for disease 
severity at diagnosis) 
Nguyen (2017) USA Retrospective 
cohort 
2008-2015 Tertiary CD= not reported (Montreal classification for disease 
severity at diagnosis) 
UC= not reported (Montreal classification for disease 
severity at diagnosis) 
Szanto (2018) Hungary Retrospective 
cohort 
2007-2015 Tertiary CD= Lennard-Jones and accepted ECCO criteria 
UC= Lennard-Jones and accepted ECCO criteria 
Banerjee (2018) India Retrospective 
cohort 
Not reported Secondary CD= not reported (Montreal classification for disease 
severity at diagnosis) *paediatric CD= Porto criteria 
Novacek, 2019 Austria Cross-sectional 2014-2015 Secondary CD= ECCO criteria 
UC= ECCO criteria 
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 Quality appraisal 
3.3.2.1 Appraisal of the cohort studies 
The twenty-nine cohort studies were appraised (Table 3.3.2). Most studies were either “somewhat 
representative” or “truly representative”, a decision made depending on the geographical spread 
of recruitment. For example, Vavricka et al. (2012) sampled from an IBD registry covering all 
regions of Switzerland so was considered ‘truly representative’. However, where studies sampled 
from only one medical establishment or from one area within a country or town, as with Nguyen et 
al. (2017), they were considered “somewhat representative”. Wengrower (1997) was not awarded 
any stars for this section, as they sampled from a ‘selected group of users’, which were military 
recruits. The “ascertainment of exposure” of IBD was determined by assessing “secure records” in 
twenty-two papers which scored one star, as medical records can be considered reliable. Only one 
paper provided no description of this. The third domain focusses on the study outcomes. Sixteen 
studies mainly used either “record linkage” to determine delay and were awarded 1 star, whilst 
participants in eight studies “self-reported” their diagnostic delay and were awarded no stars as 
there is a higher risk of recall bias with this method.  Five articles provided “no description” of how 
outcome was assessed and also scored no stars. 
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Author and 
Publication Year 
Selection Outcome  
Total 
number of 
stars 
Representativeness 
of the cohort /1 
Ascertainment of 
Exposure /1 
Number of 
stars /2 
Assessment of 
Outcome 
Number of 
stars /1 
Lind, 1985 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Foxworthy, 1985 Selected group of 
users (elderly 
population) (0) 
Secure records (1) 1 Self-report (0) 0 1 
Simone, 1987 No description (0) No description (0) 0 No description (0) 0 0 
Lee, 1987 Somewhat 
representative (1) 
Secure records (1) 2 No description (0) 0 2 
Sategna-Guidetti, 
1990 
Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Langholz, 1991 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Munkholm, 1992 Somewhat 
representative (1) 
Secure records (1) 2 No description (0) 0 2 
Wright, 1992 Somewhat 
representative (1) 
Secure records (1) 2 No description (0) 0 2 
Wengrower, 1997 Selected group of 
users (military 
recruits) (0) 
Secure records (1) 1 Self-report (0) 0 1 
Table 3.3.2- The quality appraisal of the cohort studies, using the abbreviated NOS. The number of stars awarded for each item is included in brackets 
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Yang, 2000 Truly 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Saro Gismera, 2003 Somewhat 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Aghazadeh, 2004 Somewhat 
representative (1) 
Secure records (1) 2 No description (0) 0 2 
Romberg-Camps, 
2009 
Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Roth, 2010 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Jain, 2012 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Vavricka, 2012 Truly 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Taghavi, 2013 Somewhat 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Burisch, 2014 Truly 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Li, 2015 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Parente, 2015 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
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Mo Moon, 2015 Truly 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Manconi, 2015 Somewhat 
representative (1) 
Secure records (1) 2 Self-report (0) 0 2 
Basaranoglu, 2015 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Lin, 2016 Truly 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Lee, 2017 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Cantoro, 2017 Truly 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Nguyen, 2017 Somewhat 
representative (1) 
Secure records(1) 2 Record linkage (1) 1 3 
Szanto, 2018 Truly 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
Banerjee, 2018 Somewhat 
representative (1) 
Secure records (1) 2 Record linkage (1) 1 3 
 
 61 
 
3.3.2.2 Appraisal of the cross-sectional studies 
The representativeness of the sampled population was determined by the geographical scope of 
included participants. This was varied across the six articles, as participants from four articles were 
deemed truly or somewhat representative of the population, though one paper sampled from 
selected groups of users based on age and one provided no description of the sampling strategy. 
Scoring whether sample sizes were justified or satisfactory was based on sample sizes and 
geographical range of participants and whether the paper had discussed the merits or limitations 
of their sample size. Only the two papers that scored “truly representative” were considered to 
have justified or satisfactory sample sizes. “Ascertainment of exposure” was scored on the 
presence or absence of a method used to recruit individuals with IBD. For example, in the study 
carried out by Burgmann et al., participants with IBD were identified by International Classification 
of Diseases (ICD) codes in their medical records, which is a “validated measurement tool”. As 
Harper et al. recruited by viewing the records of gastroenterologists which is highly likely to be 
reliable, specific information on how these individuals were determined to have IBD was not 
provided, so this was awarded “tool is available and described” as it was not considered that “no 
description” had been provided but a there was no discussion of a validated measurement tool. 
One article provided “no description” of identifying participants with IBD. 
For measuring the outcome of diagnostic delay, stars were awarded based on how robust the 
chosen methods were. Two stars were awarded for “record linkage” or “independent blind 
assessment”, as demonstrated by Pellino et al. (2015). “Self-report” scored one star, demonstrating 
that it is a less robust means of assessing outcomes due to the risk of recall bias. In contrast, the 
NOS for cohort studies did not award any stars for studies that used “self-report”, demonstrating 
variation between the two scores. This is discussed in section 3.4.1. Table 3.3.3 contains the 
appraisal of the cross-sectional studies. 
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 Selection Outcome  
Author and 
Publication 
Year 
Representativeness 
of the cohort /1 
Sample Size /1 Ascertainment of 
Exposure /2 
Number 
of stars /4 
Assessment of 
Outcome /2 
Number 
of stars /2 
Total 
number 
of stars 
Kyle, 1971 No description of 
sampling strategy (0) 
Not justified (0)  No description 
(0) 
0 No description 
(0) 
0 0 
Harper, 1986 Selected group of 
users (elderly 
population) (0) 
Not justified (0) Tool is available 
and described (1) 
1 No description 
(0) 
0 1 
Burgmann, 
2006 
Truly representative 
(1) 
Justified/satisfactory 
(1) 
Validated 
measurement 
tool (2) 
4 Self-report (1) 1 5 
Albert, 2007 Somewhat 
representative (1) 
Not justified (0) Tool is available 
and described (1) 
2 Self-report  (1)  1 3 
Pellino, 2015 Somewhat 
representative (1) 
Not justified (0) Validated 
measurement 
tool (2) 
3 Record linkage 
(2) 
2 5 
Novacek, 
2019 
Truly representative 
(1) 
Justified/satisfactory 
(1) 
Validated 
measurement 
tool (2) 
4 Self-report (1) 1 5 
Table 3.3.3- The quality appraisal of the cross-sectional studies, using the abbreviated NOS. The number of stars awarded for each item is included in 
brackets 
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 Diagnostic delay 
Data from studies providing diagnostic delays for IBD can be found in Table 3.3.4 and Table 3.3.5. 
The values extracted from papers providing diagnostic delay data for CD and UC have been 
presented in three tables, two displaying participant demographics (Table 3.3.6 for CD, Table 3.3.7 
for UC) and another the values for delay (Table 3.3.8). As the data within this systematic review 
was skewed, the decision was made to focus analysis on median values and interquartile ranges 
(IQR), following the format of previous literature on delay where asymmetrical distribution of  data 
was also found (Osei, Akweongo, & Binka, 2015). Skewness in data arises when there is variation in 
the median and mean values. Positive skew arises when the median is smaller than the mean, with 
negative skew being the opposite. In the context of diagnostic delay, data is often positively 
skewed as the majority of patients tend to have similar delays with a small proportion experiencing 
prolonged delay causing their delay to disproportionally contribute to the cumulative delay of all 
patients (Verhagen, Kapinga, & van Rosmalen-Nooijens, 2010). For transparency, mean values have 
been included alongside median values within tables but are not discussed further. 
 
3.3.3.1 Diagnostic delay of inflammatory bowel disease 
Eight papers provided data on delays in IBD diagnosis. As previously stated, one article provided 
information reporting the diagnostic delay of IBD only and seven provided further information on 
delays of CD and UC. These studies used IBD as an umbrella diagnosis, as participants were defined 
as having CD or UC, the two distinct disease patterns of IBD, but also IC and proctitis. Although 
participants were defined as having these sub-conditions that comprise IBD, the diagnostic delay 
provided is of IBD as a whole. With regards to geographical location, five articles (63%) are from 
European countries, and one each from North America, South America and Asia (13%). Article 
studies were conducted in a range of healthcare settings, as four were based in secondary care 
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(50%), two in tertiary care (25%) and two used population data-sets (25%). Most articles reported 
cohort study designs (75%). All articles provided information on the number of participants with 
each IBD classification included in the delay, with all papers including participants with both CD and 
UC. Two of these papers also included IC (25%) with one including IC and proctitis (13%). IBD was 
diagnosed using a variety of radioscopic or endoscopic findings and criteria, including Lennard-
Jones criteria for CD (n= 4, 50%) and ECCO criteria (n=2, 25%). This information can be found in 
Table 3.3.1. Diagnostic delay is comparable across all eight studies, as it is defined as the time 
interval between symptom onset and diagnosis. 
Median values for diagnostic delay of IBD were provided by six articles and ranged from 2 to 96 
months. Ninety-six months is considered an outlier as the result is larger than the other values. For 
instance, the median values from five articles were between 2 and 5.3 (IQR 2.3-16.4) months. A 
sensitivity analysis has been performed whereby outliers have been excluded, and this is presented 
in section 3.3.3.6. 
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      Age  
Author and Publication Year Country N Gender 
% Male 
When reported Mean age (standard 
deviation) , y 
Range, y 
Saro Gismera, 2003 Spain 1018 
CD- 415 
UC- 565 
IC- 38 
52.8% At onset 
 
At diagnosis 
37.66 (0.97) 
 
39.49 (1.08) 
 
Burgmann, 2006 Canada 112 
CD- 65 
UC- 42 
Proctitis- 3 
IC-2 
42.9% At diagnosis 38 (12.9) 16 - 77 
Romberg-Camps, 2009 Netherlands 1187 
CD- 476 
UC- 630 
IC- 81 
48.9% Not reported CD- 34 
UC- 42 
IC- 42 
CD- 5 – 79 
UC- 8 – 84 
IC- 13 - 77 
Basaranoglu, 2015 Turkey 282 
CD- 98 
UC- 184 
64.2% At diagnosis 40.1 (14.7)  
Parente, 2015 Brazil 252 
CD- 100 
UC- 152 
43.3% At onset 35.2 (14.5)  
Cantoro, 2017 Italy 3392 
CD- 1537 
UC- 1855 
53.1% Not reported 
Szanto, 2018 Hungary 911 
CD- 428 
UC- 483 
46.3% See CD and UC table 
Novacek, 2019 Austria 1265 
CD- 830 
UC- 435 
49.4% At time of study 40 (31 – 52) [median 
(IQR)] 
18 - 87 
Table 3.3.4- Participant characteristics from the included studies that provide data for the diagnostic delay of IBD, in order of publication year 
 66 
 
 
  
Author and Publication Year 
 
Definition of Diagnostic Delay Median (IQR) Mean (SD) Range 
Basaranoglu, 2015 Symptom onset to diagnosis 
 
2 3.1 (2.7) 0 - 18 
Cantoro, 2017 First likely symptoms to diagnosis 
 
3 (0 – 13)   
Romberg-Camps. 2009 Duration of symptoms before 
diagnosis 
 
3  0 - 480 
Szanto, 2018 Onset of symptoms to diagnosis 
 
3.6 (0 – 9.6)   
Novacek, 2019 Onset of first IBD-related 
symptoms to diagnosis 
 
5.3 (2.3 – 16.4)   
Burgmann, 2006 Duration of symptoms before 
diagnosis 
 
96 135.6  
Saro Gismera, 2003 Symptomatic period before 
diagnosis 
 
 21.96 (3.48)  
Parente, 2015 Onset of clinical manifestations to 
diagnosis 
 
 35.5  
Table 3.3.5- Converted data for the diagnostic delay of IBD from the included studies, from smallest median delay to largest 
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3.3.3.2 Diagnostic Delay of Crohn’s Disease 
Twenty-five articles from this systematic review provide values of diagnostic delay in CD. The 
articles arise from four continents- Europe (n= 12, 48%), Asia (n= 9, 36%), North America (n= 2, 8%) 
and Africa (n= 1, 4%). Twenty articles (80%) were cohort studies and the remaining five were cross-
sectional (22%). The research providing CD delay values was conducted in secondary care (n= 13, 
52%) secondary and primary care (n=1, 4%) and tertiary care (n= 3, 13%), with seven utilising 
population data-sets (30%). One article did not provide information on the study setting (Kyle, 
1971). Identifying individuals with CD was based upon clinical, radioscopic and endoscopic findings 
in six articles (27%), Lennard-Jones criteria in five (20%) and ECCO criteria in three (13%). There was 
no mention of how individuals with IBD were diagnosed in eight papers (35%). Diagnostic delay was 
comparable across the articles and involved the time between symptom onset to diagnosis. 
Specific definitions of diagnostic delay for each article can be found in Table 3.3.8. 
As extracted from seventeen articles, the median delay of CD ranged from 2 to 84 months which 
contains an outlier of 84 months, as this value is substantially larger than the values for delay 
extracted from other article. A sensitivity analysis has been performed and which has excluded 
outliers from the analysis, in section 3.3.3.6. Overall, the range of delay in CD diagnosis was from 1 
day to 34 years. 
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  Age 
Author and Publication 
Year 
Country N % Male When reported    Mean (SD), y Range, y 
Kyle, 1971 
 
Scotland 175 38.3% Not reported 
Lind, 1985 Norway 214 56.1% At onset 24 
[22 median] 
7 - 63 
Lee, 1987 England 215 34.0% Not reported 
Munkholm, 1992 Denmark 373 42.1% At onset 32.5 8 - 84 
Wright, 1992 South Africa 239 
 
32.2% Not reported 31.4 (12.8)  
Wengrower, 1997 Israel 53 62.3% At diagnosis 19.4 18 - 21 
Saro Gismera, 2003 Spain 415 46.5% At onset 
 
At diagnosis 
30.68 (1.4) 
 
33.53 (1.51) 
 
Aghazadeh, 2004 Iran 47 26.6% At diagnosis 31.9  14 - 83 
Burgmann, 2006 Canada 65 33.8% See IBD table 
Albert, 2007 Germany 112 34.8% At diagnosis 28 (8.0) Female 
 
31 (11.5) Male 
 
Romberg-Camps, 2009 Netherlands 476 39.3% Not reported 34 5 – 79 
Table 3.3.6- Participant characteristics from the included studies that provide data for the diagnostic delay of CD, in order of publication year 
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Jain, 2012 India 12 50.0% At diagnosis 40 21 – 80 
Vavricka, 2012 Switzerland 932 46.8% Not reported 41 (15) 16 – 88 
Taghavi, 2013 Iran 120 49.2% At diagnosis 32.97 (1.34) 9 – 80 
Basaranoglu, 2015 Turkey 98 52.0% Not reported 37.8 (13.5) 
 
17 – 79 
Maconi, 2015 Italy 83 41% At diagnosis 37.2 (15.3) 14 - 74 
Li, 2015 China 343 70.0% At diagnosis 31.8 (12.5)  
Mo Moon, 2015 Korea 1047 72.3% At onset 27.7 (12.3)  
Pellino, 2015 Italy 361 Not reported At diagnosis 32.54 (14.47)  
Lee, 2017 South Korea 165 76.4% At diagnosis 28.2 (13.8)  
Cantoro, 2017 Italy 1537 Not reported Not reported   
Nguyen, 2017 USA 110 41.0% At onset 
 
At diagnosis 
35 (17) 
 
38 (17) 
 
Banerjee, 2018 India 720 60.3% Not reported [32 (18 – 50) 
median (IQR)] 
 
Szanto, 2018 Hungary 428 45.3% At onset 
 
At diagnosis 
26.6 (11.3) 
 
30.9 (12.5) 
 
Novacek, 2019 Austria 830 48.1% At enrolment [40 (31 – 52) 
median (IQR)] 
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3.3.3.3 Diagnostic Delay of Ulcerative Colitis 
There were seventeen articles that provided information for the diagnostic delay of UC. Eight 
articles were from European countries (47%), six were from Asian countries (35%) and three from 
North American countries (18%). They were published between 1987 and 2019. There were fifteen 
cohort studies studies (88%) and two cross-sectional studies (11%). Nine studies were based in 
secondary care (53%), three in tertiary care (18%) and population data sets were used in four 
studies (24%). The study in 1987 did not provide information on the study setting (6%). The 
diagnosis of UC was not defined in seven studies (54%), whilst ECCO criteria and various clinical, 
radioscopic and endoscopic findings were used in two (15%). ICD codes and the Copenhagen 
criteria were present in one study (8%). Diagnostic delay was classified as the time between 
symptom onset and diagnosis, making the findings comparable. 
Regarding delays in UC diagnosis, eleven articles reported median values which ranged from 2 to 
114 months, including an outlier of 114 months as it is remarkably different from the other results. 
A sensitivity analysis has been performed and findings have been presented in section 3.3.6. The 
overall range of UC diagnostic delay was 3.1 to 135.6 months. 
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    Age 
Author and Publication 
Year 
Country N % Male When reported      Mean (SD), y Range, y 
Simone, 1987 France 111 57.7% Not reported 34 5 - 73 
Langholz, 1991 Denmark 1161 46.7% At diagnosis 34 2 - 88 
Yang, 2000 Korea 94 47.9% Not reported [35 median] 8 - 68 
Saro Gismera, 2003 Spain 565 48.1% At onset 
 
At diagnosis 
42.84 (1.34) 
 
43.95 (1.47) 
 
Aghazadeh, 2004 Iran 47 56.5% At diagnosis 30.5 10 - 60 
Burgmann, 2006 Canada 42 Not reported See IBD table 
Romberg- Camps, 2009 Netherlands 630 55.6% Not reported 42 8 - 84 
Roth, 2010 Canada 102 51.0% At diagnosis 39 (17.9) 9 - 85 
Table 3.3.7- Participant characteristics from the included studies that provide data for the diagnostic delay of UC, in order of publication year 
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Vavricka, 2012 Switzerland 625 53.8% At enrolment 
 
At onset 
42 (14) 
 
33 (13) 
16 – 82 
 
5 - 82 
Jain, 2012 India 160 78% Not reported 40.9  
Taghavi, 2013 Iran 620 83.8% At diagnosis 34.68 (1.44)  
Basaranoglu, 2015 Turkey 184 70.7% Not reported 41.4 (15.2) 
[41 median] 
14 - 78 
Nguyen, 2017 USA 67 44.8% At onset 
 
At diagnosis 
44 (19) 
 
45 (19) 
 
Cantoro, 2017 Italy 1855 Not reported Not reported   
Lee, 2017 South Korea 130 54.6% At diagnosis 38.8 (15.6)  
Szanto, 2018 Hungary 483 47.2% At onset 
 
At diagnosis 
30.3 (12.4) 
 
30.9 (12.5) 
 
Novacek, 2019 Austria 435 51.2% At enrolment [40 (31 – 51) 
median (IQR)] 
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 Converted Diagnostic Delay CD (months) 
 
Converted Diagnostic Delay UC (months) 
Author and 
Publication 
Year 
 
Definition of Diagnostic 
Delay 
Median (IQR) Mean (SD) Range Median (IQR) Mean (SD) Range 
CD Only 
Wengrower, 
1997 
Duration of 
signs/symptoms before 
diagnosis 
 
 4 1 - 36    
Lee, 1987 Interval between onset 
and diagnosis 
 
 11     
Mo Moon, 
2015 
Interval from first 
symptoms to 
established diagnosis 
 
 16 (33.1) 0 – 412.4    
Kyle, 1971 Onset to diagnosis 
interval 
 
6 19 0.03 - 360    
Wright, 1992 Onset of symptoms to 
diagnosis 
 
 21.2 (36.7)     
Maconi  2015 Onset of symptoms to 
dianosis 
8 (3 - 27)  0 - 324    
Table 3.3.8- Converted data for the diagnostic delay of CD and/or UC from the included studies, from smallest median delay to largest 
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Li, 2015 Onset of symptoms to 
diagnosis 
 
10 (2 – 34) 29 (44.3)     
Pellino, 2015 Symptom-diagnosis 
interval 
 
11  1 - 163    
Albert, 2007 First complaints to 
establishment of 
diagnosis 
 
13 29.4 (44) 0 – 281    
Banerjee, 
2018 
Symptom onset to 
confirmation of 
diagnosis 
 
18 (6 – 36) 25.78     
Lind, 1985 Start of symptoms to 
diagnosis 
 
24 49.2 0 – 372    
Munkholm, 
1992 
Occurrence of first 
symptoms to diagnosis 
26.4  0 – 324    
UC Only 
Yang, 2000 From onset of 
symptoms to diagnosis 
 
   6  1 - 120 
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CD and UC 
Basaranoglu, 
2015 
Symptom onset to 
diagnosis 
2 3 (2.8) 0 - 18 2 3.2 (2.6) 0 – 15 
Lee, 2017 Duration of first 
symptoms to diagnosis 
 
6.2 (1.5 – 21.5)   2.4 (1.2 – 6.2)   
Romberg-
Camps, 2009 
Duration of symptoms 
before diagnosis 
 
5  0 - 360 3  0 - 480 
Novacek, 2019 Onset of first IBD-
related symptom to 
diagnosis 
 
6.4 (2.3 – 23.4)   3.4 (1.4 – 10.3)   
Cantoro, 2017 First likely symptoms to 
diagnosis 
7.1   2.0   
Nguyen, 2017 Symptom onset to 
diagnosis 
 
9.5 (3.8 – 25.6)   3.1 (1.1 – 9.6)   
Vavricka, 2012 From first IBD 
symptoms to diagnosis 
 
9 (3 – 24)   4 (1 – 12)   
Langholz, 
1991 
Onset of symptoms to 
diagnosis 
 
   12  0 - 444 
Roth, 2010 Time of symptom onset 
to time of diagnosis 
 
    21.6 (54) 0 - 408 
Simone, 1987 Appearance of initial 
symptoms and timing 
of diagnosis 
 
    30  
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Szanto, 2018 Onset of symptoms to 
diagnosis 
 
25.2 (0 – 103.2)   55.2 (0 – 
123.6) 
  
Burgmann, 
2006 
Duration of symptoms 
before diagnosis 
 
84 121.2  114 150  
Jain, 2012 Onset of symptoms to 
diagnosis 
 
 15.3 1 - 72  1.5 0.2 – 4.8 
Saro Gismera, 
2003 
Symptomatic period 
before diagnosis 
 
 34.2 (6.48)   13.32 (2.76)  
Aghazadeh, 
2004 
Onset of complaints to 
definitive diagnosis 
 
 17.7   13.9  
Taghavi, 2013 Interval between onset 
of symptoms and 
diagnosis 
 
 16.56 (14.3)   14.36 (13.1)  
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3.3.3.4 Comparing the diagnostic delay of Crohn’s disease and ulcerative colitis 
There were thirteen papers that compared diagnostic delays of CD and UC. Generally, diagnostic 
delays of CD were longer than UC. For instance, in a cohort study conducted by Vavricka et al. 
demonstrated a median delay for CD of 9 months (IQR 3 -24) compared to a median delay of 4 
months (IQR 1-12) for UC. Similarly, Nuygen et al. found that the median delay within their sample 
was 9.5 months (IQR 3.8-25.6) for CD and 3.1 months (IQR 1.1-9.6) for UC.  However, this pattern 
was not represented in studies by Szanto et al., where the median diagnostic delay of CD was 25.2 
(IQR 0-103.2) months and 55.2 (IQR 0-123.6) months for UC, or Burgmann et al., where median 
delay was 84 and 114 months for CD and UC respectively.  
 
3.3.3.5 Diagnostic delay over time 
The extent of diagnostic delays reported by patients with CD does not appear to have changed over 
time when ordering articles in ascending year of publication. The oldest paper providing delay data 
for a CD population was published by Kyle in 1971. They reported a median diagnostic delay of 6 
months (Kyle, 1971). However, the range of median values reported in papers published between 
2017 and 2019 was 6.4 (IQR 2.3-23.4) to 25.2 (IQR 0-102.3) months. Figure 3.3.2 demonstrates the 
diagnostic delay of CD over time. Changes in diagnostic delay of UC are presented in Figure 
3.3.3.These graphs have been reproduced following exclusion of outliers (section 3.3.3.6). 
Alternatively, the delay that patients with UC experience appears to be decreasing over time when 
excluding the 55.2 and 114 month outliers. The oldest paper reporting a median value for delayed 
diagnosis in UC, published in 1991, was 12 months, which reduced to 6 months in 2000 then to 3.1 
(IQR 1.1-9.6) and 3.4 (IQR 1.4-10.3) in 2017 and 2019 respectively. 
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In a Turin case series of 153 patients with CD conducted by Sategna-Guidetti et al., data was 
provided for diagnostic delay depending on year of diagnosis. This data does demonstrate some 
improvement in median diagnostic delay. For instance, median diagnostic delay in 1965 to 1977 
was 30 months, with an overall range of delay of 0 to 324 months. Between the years 1978 to 
1988, the median diagnostic delay had reduced to 24 months, though the overall range was 
between 0 and 432 months (Sategna-Guidetti & Marucco, 1990). A study by Cantoro et al. 
compared diagnostic delay of IBD between a historical cohort, between 1955 and 1987, and the 
modern cohort, 1985 to 2014. Although there was no change in diagnostic delay between both the 
historical and modern cohort, where median delay was 4.0 months (IQR 0 – 24) and 3.0 months 
(IQR 0.8 – 12) respectively, there was a decrease in the proportion of patients experiencing delays 
over 24 months in the modern cohort compared to historical. 
 
Figure 3.3.2- A graph showing changes in the extent of diagnostic delay in CD compared to year of 
publication 
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3.3.3.6 Sensitivity analysis 
As outlined previously, outliers have been identified during this analysis. The outliers identified 
include the study by Szanto et al. and Burgmann et al. With the inclusion of outliers, the median 
diagnostic delay ranged from 2 months to 96 months for IBD, 2 to 84 months for CD and 2 to 114 
months for UC. Following the exclusion of outliers, these ranges change, becoming 2 to 5.3 months 
for IBD, 2 to 26.4 months for CD and 2 to 12 months for UC. When comparing the delays for CD and 
UC, CD demonstrates longer diagnostic delays than UC following exclusion of the outliers. Figure 
3.3.4 and Figure 3.3.5 demonstrate the changes in CD and UC diagnostic delay respectively over 
time. 
Figure 3.3.3- A graph showing changes in the extent of diagnostic delay in UC compared to year of 
publication 
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Figure 3.3.4- A graph showing changes in the extent of diagnostic delay in CD compared to year of 
publication, following exclusion of outliers 
Figure 3.3.5- A graph showing changes in the extent of diagnostic delay in UC compared to year of 
publication, following exclusion of outliers 
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3.3.3.7 Consultation and Healthcare Delays 
Of the thirty-five papers, there were four (11%) that provided information on the extent of 
diagnostic delay of CD and UC which was attributed to consultation and healthcare delay (Table 
3.3.9). There was one cross-sectional study (25%) and three retrospective cohort (75%) studies 
from population data-sets (n= 2, 50%), secondary care (n= 1, 25%) and tertiary care (n= 1, 25%). 
Two arose from European countries (50%), one from Asia (25%) and one from North America 
(25%). With regards to the four articles providing this information for CD, three papers 
demonstrated greater consultation delays compared to healthcare delays. Median consultation 
delay ranged from 1 (IQR 0.2-4.9) to 2 (IQR 0-6) months whereas healthcare delays were between 
0.7 (IQR 0.1-4.6) to 6 months. A similar pattern was not found for UC, as described in three papers 
where consultation delays were longer, shorter and equal to healthcare delays. Median 
consultation delays ranged from 0.7 (IQR 0.3-3.0) to 1.9 (IQR 0.9-4.9) months and for healthcare 
delays, this range was 0.2 (IQR 0.1-0.6) to 1.1 (IQR 0.4-5.4) months. In addition to the four articles 
described, Cantoro et al. provided mean values of consultation and healthcare delays for a sub-
cohort of 558 IBD patients, which were 10.8 (SD 30) and 3.1 (SD 12) respectively.
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    Consultation Delay (months) 
 
Healthcare Delay (months) 
Author and 
Publication Year 
Country Definition of 
Consultation Delay 
Definition of Healthcare 
Delay 
CD UC CD UC 
Nguyen, 2017 USA Time from symptom 
onset to initial 
physician visit 
 
Initial physician visit to 
IBD diagnosis 
1 (0.2 – 4.9) 
median (IQR) 
0.7 (0.3 – 3.0) 
median (IQR) 
3.5 (1.2 – 20.5) 
median (IQR) 
1.1 (0.4 – 5.4) 
median (IQR) 
Lee, 2017 South Korea From first symptoms 
to physician visit 
Physician visit to 
diagnosis 
1.9 (0.6 – 8.5)- 
median (IQR) 
1.9 (0.9 – 4.9) 
median (IQR) 
0.7 (0.1 – 4.6) 
median (IQR) 
0.2 (0.1 – 0.6) 
median (IQR) 
 
Vavricka, 2012 Switzerland Time from first 
symptoms to physician 
visit 
 
Time from physician visit 
to IBD diagnosis 
2 (0 – 6)- 
median (IQR) 
1 (0 – 4)- 
median (IQR) 
4 (0 – 18)- 
median (IQR) 
1 (0 – 5- 
median (IQR) 
Albert, 2007 Germany First complaints to first 
consultation 
First consultation of 
doctor to establishment 
of diagnosis 
2 (0 – 171)- 
median (range) 
 
8.6 (2.1)- 
mean (SD) 
 
 6 (0 – 207)- 
median (range) 
 
20.8 (38)- 
mean (SD) 
 
Table 3.3.9- Data for consultation and healthcare delay, from shortest consultation delay to longest 
Key: IBD; Inflammatory Bowel Disease, CD; Crohn’s Disease, UC; Ulcerative Colitis, IQR; Interquartile range, SD; Standard deviation 
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 Subgroup analysis 
3.3.4.1 Subgroup analysis- age and diagnostic delay 
There were three papers that explored diagnostic delay according to age at diagnosis, though only 
one reported median data. In all of these papers, an older age at symptom onset or diagnosis was 
linked to diagnostic delay. For instance, one study compared CD diagnosis after the age of 60 years 
old against individuals with a mean age of 27 years old at diagnosis and found that the median 
diagnostic delay for both cohorts was 16 and 5 months respectively (Foxworthy, & Wilson, 1985). 
 
3.3.4.2 Sub-group analysis- Western and Eastern Europe 
A prospective cohort study by Burisch et al. across European countries grouped into Western (n= 
14) or Eastern (n= 8) Europe found that diagnostic delay was longer in Western European 
countries. Of the Western countries, there was a total of 430 patients with CD and 668 with UC. 
There were 105 patients with CD and 145 with UC across the Eastern European countries. Median 
values for Western and European countries were 4.6 and 3.4 months respectively for CD and 2.5 
and 2.2 months for UC (Burisch, 2014). 
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 Systematic review discussion 
This systematic review examined the extent to which a diagnosis for IBD is, on average, delayed. 
This work found that overall diagnostic delay continues to be a substantial problem for patients 
with IBD, though the extent of this does vary between the two main subtypes of IBD, Crohn’s 
disease (CD) and Ulcerative Colitis (UC). Patients with UC are experiencing less delay in receiving 
their diagnosis than patients with CD, particularly as delays in UC diagnosis seem to have decreased 
over the last five decades, whereas this is less clear for CD. Additionally, patient-related 
(consultation) and clinician-related (healthcare) delay is similar in patients with UC. This is in 
contrast to CD, where delay predominantly occurs once the patient has entered the healthcare 
system. Following a sensitivity analysis, there was a difference in the spread of median delay, 
demonstrating that outliers appear to impact on the findings of the systematic review. 
 Following sensitivity analysis, the median delay in IBD diagnosis was found to range from 2 to 5.3 
months. For CD and UC, delay ranged from approximately 2 months to 2 years and 2 months to 1 
year respectively. Where articles had directly compared the delay between CD and UC, delay in CD 
was generally longer than UC delays. Systematic reviews have been conducted into the delay in 
diagnosis of many medical conditions, including gynaecological cancers, myeloma, giant cell 
arteritis and tuberculosis (Getnet, Demissie, Assefa, Mengistie, & Worku, 2017; Koshiaris et al., 
2018; Prior et al., 2017; Williams, Murchie, & Bond, 2019). Possible reasons for protracted delays in 
CD may include diagnostic uncertainty from varied presenting symptoms (Gallinger, Ungaro, 
Colombel, Sandler, & Chen, 2019). This could be because CD can affect any part of the GI tract 
whereas only the large bowel is affected in UC (Xavier & Podolsky, 2007). Similarly, the type of 
symptoms may contribute to diagnostic delays, as it could be assumed that symptoms like rectal 
bleeding would encourage someone to seek medical advice, a symptom which is more common in 
UC (Novacek et al., 2019). There is an increased incidence of EIM in CD, approximately 25% as 
opposed to 10-20% in UC, which could also delay diagnosis (Ephgrave, 2007; Magro et al., 2017; 
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Vavricka et al., 2015). Delays in diagnosis may be protracted in CD as overlapping symptoms may 
mean in some cases it is initially misdiagnosed as UC (Munkholm et al., 1992). 
The findings from the comparison of consultation and healthcare delay demonstrate that the 
identification of IBD is still problematic, particularly in CD where delays were longer following the 
patient entering the healthcare system. This could be due to many factors, including the absence of 
a gold-standard diagnostic test, focussing on the most likely diagnosis and inadequate education of 
the condition meaning that appropriate investigations are not requested. Consultation delays were 
mostly found to be between 0 to 2 months, which may have been due to vague symptoms or 
patient perseverance with symptoms before seeking medical help (Moore, Grime, Campbell, & 
Richardson, 2013). Systematic reviews of diagnostic delay of other medical conditions have also 
explored participant (consultation) and clinician-led (healthcare) factors for delay. For instance, a 
systematic review into the delays in diagnosis of myeloma also reported data on consultation and 
healthcare delays. Similar to the findings for CD, consultation delays were shorter to healthcare 
delays, with a median consultation delay of one month and median delay of 108 days following 
presentation (Koshiaris et al., 2018). The same pattern was also found in a systematic review on 
the delays in diagnosis of colorectal cancer, where median patient delay ranged from seven days to 
five months and practitioner delay from zero to fifteen months (Mitchell, Macdonald, Campbell, 
Weller, & Macleod, 2008). This systematic review exploring colorectal cancer also provided 
potential causative factors for patient and healthcare delays. Patient delays were linked with 
patient interpretation of symptoms, awareness of symptoms and knowledge about screening 
availability; and fear of cancer was seen to both delay and expedite presentation to healthcare 
services. Attributing symptoms to other medical conditions, negative test results and failure to 
examine the patient were examples of healthcare delays (Mitchell et al., 2008). Interviews with GPs 
in South Australia found that most were only seeing up to five patients with IBD per month and 
some GPs uncomfortable with IBD management (Tan, Holloway, Lange, & Andrews, 2012). The 
reduced exposure of GPs to IBD could explain the protracted healthcare delays. Possible factors 
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contributing to consultation and healthcare delays, from the participant’s perspectives, are 
explored further in the qualitative research presented in Chapter 4. Certain cognitive processes 
which may lead to diagnostic delay were discussed by twenty-five GPs in a qualitative study by 
Balla, Heneghan, Goyder and Thompson. The GPs interviewed proposed that diagnostic errors 
could occur when failing to consider red flags, ignoring the possibility of a serious disease with low 
probability and using a previous diagnosis to explain current symptoms  (Balla, Heneghan, Goyder, 
& Thompson, 2012). 
The overall diagnostic delay experienced by patients has remained relatively consistent over the 
last 48 years, implying that there are still limitations in the prompt diagnosis of IBD. The diagnosis 
of IBD is dependent on the assimilation of results from many investigations, like blood tests, faecal 
calprotectin, endoscopy and histology. Although the absence of a single, simple investigation to 
diagnose IBD is likely to make diagnosis more challenging, it would be logical to consider that 
recent advancements in diagnostics, particularly the introduction of the faecal calprotectin test, 
would have reduced the interval to IBD diagnosis. Raised faecal calprotectin levels indicate GI 
inflammation and is used to diagnose and monitor IBD. It is recommended by NICE (2013) that 
levels should support clinicians in diagnosing IBD and IBS. Therefore, any abnormal faecal 
calprotectin levels should prompt referral for a diagnosis of IBD and reduce diagnostic delays. 
However, this review is unlikely to have captured this because patient recruitment period for 
included articles ended in 2015, and as the faecal calprotectin test was introduced into the NHS in 
2013, it may not have been as commonly used (NICE, 2013). 
Studies providing diagnostic delay data ranged from ‘Westernised’ countries including Denmark, 
the UK, Italy and France as well as from less affluent countries such as Iran and India. There 
appeared to be no discernible differences in diagnostic delay between these countries despite 
disparate access to healthcare across these territories. Certain factors may have been linked with 
longer delays in developing countries, including reduced availability of medical equipment, for 
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example. However, similarities in delay data suggest this is not an issue. Even if there was a risk of 
abdominal tuberculosis impacting on diagnostic delay in endemic countries, similar delays were 
seen in non-endemic countries. The incidence of IBD is increasing in countries that were previously 
less affected (Ray, 2016; Thia et al., 2008), therefore there is a need to improve the diagnosis of 
IBD in such countries, but an attempt to reduce delay above and beyond that of westernised 
countries may not be pivotal.  
From the sub-group analysis, an older age at symptom onset could contribute to the delays of IBD 
diagnosis. Reasons for this are largely unclear, although certain abdominal pathology, such as 
diverticular disease, becomes more common with increasing age and may obscure the IBD 
diagnosis (Gisbert & Chaparro, 2014). Additionally diagnosis amongst older people may be more 
challenging as they are more likely to have other health co-morbidities and the presence of 
cognitive impairment can make obtaining a clear history difficult (van Duin, 2011). These prolonged 
delays suggest the need to improve the identification of IBD in the older population. In the UK, 
identification of IBD in older people may also be facilitated by the introduction of screening 
programs for colorectal cancer, which could uncover asymptomatic or mild IBD. Current NHS 
screening programs for colorectal cancer include a screening sigmoidoscopy at the age of 55 and 
faecal immunochemical testing (Gov.uk, 2017). This detects levels of human globin from 
haemaglobin in faeces, and has replaced the faecal occult blood test that detects haem, which is 
not as specific at identifying human blood in stool. Further research into the reasons for delays in 
IBD diagnosis in the older population is needed in order to identify improvements in detection. 
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 Strengths and limitations 
This systematic review has successfully condensed and appraised the data from multiple articles 
within a single paper, providing the reader with a comprehensive overview of the diagnostic delays 
in IBD reported within the literature.  
As discussed previously, there is a risk of bias when conducting a systematic review, therefore a 
comprehensive protocol was devised and followed before the systematic review was commenced. 
This protocol was also registered with PROSPERO, to ensure that the method for the review was 
followed and that duplication of the review by other researchers did not occur.  
The use of the PICOS framework for inclusion and exclusion criteria ensured that sufficient 
consideration of all aspects of these criteria, from a population and study design level, were clear 
enough to all reviewers. This reduced the risk of bias which may be introduced if reviewers have to 
rely on their previous knowledge of the subject matter if the criteria is ambiguous. Every effort was 
made to ensure the inclusion of foreign language articles, as they were only excluded in the 
absence of a translator to conduct the review and extraction. This is in contrast to other systematic 
reviews where foreign articles are excluded without attempts at translation (Davis et al., 2015; 
Rispo et al., 2018). 
Another strength of this systematic review is the choice of databases used to source articles. A 
wide geographical area was covered by selecting an American- and European-based database. 
Similarly, research from a wide range of specialties was ensured, as MEDLINE provides life sciences 
and biomedical literature, EMBASE offers pharmacological literature and CINAHL contains 
literature about nursing and allied health professionals. 
The volume of literature found from the search is a key strength. Amongst the thirty-five articles 
included, there were a total of 14,524 participants. In addition, these studies were conducted 
across a broad geographical area and based in many healthcare settings, largely secondary and 
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tertiary care. As such, the findings of this systematic review are relevant across many countries 
with differing healthcare settings. 
One key limitation of the systematic review was the exclusion of paediatric literature. Whilst the 
decision was justified due to time constraints in which to complete the research, IBD is a condition 
that is common in children and it would be important to explore delays in diagnosis of paediatric 
IBD. 
Another limitation is the process by which titles were reviewed. Due to time constraints, both 
reviewers (EC and JP) reviewed 50% or the articles by title, which could have led to the accidental 
exclusion of relevant titles due to human error. The likelihood of this happening from the abstract 
review stage was reduced, as second reviews were conducted for both abstract and full-text 
screening. 
Although there are similarities between the NOS adaptations for cohort and cross-sectional 
studies, as they identically assess the representativeness of the sample compared with the target 
population and both provide evidence of assessing the ascertainment of exposure, there are 
differences in the scoring systems. For instance, the items used to assess outcome contains 
identical statements, however the number of stars awarded varies, as in the cohort NOS 
independent blind assessment or record linkage are awarded one star each and self-report is not 
awarded stars. In the cross-sectional NOS, blind assessment and record linkage are awarded two 
stars each and self-report is awarded one star. The variation between the NOS scale for cohort and 
cross-sectional studies reduces comparability of quality between the two study designs.  
 
 Conclusion 
The findings of this systematic review demonstrate that the diagnostic delay of IBD remains an 
important issue to rectify, particularly as reductions in diagnostic delay were only seen in UC. As 
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demonstrated in the findings for consultation and healthcare delay, improvements must be made 
in the identification of IBD, particularly amongst healthcare professionals.  
 
 Chapter summary 
Alongside the completion of this systematic review, interviews were conducted with patients who 
have experienced delays in IBD diagnosis may be able to shed light on where problems in the 
diagnostic pathway of IBD lie. A convergent mixed method design is demonstrated by the 
combination of findings from both the systematic review and qualitative research, which are 
presented together in Chapter 6. 
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4 Reasons for Diagnostic Delay in Inflammatory Bowel Disease- 
Qualitative Research 
 
A qualitative approach was adopted to answer the specific research objective outlined in Chapter 
1, section 1.3, which was to explore possible reasons for, and consequences of, diagnostic delay, 
from the perspective of individuals who have experienced a delay in Inflammatory Bowel Disease 
(IBD) diagnosis. Qualitative methods have previously been used to explore the reasons for 
diagnostic delay in other conditions. For example, semi-structured interviews were conducted by 
Liddle et al. (2015) with UK participants following their experiences of gout from symptom onset to 
diagnosis. Confusion over symptoms, self-diagnosis or self-medication were cited by participants as 
being patient-level factors contributing to delay, whereas atypical presentation of gout and female 
gender were perceived healthcare factors for delay. Using similar methods to explore the 
experiences of individuals with IBD may lead to the identification of common contributing factors 
for delay in diagnosis across different conditions, as well as factors that are specific to IBD; and will 
also allow for investigation of the perceived impact of diagnostic delay on the clinical course of IBD. 
 
 An overview of the qualitative research conducted in this thesis 
Qualitative research is generally concerned with formulating an in-depth understanding of a topic 
across a variety of dimensions. This research aimed to obtain accounts from patients about their 
opinions towards their delayed diagnosis, so adopting a qualitative approach enabled an 
understanding of how participants process and interpret their experiences, as well as 
demonstrating how personal circumstances can impact on these experiences. In particular, the use 
of semi-structured telephone interviews in this study allowed for flexibility so that the participant 
could set the agenda and expand on areas within their experience deemed significant or important 
to them (Almeida, Faria, & Queirós, 2017). This has been outlined in further detail in section 4.6. 
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Where the systematic review presented in the last chapter gave a benchmark value of diagnostic 
delay, establishing that delays in IBD are a pertinent issue, the qualitative study builds upon this 
and provides further context, through identifying possible causative factors and consequences of 
delay. As described in Chapter 1, section 1.4, a pragmatic methodological approach was adopted as 
the choice of research methods were selected based upon fulfilling the aims of the research 
(Brierley, 2017). 
 
 Participant recruitment 
Ethical approval for the qualitative research was granted by Keele University’s Research Ethics 
Committee (ERP 2402).  
 
 Sampling framework 
To ensure the most suitable participants were selected for the qualitative study, the following 
inclusion and exclusion criteria were applied (Table 4.2.1). In order to sample from an appropriate 
population, the inclusion threshold of delay of three months was decided. This would ensure 
inclusion of people with a comparatively small delay and reduce the risk of bias by only selecting 
people who had protracted delays, as such individuals may have a worse disease course. This 
decision was influenced by a study in which the median delay of diagnosis for IBD was three 
months (Cantoro et al., 2017). As the systematic review pertained to adult diagnostic delay, 
participants of 18 years or older were invited to participate to ensure comparability of the 
systematic review and qualitative research findings. 
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Table 4.2.1- Inclusion and exclusion criteria for participant selection 
Inclusion Criteria Exclusion Criteria 
 Over 18 years old 
 Diagnosis of IBD, specifically CD 
or UC 
 Can communicate in English 
 Diagnostic delay of more than 3 
months 
 NHS treatment (previously or 
ongoing) 
 Younger than 18 years old 
 Diagnosis of indeterminate colitis 
 Unable to communicate in 
English 
 Diagnosis within 3 months 
 Have not received 
previous/current treatment from 
the NHS 
 
 
 Sampling and recruitment 
Recruitment took place between 31st October 2018 and 23rd January 2019 by posting on social 
media and advertising the study at an event hosted by Crohn’s and Colitis UK (C&CUK) in the 
Midlands, UK. C&CUK are a nationwide charity supporting people with IBD (Crohn’s and Colitis UK). 
There are branches across the UK that organise events to increase awareness and support those 
living with IBD. The C&CUK website provides information about IBD for the general population and 
healthcare professionals, avenues of support, advertising research and fundraising. 
 A poster was created which contained an overview of the study and contact details for the 
research team, which was used to recruit through social media (Appendix 6).  
 
 The use of convenience sampling 
Convenience sampling involves recruiting participants into a study based on accessibility or 
proximity to the research (Etikan, Musa, & Alkassim, 2016). Eligible individuals that responded to 
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the study advertisements and subsequently agreed to take part in an interview were recruited. The 
decision to adopt this sampling method focused around time constraints in which to complete the 
research. It is important to acknowledge that the nature of convenience sampling means it is more 
difficult to control the characteristics of the participants who volunteer for the study (Smith & 
Noble, 2014). Although eligibility for the study was ensured by distributing the inclusion and 
exclusion criteria to participants, the extent of their delay was not disclosed before the interviews 
were conducted, meaning that there was a risk of a reduced range of delay from the sampled 
participants. Similarly, participant demographics including age and gender were unable to be 
controlled for, besides confirming that the participant was over 18 years old and eligible to 
participate in the study. 
 
 Avenues of recruitment 
The decision to recruit through social media was made as it allowed access to a large, 
geographically dispersed population from which to recruit participants. With increasing popularity 
of social media, it is considered an effective means of recruitment to research (Frandsen, Walters, 
& Ferguson, 2014; Gelinas et al., 2017; Yuan, Bare, Johnson, & Saberi, 2014). Social media can be 
an avenue of support to people with a multitude of health and social issues (Patel, Chang, Greysen, 
& Chopra, 2015) including IBD, therefore this is a useful method to access individuals who engage 
in online support groups, and who may be willing to participate in research. In addition, the study 
was advertised on the Crohn’s and Colitis UK (C&CUK) website, in the ‘take part in research’ 
section. 
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4.3.2.1 Twitter 
A Twitter account (@IBDresearchKLE) was created to produce public tweets advertising the study 
using the poster described in section 4.3 (Appendix 6). From 31st October to 21st December 2018, 
12 tweets advertising the study were posted, which were retweeted 62 times and ‘liked’ 54 times. 
‘Retweeting’ these tweets was encouraged so my posts could extend information of this study into 
social media user feeds. I also used ‘hashtags’ within recruitment tweets, which act as a label and 
group them with other tweets bearing the same hashtag, again potentially allowing access to a 
wider audience (Shapp, 2014). Examples of hashtags used in advertising tweets included #IBD, 
#crohnsdisease and #ulcerativecolitis. 
 
4.3.2.2 Facebook 
I also recruited participants by uploading a status advertising the study to my personal Facebook 
account. This post was shared by 26 Facebook users allowing their Facebook contacts to see this 
status. A Facebook group run by Keele University for students was also utilised as a platform for 
recruitment, with one post uploaded to this group which could be viewed by all members. 
 
4.3.2.3 Crohn’s and Colitis UK  
On 25th November 2018, I advertised the research to guests attending an event hosted by the 
North Midlands branch of the national charity C&CUK. The existing knowledge of delays in 
diagnosis, as well some literature discussing the impact of this delayed diagnosis, was presented. 
Despite the small geographical scope, individuals were recruited who may not have been accessible 
through social media. The study was also advertised on the C&CUK website. C&CUK are nationally 
recognised in so the support from this charity was invaluable in giving credibility to the research. I 
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provided an email address and telephone number to ensure I could be contacted directly. The 
website address was also added to tweets sent from @IBDresearchKLE to allow people to find out 
more about the study.  
 
 Participant correspondence 
After they had made initial contact expressing interest in the study, the contact details of potential 
participants were obtained depending on the individual’s preferred means of contact. All of those 
who expressed an initial interest in participating in the study agreed to be contacted by email. 
Prospective participants were contacted using a generic email that outlined the study aims and the 
inclusion criteria for the study. A participant cover letter, information sheet and consent form 
(Appendix 7 to Appendix 9) were attached to this email and those who met the inclusion criteria 
were asked to read these documents and complete the consent form. If the participant did not 
fulfil the criteria outlined in the email, they were thanked for their interest but informed that they 
would not be included in the study. 
The participant information sheet provided a further overview of the study, how participant data 
would be used, the potential risks and benefits of taking part and steps participants can take if they 
choose to withdraw from the research. Eligible participants were asked to return the completed 
consent form either by email or post. Upon receipt of the consent form, the participant was 
contacted by email or telephone to arrange a convenient date and time to conduct the telephone 
interview and asked to provide a contact number. 
 
 The interview process 
Interviews were conducted between the 5th December 2018 and the 7th February 2019. 
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 Topic guide 
A topic guide was developed based on the research aims and existing literature (Kallio, Pietilä, 
Johnson, & Kangasniemi, 2016). This guide was used as an aide memoire to steer the interview 
proceedings. I decided against restricting myself to following the guide rigidly as I wanted to 
maintain an inductive approach through the data collection and this may have provided too much 
structure for my semi-structured interviews. 
The topic guide was split into six sections to explore different aspects the participant’s experience 
of diagnostic delay (Appendix 10). The topic guide was iteratively revised throughout the interview 
process based on emergent findings. For instance, in an early interview one participant explicitly 
talked about their emotional reaction to delayed diagnosis, and this was something I explored 
further in subsequent interviews. On the other hand, asking participants about the time taken to 
get a GP appointment was removed from the topic guide as for some individuals their diagnosis 
was many years ago and they could not recall this information accurately. Whilst reference to 
participant and healthcare factors for delay was initially included in the topic guide, I decided to 
expand on this, by asking specifically about GP and hospital delays, as a result of the preliminary 
analysis of literature included in the systematic review that has previously explored this concept. 
 
 Telephone interviews 
I chose to use telephone interviews as they are an established means of collecting qualitative data 
and allowed for the inclusion of people with IBD across a broader geographical area within the UK, 
within a shorter time period (Novick, 2008).  
Prior to conducting the interviews, I was mindful of the challenges that can arise when building 
rapport during telephone conversations. I was aware that I would be asking participants about 
possibly sensitive or personal issues, therefore I wanted to put them at ease so they would be 
 98 
 
comfortable discussing this information. I decided to have a brief conversation with the participant 
before commencing the interview, as opposed to beginning the interview questioning 
straightaway. All participants were open and willing to share their accounts therefore the 
telephone was not a barrier to the interview process.  
Each interview was recorded on an Olympus WS-6505 recorder to ensure clear sound quality for 
transcription.  
 
 An outline of the interviews 
 
When the participant answered the phone, I confirmed my identity and checked that they were 
available for the interview. I decided to present myself as a researcher who had taken a year away 
from my medical studies to participants. I questioned whether knowing I was a medical student 
from the start would influence how they answered my questions, as they may assume I am 
knowledgeable in IBD. I wanted participants to fully explain their accounts and not allow my 
knowledge of the subject influence their responses. 
Participants were then asked to confirm their consent to be involved in the study and I checked 
that they were happy for the interview to be recorded. Though this information was included in the 
participant information sheet, I decided that each participant should reaffirm consent before the 
interview began. For one participant who requested to provide consent over the phone, the 
consent form was read out and they then gave me permission to complete and countersign the 
form. As this participant was unable provide signed consent, this conversation was audio-recorded. 
I aimed to achieve an understanding of the participants’ overall journey to diagnosis including 
impact of a delayed diagnosis and factors they thought could have contributed to their delay. 
Where I sensed that participants were not forthcoming in providing information, such as when they 
expressed concern that their responses were not relevant to the research, I would use open 
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questioning to encourage participants to consider their responses, including “can you tell me a little 
bit more about...” and “how else do you think…”. I wanted to empower the individual to discuss 
matters deemed important to them and dissolve any perceived power-imbalance they may feel 
exists in this researcher-participant interaction. I also did this by reiterating my gratitude to the 
participant for their involvement in the study and that their help in this research would improve 
understanding of diagnostic delays in IBD. This demonstrated to the participant my desire to 
include them as a collaborator in the research (Mishler, 1986). 
The interview concluded with a brief summary of the conversation to allow any final questions or 
areas of discussion to be raised by the participant or myself. Again, consent to participate in the 
research was checked. The participant was thanked for their contribution to the study and asked if 
they would like to receive a summary of research findings at the end of the study. All participants 
expressed an interest in receiving information regarding the research outcomes. 
 
 Note-taking 
Brief notes were taken during the interviews as a reminder of interesting points to discuss further. I 
felt that taking short notes enhanced the semi-structured nature of the interviews as it reminded 
me to return to points that the participant deemed significant. For this reason, it was advantageous 
that interviews were conducted over the phone rather than in face-to-face interviews, as I was 
concerned participants may feel uncomfortable if they were watching me take notes. Participants 
were told that I would be taking short notes during the interview to signpost the interview, which 
they consented to and note-taking was done concisely and unobtrusively during the interview. 
These notes, which were only single words or short phrases used as cues to guide conversation, 
were subsequently destroyed as I felt they would not contribute to the analysis phase as all 
relevant information was included within the transcripts.  
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 Data storage 
Achieving a balance between protecting participant anonymity whilst simultaneously maintaining 
the richness of the data for analysis can be complex and it is important to acknowledge that 
anonymity cannot always be guaranteed when managing interview data, however steps were 
taken reduced this risk (Saunders, Kitzinger, & Kitzinger, 2014). All documents containing 
participant information were stored on a secure drive that only the research team could access. 
Paper copies of consent forms were printed and stored in a locked drawer. Once each interview 
was completed, the recording was uploaded to this drive. Each participant was assigned a number, 
all identifiable information such as names of clinicians and hospitals was removed from the 
transcripts and participants’ real names were replaced with pseudonyms.  
 
 Interview transcription 
I transcribed six interviews in full, which was an important learning opportunity and also allowed 
for full immersion into the data, which is discussed below. Due to limited time in which to 
complete the research, the remaining 10 recordings were transcribed using a transcription 
company with a confidentiality agreement in place (The Transcription Company). Whilst all 
interview content was transcribed, extra-linguistic features such as pauses, ‘erm’ et cetera, were 
omitted as they were not considered pertinent to the data analysis. 
 
 Data saturation 
Data collection ceased when data saturation was perceived to have been achieved. I adopted an 
inductive definition to saturation, where data collection was stopped when novel codes were no 
longer arising from the data during analysis (Saunders et al., 2018; Urquhart, 2012). Assessing 
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saturation from the coding stage was possible as data collection and data analysis occurred in 
parallel. 
 
 Data analysis 
Data were analysed using thematic analysis. Thematic analysis is a method for identifying, 
analysing, and reporting patterns (themes) within data (Braun & Clarke, 2006). The decision to use 
thematic analysis was based on the advantages of flexibility when creating and assimilating codes. 
Thematic analysis also allows the ability to draw comparisons of key concepts arising across the 
data and between participant experiences (Braun & Clarke, 2006). I believed that developing broad 
themes that combined key findings from accounts from multiple participants provided a stronger 
insight into patient experiences of delay rather than focusing just on individual accounts without 
drawing connections between these. 
The thematic analysis was guided by an approach outlined by Braun and Clarke. This approach 
provides the freedom and flexibility to comprehensively analyse participant data as a collective, 
whilst providing the structure to ensure that a thorough analysis of the data was completed (Braun 
& Clarke, 2006). This structure includes guidance on data immersion as well as creating and 
reviewing codes and themes, which comprise the following sub-headings under which further 
detail on the analysis is provided. Data collection and analysis were concurrent to allow for 
reflection and refinement of the interview process as a result of the analysis. 
The constant comparative method was adopted when developing codes and assimilating them into 
themes, which involves evaluating the current coded extract with extracts that have been 
attributed the same code. This allows the identification and development of certain features or 
properties within extracts that make up certain codes, allowing the ability to later form themes 
(Glaser, Strauss, & Strutzel, 1968).  
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 Data Immersion 
The first step of thematic analysis involves immersing oneself within the data to increase 
awareness of content. This was done during the transcription process and by close reading and re-
reading of transcripts before coding. This was particularly significant with the transcripts produced 
by the transcription company, where data immersion occurred alongside quality controlling the 
returned transcripts by comparing them to the audio recording as well as anonymising and refining 
transcripts by removing any extra-linguistic features, as described previously. As acknowledged by 
Braun and Clarke, data immersion is a time-consuming and arduous process but it is invaluable to 
be familiar with the data (Braun & Clarke, 2006).  
The main reason I felt this step was so important was that I was reminded of certain discussions 
from interviews which was useful when time had lapsed since the interview. By refreshing my 
memory of the interview, when the time came to code the data I was able to navigate through 
transcripts efficiently. In addition, I was also able to reflect on my performance as the interviewer 
during this process and identifying weaknesses in my interview technique, such as asking multiple 
questions at once or moving away from a topic without exploring it in more depth. I was therefore 
able to refine my technique for future interviews. 
 
 Initial coding 
Following data immersion, coding allows meaning to be assigned to key sections of the data 
depending on the interpretation of the analyst. In this analysis, an inductive or data-driven 
approach was used to coding, where codes are constructed based on the presented data and not 
selected from a previously assembled list of codes. This demonstrates a grounded approach, where 
efforts have been made to prevent the analysis of data being influenced by pre-existing ideas or 
opinions (Glaser and Strauss, 1967). As proposed by Boyatzis, deductive coding is based on 
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assumptions that certain principles can be applied to any phenomenon, which moves the 
researcher away from data-driven coding (Boyatzis, 1998). I was concerned about the risk of being 
led by pre-selected codes instead of the content of the data. When adopting an inductive 
approach, I initially coded the data on a line-by-line basis to ensure that I did not omit any valuable 
data. I made a concerted effort to ensure I adopted this inductive approach and not allow my prior 
understanding of IBD or healthcare to influence my coding, which is commonly known as 
‘bracketing’ one’s own knowledge and assumptions. In practice, interpreting the data without 
applying my prior knowledge of the subject matter was sometimes challenging and I have explored 
this further in section 4.11. The qualitative management software used to complete this step of the 
analysis was Nvivo 12 (version 12.2.0, QSR international). I decided to code the data using Nvivo 12 
as there is increased flexibility to change or delete codes. When electronically coding, groups of 
extracts from different interviews with the same code can be viewed simultaneously, allowing me 
to quickly see the relevant data for a certain code. 
 
 Creating themes 
As described by Braun and Clarke, the creation of themes involves looking at the data in a broader 
sense through analysing each code and combining them based on common meanings (Braun & 
Clarke, 2006). 
As the coding process progressed, I felt that there were key categories that were developing, which 
were grouped with other categories to eventually form the over-arching themes. My method of 
generating themes was guided by the constant comparison method, which was previously 
described (Glaser and Strauss, 1968). If the groups of codes within themes were more clearly 
connected, these were collated into sub-themes. 
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 Reviewing themes 
There are two levels of review that form this part of the analysis, including reviewing the data by 
codes and then by themes. Reviewing at code-level involves checking whether the interview 
extracts correspond to the assigned code, whereas reviewing at theme-level analyses whether the 
themes reflect the broader meanings of the data set (Braun & Clarke, 2006). This may involve 
refining, merging or excluding the initial themes. 
I used Nvivo 12 to review the quality of the coded information as there is a feature which highlights 
extracts based on their code. I reviewed all transcripts to confirm that my interpretations were 
sufficiently grounded in the data. The quality of my themes was reviewed through the generation 
of mind maps (Appendix 11). Using mind maps allowed me to identify emerging themes and any 
connections between these, which was recommended by Braun and Clarke (2006) and utilised by 
Lynass, Pykhtina and Cooper (2012) within their research. Emerging themes that I perceived to be 
strongly related were combined to create the overarching themes presented in the results. 
 
 Ethical considerations 
Confidentiality and anonymity was ensured by privately corresponding with participants, using 
email or private message on Twitter, for example. I ensured that all telephone interviews were 
conducted in a private room where conversations could not be overheard. Personal details of the 
participants were stored on a password-protected laptop and the audio files were uploaded to a 
secure drive and were deleted after being transcribed. The data collected from the interviews was 
anonymised by omitting locations from transcripts and pseudonyms were used when presenting 
the findings during data immersion, outlined in section 4.8.1.  
It was important to have arrangements in place if participants became distressed or upset. 
Although the risk to participant mental wellbeing was considered low, a protocol was in place if 
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needed. Following advice from the university ethics committee, I included contact information that 
participants could use to access support if necessary, i.e. their GP and NHS 111, or by contacting 
myself for further guidance. Suitable avenues included the Crohn’s and Colitis UK charity or 
Samaritans. After the interview, participants were signposted to this information in case they felt 
distressed after the interview. In the event that a participant became emotional during the 
interview, I planned to pause or terminate the interview, offer verbal support and direct them to 
appropriate assistance. 
 
 Reflexivity 
An important aspect of the research process is the researcher’s awareness of how they influence 
and transform the research. According to Finlay, this influence is not a negative event, rather it is a 
by-product of the researcher’s interaction with the research, though it should be acknowledged 
and described where possible to allow the reader to view the data through the eyes of the 
researcher (Finlay, 2002). 
When regarding my own reflexivity, I believe that my role in healthcare is important to discuss. For 
instance, the role of a training doctor is to identify the disease from the presenting symptoms, 
therefore I was concerned I would view the patient from a biomedical perspective without fully 
exploring their thoughts and feelings. When interviewing, I found this was not an issue as the semi-
structured interviews were flexible and void of time constraints, which is very different to the 
common time-pressured scenario in clinical medicine that I have had to adapt to. 
I was aware that I may influence the collection of data through my experiences as a medical 
student as I may have tried to justify the actions of the GPs and specialists discussed in the 
interviews as opposed to appreciating and accepting what the participant has described, 
particularly where negative experiences of healthcare were described. This was because of my 
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appreciation of certain pathways and thought processes that occur behind the scenes in clinical 
practice that the patient may be unaware of. However, my clinical experience as a student has also 
taught me that clinicians may not always acknowledge the perspective of the patient, and as these 
interviews focused on the patient experience of delay, therefore I avoided making assumptions. In 
practice, adopting an inductive approach to data collection and analysis can be difficult, particularly 
with my knowledge of IBD and experience of healthcare, therefore I challenged any assumptions I 
made during this process and focussed on the experience of the patient as opposed to my own 
opinions. 
Primarily identifying myself to participants as a researcher as opposed to a medical student proved 
to be a more effective approach. I had considered the participants’ expectations of my knowledge 
and also that my position as a student may influence their interaction with myself. For instance, 
they may assume that I am more focused on their medical history as opposed to their viewpoints 
and opinions and as many participants described feeling that their doctor did not want to spend 
the time discussing their symptoms, I did not want this to project onto our interview. However, I 
felt that I asked many open questions and focused on participant thoughts and opinions besides 
their medical history, therefore for participants that were aware of my medical background, this 
was not an issue. 
 
 Chapter summary 
A semi-structured approach to interviewing was utilised to gain insight into participants’ 
experiences of diagnostic delay in IBD. Participants were recruited through social media and a local 
IBD charity event in order to maintain voluntary involvement in the study. Thematic analysis was 
used to analyse the data, which involved the generation of codes that were aggregated into 
overriding themes. The following chapter outlines the findings of this research. 
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5 Qualitative Findings 
This chapter outlines the findings from the patient interviews. As discussed in Chapter 4, the data 
were analysed using thematic analysis. Three key themes, and sub-themes, were developed from 
the analysis which are labelled as such: 
1) Misdiagnoses 
2) Contributors to Delay 
- Participant factors for delay 
- Primary care factors for delay 
- Systemic factors for delay 
3) Consequences of Delay  
In what follows, the characteristics of the participant sample will first be outlined, before reporting 
on the findings in relation to each of these three key themes, in turn.  
 
 Participant Demographics 
Sixteen participants were interviewed, out of twenty-seven individuals who expressed interested in 
partaking in the study. Of those who did not participate, most failed to return a signed consent 
form, whilst three made contact after saturation had been reached. Six participants (38%) were 
recruited from the Crohn’s and Colitis UK (C&CUK) event, six (38%) were recruited from Twitter and 
four (25%) from Facebook, with one of these individuals (6%) being recruited from the Keele 
University Facebook post. Ten females were interviewed (63%). The mean age of participants was 
41 years old with a range of 20 to 65 years. The mean age of symptom onset as cited by 
participants was 20 years old, ranging from early childhood to 50 years old. Mean age at diagnosis 
of Inflammatory Bowel Disease (IBD) was 29 years, range 15-60 years. Median diagnostic delay was 
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six years. Four participants were diagnosed with Ulcerative Colitis (UC), 11 with Crohn’s Disease 
(CD) and one female participant described being diagnosed with both UC of the large bowel and CD 
of the small bowel. Further information about the participants can be found in Table 5.1.1. 
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Pseudonym Gender IBD Phenotype Occupation Age Symptoms 
Began 
Age at Diagnosis Diagnostic 
Delay 
Current Age 
Helen Female UC Healthcare 40 40 <1 year 53 
Joanne Female UC Healthcare 16 30 14 years 34 
Derrick Male UC Professor 8 10 2 years 62 
Josie Female UC Student 12 16 4 years 18 
Charlotte Female UC and CD Student 14 15 1 year 28 
Darren Male CD Student 9 17 8 years 25 
Jess Female CD Unemployed 16 23 17 years 38 
Sandra Female CD Retired 50 60 10 years 65 
Brian Male CD Retired Early childhood 50 50 years 57 
Pamela Female CD Teacher 25 26 1 year 45 
Alicia Female CD Office Work 16 19 3 years 22 
Emily Female CD Office Work 10 18 8 years 20 
Callum Male CD Healthcare 19 20 1 year 23 
Lauren Female CD Unemployed 16 42 26 years 45 
Simon Male CD Retired 36 47 11 years 65 
John Male CD Retired 29 31 2 years 56 
Table 5.1.1- Demographic information of the participants included in the study 
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 Misdiagnoses 
This theme refers to participants’ accounts of the incorrect diagnoses given to them before being 
diagnosed with IBD. Also included in this theme is an overview of the presenting symptoms that 
the participants initially recalled seeking medical advice for. A common feature amongst some 
participants’ diagnostic journeys was initially being diagnosed with gastroenteritis when they 
presented with recent-onset symptoms, but later being diagnosed with IBS when the same 
symptoms persisted. This is discussed below. 
Irritable Bowel Syndrome (IBS) was cited as a misdiagnosis amongst eight participants. As discussed 
in Chapter 2, IBS is a common functional disorder of the GI tract. Symptoms include a change in 
bowel habit and abdominal pain, which can be managed with changes in diet and antispasmodics. 
(Weaver et al., 2017). IBS is not considered as serious as IBD, though symptoms may still 
significantly impact on an individual’s life. 
Participants reported that symptoms of diarrhoea, nausea and abdominal pain were often 
attributed to gastroenteritis and later IBS by their GP. Some described not having any 
investigations performed before receiving this diagnosis: 
 I went to my GP at the time, I’m not there now [i.e. no longer registered at the same GP 
practice], and they just said ‘ooh you’ve got a tummy bug’ first of all and when it didn’t clear 
up, ‘it’s probably IBS’. You know slightly different things but not sending me for any 
exploratory tests or anything. So just sort of saying ‘it’s probably this, it’s probably that’ and 
not really giving me any answers; so that was the initial thing.   [Jess, 38, CD] 
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Participants recalled their GP diagnosing them with IBS due to stressors in their lives, particularly 
occupational. John recalled how his reports of experiencing stress at work seemed to influence his 
GP’s diagnosis: 
EC- So do you mind starting off from 29 [i.e. the age of symptom onset]. What symptoms you 
were getting at the time? 
John- Yeah, so diarrhoea, very frequent diarrhoea, probably, trying to think back, some blood 
in the poo as well, mucus and also general feelings of fatigue, absolutely shattered most of 
the time, so initially the word IBS was mentioned as I had quite a stressful job but symptoms 
kept getting worse       [John, 56- CD] 
 
A small number of participants remembered being investigated for their symptoms upon 
presentation, however normal results appeared to confirm a diagnosis of IBS to their GPs. Helen 
recalled her GP repeatedly sending stool samples for analysis which all came back normal. She later 
discussed how she felt that her GP thought she would keep presenting which is why he decided to 
test her stool, suggesting that he did not take her symptoms seriously: 
Well it was 13 years ago I was 40 when I was diagnosed and I'd gone through an awful lot of 
stress and I lost a lot of weight through stress I think and I started with what I thought was a 
bit of a bug or a virus. It started with nothing major, no major issues, but there was a lot of 
bloating and then it started to get like cramping in my stomach and diarrhoea a lot and I lost 
more weight so I went to the doctors and eventually after about 3-4 visits to the doctor 
saying 'look I'm no better' he started to send stool samples away, and every stool sample he 
sent away came back clear. So he said “I don’t really know what we can do it’s just IBS you're 
just going through a period of stress” … I don't think he did really [interpret her symptoms], 
he just said if it’s something you've eaten or a bug it'll go, you know, he initially thought I 
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wasn't gonna go away … but all he was giving me then was loperamide [anti-diarrhoeal 
medication] which did nothing and he thought it was just IBS through stress really.  
          [Helen, 53- UC]                                        
 
Some participants described being diagnosed with IBS for a long period of time, often years, 
despite ongoing severe symptoms. Joanne demonstrated an earlier acceptance towards her 
diagnosis of IBS, implying that she thought at the time it was a plausible explanation for her 
ongoing symptoms: 
“Then I was told it was IBS, so I lived my life without having any actual other tests believing I 
had IBS for a very, very long time until about four or five years ago, I just became quite 
unwell”         [Joanne, 34- UC] 
 
Perceived flaws in the diagnostic pathways used with patients presenting with gastroenterological 
symptoms was discussed. John argued that the diagnosis of IBS could be an easy explanation on 
the part of GPs for patients’ symptoms. In addition to missing an IBD diagnosis, he describes a 
similar concern of cancer being misdiagnosed as IBS: 
“Yes well all GPs have a pathway don't they? And because a number of things along the lines 
of IBD can be nicely sort of glossed over as being IBS to start with, probably many people are 
palmed off with that and I know, I do a lot of volunteering for Bowel Cancer UK, I do a lot of 
speaking for them and you know the number of people you speak to you who were told they 
had IBS when they actually had bowel cancer you know, so statistically it’s probably not a 
huge number but it seems to be quite significant. IBS covers thousands of sins and yeah it’s 
IBS, but in others its masking you know something more serious so it’s, quite whether there is 
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a diagnostic tool for GPs to perhaps refer sooner rather than later I don't know…”    
          [John, 56- CD] 
John suggests that the reliance by GPs on IBS as almost being a blanket diagnosis for generic 
gastroenterological symptoms, could be a barrier to diagnosing “something more serious”, as in his 
view, GPs are discouraged from investigating the patient any further. 
 
A diagnosis of haemorrhoids was initially given to two participants. In Sandra’s case, she felt like 
this diagnosis was acceptable as she presented with rectal bleeding: 
Sandra- It actually started I think 10 years previously when I was about 50, I got a very tiny 
amount of blood each morning when I went to the toilet and then, I mean it takes a while to 
go to the GP, but anyway… I went to the GP and she examined me and she said 'I can't find 
anything, so it’s probably haemorrhoids, use some cream. I used some cream and it didn't 
have any effect really at all. Sometimes I was ok sometimes I wasn't … 
EC- Did you think at that point there was something else going on or did you think that was 
the correct diagnosis? 
Sandra- No, originally I just accepted it.     [Sandra, 65- CD] 
 
In addition to stress-related IBS, other mental health conditions were cited by participants as 
misdiagnoses they had received before their IBD diagnosis. As discussed above in relation to IBS, 
receiving normal tests results seemed to reassure the GP that there was no physical cause to the 
symptoms, further reinforcing their original diagnosis. Brian recalled being diagnosed with viral or 
stress-related illnesses before his formal diagnosis of severe depression:  
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Brian- They'd say to me 'your bloods are normal, it must be psychological, or you've got a 
virus, here are some antibiotics'. And all this time my body was readjusting 
EC- So did they, so you mentioned then 'oh its viral or an infection' 
 Brian- Yes, prone to viruses … It was the waking up and going to the toilet and I'd say 'so tell 
me why I keep going to the toilet then?', 'well you know because you're maybe getting 
stressed and it’s coming out on you that way'. There was all sorts… [Brian, 57- CD] 
 
Brian reported that his symptoms continued until he was eventually admitted to a psychiatric 
hospital for ‘severe depression’ due to extreme fatigue, which in hindsight he felt was a 
consequence of his undiagnosed CD. However, he reported that at one stage, he did believe that 
his symptoms may have had psychological causes: 
Brian- I saw a consultant, this particular day, she sat there as well and she, it was a 
conference thing, meetings whatever, and he was asking me to lift my arms up and I had 
such a job and she said 'he really has got severe depression'  
… 
EC- Did you at the time feel like you had mental health problems that they were diagnosing 
you with? 
Brian- No, what I mean is, I was convinced in the end that I had [got mental health problems] 
because I thought it must be then that I've got something like my mum's got… I think it was 
Crohn's Org that [later] told me it is quite common that these things have happened to 
people [prior to their IBD diagnosis], you know to be put in a mental institution.  
          [Brian, 57- CD] 
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Derrick, who was diagnosed with IBD at the age of ten, recalled originally being described as a 
“nervous child”, though he attributed this behaviour to the distress at the possibility of 
experiencing incontinence at school due to his IBD: 
I was a very nervous child, which is a continual bugbear when people say that I'm sure 
you're familiar with it. You're nervous because you're running to the toilet, you know 
desperately not trying to go to the loo in front of everybody. Especially when you're at prep 
school and you're wearing shorts, it makes my skin crawl thinking about it actually, but 
that’s why you're nervous. So they were thinking that it was my nerves that was causing the 
diarrhoea, do you see?       [Derrick, 62-UC] 
 
One participant recalled how her pre-existing mental health conditions seemed to influence 
doctors into attributing her gastrointestinal symptoms to psychological factors rather than to IBD. 
Whilst she was initially told that her GI symptoms were stress-related, the weight loss she 
subsequently experienced led to her being misdiagnosed with an eating disorder; a diagnosis that 
she reports not accepting at the time: 
So from then onwards I was back and forth, back and forth, back and forth [repeatedly 
seeing the GP], all of those years, again it was “stress, anxiety”… because I’ve got panic 
disorder, as soon as I got that label, that was it, and then 2013 I suffered significant weight 
loss so then the next diagnosis was that I had a borderline eating disorder. I don’t know 
where this came from! The psych team basically went ‘oh you are far too thin, you know, this 
needs to be addressed’. So I saw a dietician once and then I self-discharged from those people 
because I thought I really don’t have an eating disorder, everything they were saying to me, I 
kept on saying no that’s not what happens.    [Lauren, 45- CD] 
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Memories of the emotions felt by participants were discussed when they recounted their 
misdiagnoses. The frustrations that participants felt during this time about not having a satisfactory 
diagnosis were compounded by the effect of their symptoms and how unwell they felt:  
I felt quite annoyed and upset because I was basically being told there was nothing wrong 
with me when I felt very incredibly ill and I knew there was something wrong, but the 
doctors were still telling me that there was nothing wrong. So I felt like I wasn’t being taken 
seriously.        [Josie, 18- UC] 
 
Brian described concern and worry for his family when he was admitted to the psychiatric hospital 
for his severe depression: 
I had every emotion going on, and I was worried about my kids worrying about her [his wife] 
but there was nothing I could do about it because of how poorly I felt as well. You actually, I 
actually felt like it was gonna be the rest of my life, I actually thought, I actually convinced 
myself I was never gonna come out     [Brian, 57- CD] 
 
 Contributors to Delay 
Factors which participants believed led to their delayed diagnosis are discussed within this theme. 
These factors are divided into three separate subthemes: participant factors, primary care factors 
and systemic factors. 
 
 Sub-theme: participant factors for delay 
Participants acknowledged that they may have been, at least in part, responsible for the delay in 
their diagnosis due to delaying initial help-seeking. Key reasons why participants believed they did 
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not seek medical advice when symptoms first presented, or why they did not push harder to gain a 
diagnosis, are discussed below. Within this sub-theme, the trigger for participants to pursue an 
explanation for their symptoms is also discussed, as when discussing delay with participants, they 
naturally began to talk about how they overcame certain barriers, which was the first step towards 
the correct diagnosis. 
One participant cited embarrassment as a reason why she did not see her GP sooner. It is 
important to note that other participants discussed embarrassment as a cause of reluctance to 
discuss symptoms or IBD with friends, though not necessarily towards seeking help for their 
symptoms by a doctor. Sandra described waiting “a couple of months” before consulting her GP 
and implied that she was reluctant to discuss her symptoms with her GP: 
EC- do you think there any factors that you're maybe responsible for as to why you didn't get 
a quick diagnosis? 
Sandra- Part of it is because first my symptoms were so minute and weren't really affecting 
me that much, obviously there’s the embarrassment factor because of where the problem is 
but I was old enough to get over that eventually  
EC- Do you know the timeframe that it was when symptoms started to when you went to see 
your GP the first time? 
Sandra- The first time I'd probably had this tiny bleeding for a couple of months before I 
thought 'oh, I'd better go'. It was that sort of thing- I think embarrassment is a terrible sort of 
thing but you do put it off as long as you can and because it didn't seem that important you 
give yourself all sorts of excuses      [Sandra, 65- CD] 
 
For one participant who was diagnosed at 15 years old, she believed her reluctance to discuss her 
symptoms with her mother contributed to her delayed diagnosis. It was only when she noticed 
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blood in her stool that she disclosed these symptoms as she appeared to perceive the bleeding as 
more serious than her abdominal pain: 
Essentially I wasn’t telling people about the pain and stuff that I was getting and if I did, I 
only ended up telling my mum because the fact that I saw blood and obviously seeing blood 
as a child is a scary thing so that’s the only reason why I told my mum then. But if I had told 
her that I was getting abdominal pain that was not easing back when I started experiencing 
symptoms, maybe that would have kind of pushed, maybe I would have been diagnosed 
before the April time and before she took me back to the GP in the January 
[Charlotte, 28- UC and CD] 
 
Another participant described ignoring her symptoms as a reason for not initially consulting, which 
she perceived as contributing to her delayed diagnosis: 
“At the beginning of the year I did put it down to just like stress at work, you know, OFSTED 
[school inspection at work] and stuff like that, you know I assumed because I’d never been ill, 
I’d hardly ever been ill before, I think I thought oh god I’ve had a burst abscess but now my 
operation’s cleared up, I thought I’d just go back to how I was and I think maybe there is a bit 
of burying your head in the sand sometimes as well, you know, maybe knowing things aren’t 
quite right but hoping they’d just sort themselves out on their own but it got to the stage 
when it can’t be ignored really, and you felt that was early spring, summertime, when things 
were getting much worse yeah     [Pamela, 45- CD] 
It can be inferred that Pamela is a resilient individual who otherwise considers herself as healthy. It 
was easy for her to deny and normalise her symptoms by “burying [her] head in the sand” and 
hoping they resolve, particularly in light of her work commitments. 
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In addition to fear of the cause of symptoms, one participant recalled how his fear of hospitals 
contributed to his delayed diagnosis. Simon did not follow advice from his GP to attend Accident 
and Emergency when suffering from severe abdominal pain: 
Simon- I just don’t know what my thinking was at the time, I think it was morbidly afraid of 
being taken into hospital because I’d never been in hospital or anything and I had a real thing 
about not going into hospital so I didn’t want to particularly, maybe face it 
EC- Do you think that you’ve kind of contributed to this delay in diagnosis? 
Simon- Well I always think it’s a 50/50 [half his personal contributors for delay, half 
healthcare factors]. I think as a patient I did have; I definitely had some kind of fear about 
hospitals and having things put down me and basically that was a big, I’m not saying an 
irrational fear but you know…      [Simon, 65- CD] 
 
One participant who had been misdiagnosed with IBS attributed his reluctance to accept stress as a 
cause of his symptoms as a contributor to his delayed diagnosis. The connection between stress 
and IBS had been discussed in his GP consultation and it can be inferred that he did not visit his GP 
as much as he may have done if stress had not been linked to his symptoms. 
EC- Do you think that you yourself created any barriers that prevented you from being 
diagnosed early? 
John- I didn't like the inference that I could be stressed, that stress could be affecting my 
health so I did sort of rail against that a bit, so I would have mentioned it was a possibility 
that I didn't like the thought that I had a sort of stress-induced illness at the time  
          [John, 56- CD] 
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For those participants who described delaying help-seeking for their symptoms, a worsening of 
their symptoms, to the point where they could no longer be ignored, triggered them to seek 
further medical help. Pamela realised she could not ignore her symptoms any longer when they 
worsened: 
I was just getting worse, you know and it got to the stage where, you know, I couldn’t leave 
the house and you know I tried to go back to work in the September but I think I barely did a 
week and it was obvious that wasn’t going to work so yeah I think at that stage I was going 
[to the GP] quite a lot and then you know they put me through to the hospital for tests 
          [Pamela, 45- CD] 
 
As well as the impact of her worsening symptoms on everyday life, another factor that prompted 
Sandra to consult at this point was her concern that her symptoms were due to bowel cancer: 
EC- And then it got worse, do you think that was the trigger for you to go and see your GP 
again? 
Sandra- When it got really bad it took a couple of days before I went because I just thought 
'no, this certainly isn't right' and because I was 60 I automatically assumed I'd got bowel 
cancer.         [Sandra, 65- CD] 
 
There was some variation evident across the dataset, as unlike in the extracts above, not all 
participants felt that their own actions contributed to the delay in diagnosis: 
EC- Do you think there are any factors that occurred and your diagnosis was delayed because 
of you? 
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Callum- I’m not the one who will shy away from symptoms and be embarrassed about going 
to the doctors or whatnot        [Callum, 23- CD] 
 
 Sub-theme: primary care factors for delay 
Common primary care delays that participants reported included poor GP engagement with 
symptoms and delayed referral. Many participants described not feeling that their GP was taking 
their symptoms seriously. Alicia recalled experiencing longstanding symptoms of abdominal pain, 
rectal bleeding and constipation and struggled to get a referral from her GP despite being 
concerned that her symptoms were serious: 
Alicia- It got to the point where I just, I worked about five minutes away from the doctor, a 
five minute walk and every day, well probably once a week, I just used to go down to the 
doctor and go, ‘can you help me, can you refer me?’ and they just used to fob me off, 
peppermint capsules et cetera and I just went every single week for what must have been 
eight or nine weeks, that’s when someone actually referred me so yeah, I must have been to 
the GP 30 times…  
EC- So in what way do you think the doctors that you saw led to you having a delayed 
diagnosis? 
Alicia- I would put most of the blame on the GPs to be honest I think I kind of knew that it was 
something to do with my bowels that was making me so ill and I basically spelt it out to him 
that I had virtually all of the symptoms my grandma had [who was diagnosed with CD]’ 
 [Alicia, 22- CD] 
Alicia was eventually referred, though she portrayed considerable frustration at the delay caused 
by her GP, especially as she had explained her family history of IBD to her GP.  
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A lack of GP knowledge when interpreting symptoms was described by participants. For Derrick, his 
GP admitted that he was unsure of what was causing his symptoms: 
Around the age of 8 or 9, I was losing blood in the stools and I was told, although I 
remember the discussions with the GP, he didn’t understand what was happening. If I 
obviously weren't so young he'd have said I had liver disease. But he discounted that 
because I was too young and I was anaemic as well so they started giving me vitamin B12 
injections so I was having those at school regularly … Its more that the doctor couldn’t work 
out what was happening. So he didn't see it so, I remember the conversations, well some of 
them, I remember the conversation emphasis was 'I don’t know what’s happening' … I must 
admit, my mother did say that moving house saved my life. That’s what she said, changing 
GP         [Derrick, 62- CD] 
 
One participant believed financial incentives were associated with her GP’s reluctance to refer her 
to a specialist: 
EC- Do you think they acted as a barrier to your delay in diagnosis? 
Lauren- The GP did, definitely, I did an OU in Health & Social Care and the gatekeeper to the 
NHS, the GP, yes, categorically, without a doubt. I was under NHS Scotland then and at the 
time, I don’t know if it’s still practice, NHS Scotland used to give them GP practice bonuses for 
not referring, so they used to get bonuses for not referring and I 100% believe that to be a 
factor as well.        [Lauren, 45- CD] 
 
Further to delays in referral, there was evidence of GPs referring participants to incorrect 
departments in secondary care: 
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Alicia- I got the referral for gastro but I’d been first to other places like colorectal surgeons 
and everything, so once we got to gastro that was it then. 
EC- How many times were you referred to the hospital before you went to gastro and they 
sorted you out? 
Alicia- I think it was about three times … Yeah I saw two colorectal surgeons and then I think I 
saw, what’s the one that deals with hormones and things Gynaecologist [sic endocrinologist], 
yeah I saw one of them as well to do with my periods.   
[Alicia, 22- CD] 
 
Simon began to suffer with soreness in his back as well as his gastrointestinal symptoms, and was 
referred to a specialist. This specialist then referred him to the gastroenterology department: 
I can remember going to see my GP around about the turn of the year, that year, 2000, and I 
think because I was going on about this soreness in the back, he referred me to a back 
specialist, or neuro specialist, I think he was trying to get rid of me actually, I think he 
thought, oh, I don’t know what to do with you, you keep coming back and forth with this, 
maybe there's something going on, you know, so he referred me sideways to this gastro. 
          [Simon, 65- CD] 
 
There was evidence of patients struggling to access their GP due to the nature of their symptoms. 
One participant recalled how her GP would not visit her at home due to her symptoms, which were 
perceived to be infectious. In the end, she became very unwell and was seen by an Out of Hours GP 
who admitted her to hospital: 
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But within those few days I then, I threw up the once. I had a telephone conversation with my 
GP at the time and they basically refused to see me and they refused me to go and see them 
and they refused to come and give me a home visit.  So at the time I said you know ‘I am 
really not well’ and I’d started to have blood in my urine now because every time I drink it’s 
coming out the other end [yeah]. So they were like ‘Well you need to drink more’, so I was like 
okay well you know, I work in the profession, I’m not silly but I didn’t want to tell them that. 
So at the time I thought ‘Well okay, just keep going, maybe I’m just being silly’. 
          [Joanne, 34- UC] 
What is particularly noteworthy about Joanne is that her career in community healthcare suggests 
she likely has good health literacy. However, she did not seem to challenge her GP’s management 
plan despite working in healthcare and believing that her symptoms were serious. 
 
The reliance of the GP on blood tests to confirm or refute the presence of any illness was at the 
root of one participant’s frustration, as he suggested that his GP was not very proactive in 
investigating his symptoms. Darren had symptoms of fatigue, abdominal pain, growth failure and 
diarrhoea. As a result of his GP’s reluctance to refer him to a specialist, Darren’s family decided to 
pay privately for a specialist appointment: 
EC- I know you mentioned before that, you know, you were pushing to get this referral and at 
one point it did seem like your GP was going to refer you but then obviously you ended up 
going private.  What happened with your GP there then? 
Darren- Well…if I remember correctly…they did the blood tests and I had a blood test and 
another blood test and another blood test, and that was seemingly their only method of 
confirming or denying anything.  And…they basically said at some point we may have to refer 
you if, you know, if something comes up on the blood test.  So it was a bit of a, they started 
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mentioning it but then there was never really any ‘yeah, we’ll give you a referral’.  And the 
blood tests, I don’t know why the blood tests didn’t seem to show anything  
[Darren, 25- CD] 
 
Simon, who was discussed previously when he described his fear of hospitals as contributing to his 
delayed diagnosis, reported that he wished his GP had encouraged him to have further 
investigations to identify a cause for his symptoms, in spite of his own reluctance. Simon suggests 
that his GP did not properly communicate the importance of these investigations, leading him to 
decline these tests for many years before being diagnosed: 
They should have been more proactive, I think they should have put it to me a bit clearer and 
not allow me to kind of dodge the bullet, I think the patient, you know, if the patient turns up 
with certain symptoms, you know, they're ongoing and they're not clearing and you 
know…they really need to have some exploration to see what's going on, you shouldn’t let 
the patient dictate the treatment, you know, you should say to the patient, you should try 
and find a way to understand that patient, to understand…what is it they're worried about… 
you really need to use a bit of psychology to get them to understand the need to go for these 
tests and I think that was a mistake on their part and I’ll hold my hands up cause I didn’t help. 
So you know, I could have had treatment a lot earlier, probably got an earlier diagnosis, I 
don’t know, you know … I think nowadays, I think I have a feeling they would probably be a 
bit more, certainly forceful in their approach to me than it was then”   
          [Simon, 65- CD] 
 
Lost or incorrect medical records and results was another factor for primary care delays as outlined 
by some participants: 
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I was lied to as well, things like they did a test like a calprotectin test to see what my 
inflammation levels were like and I’d ring up and they’d say ‘oh yeah they’re fine, yeah, no 
worries’, and I went and when the hospital later looked back at them they realised that they 
were actually off the scale and then they were just telling me that there was nothing wrong 
with me …          [Alicia, 22- CD] 
 
Being unable to access test results was a considerable issue faced by one individual, particularly as 
she had to ask for the test to be done in the first place: 
As soon as I went a few years later, when I was 17, and I said, 'I've got a sister with Crohn's. I 
want you to do a calprotectin,' because my mum said, 'You're just going to have to go in and 
ask for what you want’.  They did do a calprotectin.  I never heard back and I was told, 'If you 
don't hear back, everything is fine.'  Six months later, I lost loads of blood.  My mum said, 
'That's absolutely definitely not fine. That's not normal.'  I rung up and I said, 'What were my 
calprotectin results six months ago?'  They refused to give it me.  I still haven't had that and 
I've been told now that it's been lost.     [Emily, 20- CD] 
Emma reported that approximately 6 months after this incident she returned to her GP and 
another faecal calprotectin test was ordered. Her results showed significant inflammation and as 
her symptoms had not changed during this time, she believes the first calprotectin level was also 
abnormal. She was therefore of the view that had she received the results from this first test, she 
possibly would have been referred and diagnosed with CD.  
 
Finally, prolonged and ineffective management for what was thought to be IBS was identified as a 
contributing factor to diagnostic delay. Participants felt that when the management for IBS was 
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ineffective at relieving their symptoms, their GPs should have investigated further or tried different 
medication: 
Well it just seemed to be forever pepperminty things you know drinks and tablets and… I 
don’t recall anything else coming to light, no … I think with them knowing my sister had got it 
[CD], I think they probably seriously suspected that from an early stage but still kept treating 
it as IBS which was a bit frustrating, but I guess I mean I think that’s what you hear with most 
people with Crohn’s that we tend to have to go down the IBS route first   
          [Pamela, 45- CD] 
 
Participants felt worried when they believed their symptoms were not being considered seriously 
by their GP: 
I think maybe as well I was a bit afraid of what it could be, but I think I was a bit frustrated 
because I knew that there was more to it than what they were telling me to begin with and 
then the more you feel like you’re not being listened to, I think you can blow things out of 
proportion and then I started to worry it was something really serious as well   
[Jess, 38- CD] 
Worsening symptoms, due to inactivity from participants’ GPs, finally led them to establish their 
diagnosis. John had persisting symptoms over a long period of time, though he recalled that it was 
only when he rapidly lost weight that his symptoms were taken seriously: 
John- I was having some weight loss, some unpleasant symptoms, yeah a massively increased 
bowel habit and maybe that was a factor, it wasn't really until things started speeding up 
that, you know the symptoms were dramatically worsening, that things began to change 
EC- Yeah, you felt like you were dealt with more urgently then? 
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John- Yes, yes, I think that they thought 'right the weight, almost a stone a week I was losing' 
then suddenly it was like let’s get you into hospital   [John, 56, CD] 
 
Moreover, issues were raised about delays in commencing IBD management as well as delays to 
diagnosis. Helen’s consultant wrote to her GP asking to prescribe her Asacol (mesalazine) for her 
UC, however her GP did not do this, and suggested that it was Helen’s responsibility to request the 
medication despite her being unaware about a prescription in the first instance: 
I had mild, left-sided ulcerative colitis and I just found that out by ringing the doctors to ask if 
they'd had a report from the consultant and it came back 'yes you've got UC and they're 
going to send for you again in about 3 months'. I didn't have any treatment all the doctor was 
giving me during the summer was Buscopan. When I had my appointment to go back to see 
the consultant which by then was early the following year, he said 'how are you getting on 
with your Asacol?' and I said 'whats Asacol?' and he said 'it’s what I told your GP to give you 
when we diagnosed your colitis'. I said 'well I've not had any'; so he was a bit cross about that 
and told me to go back to the doctor and find out why I hadn't been given it and it was just 
that because I was well, I wasn't moaning or nagging they just didn't prescribe it  
          [Helen, 53- UC] 
 
Whilst most participants reported a lack of knowledge from their GP, Joanne reported a very 
different experience, recounting a consultation with an out of hours doctor who promptly 
identified the possibility of UC:  
So I went to the out of hours doctor and it was just because by chance I think that this doctor, 
she agreed for us to go in to see her, she took one look, she said ‘You’re so dehydrated’ … She 
looked through my medical history and she was like, she took time, I think that was the 
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difference. She knew I was unwell, she did my observations, they weren’t obviously good 
because I wasn’t very well. But she took time to read about my past medical history, she’s an 
out of hour’s doctor, but she’s a fresh pair of eyes and then that’s when she said ‘Has anyone 
ever told you, you could have colitis?’     [Joanne, 34- UC] 
 
 Sub-theme: systemic factors for delay 
This sub-theme describes the organisational and administrative factors that contributed to delays 
in diagnosis as outlined by participants. These include long waiting times for specialist 
appointments and cancelled procedures. IBD was included as a differential diagnosis in one 
participant’s case, though this was not identified by his GP practice. This previous diagnosis of IBD 
was only noticed when the participant read through his GP medical records, after he had been 
diagnosed with CD. He also describes reading comments left by his GPs that “labelled” him with 
mental health problems: 
Brian- My son went through my notes with me and you can see this path before I went in- 'we 
don’t know what other tests to do' and there again in big capitals- ‘CROHNS’ with three 
question marks then it actually said, 'been to the doctors again' … In my medical records it 
says 'this patient takes up too much time’ 
EC- How did you feel when you were reading that back? 
Brian- Appalled, upset, because I thought this has gone on for so long. This is after I got 
diagnosed going through my GP records and they'd been so nice to me, I just look at is at 
yeah, labelled, he's got mental health issues    [Brian, 57- CD] 
Brian was upset to realise that a diagnosis of IBD had been considered by specialists but pursued 
no further, particularly as his GP implied he wasted their appointment time. 
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There is evidence that long waiting times to outpatient hospital appointments also contributed to 
diagnostic delays, as with Emily who was told she would wait 6 months to see a consultant: 
They'd told me that they were going to refer me to the hospital and that I would probably 
end up needing a colonoscopy to do further investigations but before I'd have a colonoscopy, 
I'd have to see a consultant. This was in December and I was told that the wait time would be 
at least six months to see a consultant. We then paid privately for me to see a consultant two 
weeks later, purely because we knew how ill my sister [who also has CD] got in the six months 
that she was waiting to see someone     [Emily, 20- CD] 
As previously discussed, Emily was not told the result of her first calprotectin level as, according to 
the GP practice, it had been lost. Therefore, she could have been waiting even longer to see the 
consultant if she had been diagnosed under the NHS. This was a problem that she reported her 
sister had also experienced before being diagnosed with CD. 
 
Even though her GP was proactive in referring her, Charlotte recalled experiencing a long wait until 
the appointment: 
I went to the GP like straight away, I managed to get an appointment quite quickly but the 
GP said to come back when I had the abdominal pain and just to keep an eye on the blood 
cause he didn’t know whether it’s just an infection … So I took that [rehydration sachet] away 
and tried that, I think 48 to 72 hours and I just still wasn’t well at all, and the blood was 
getting more and more like every day, my mum took me back to the GP and then he said, we 
need to pursue it a bit further and investigate it and then sent me for an urgent referral, but 
even that took about five to six weeks take to be urgently referred across to the paediatric 
department       [Charlotte, 28- CD and UC] 
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Delayed colonoscopy was revealed as another systemic factor contributing to overall diagnostic 
delays. Despite being aware of a possible IBD diagnosis, Pamela’s consultant did not wish to 
commence treatment before a colonoscopy confirmed the presence and extent of CD: 
They put me through to the hospital for tests but obviously they take time and I think I had a 
barium meal quite quickly but the colonoscopy one was the one that just kept getting 
cancelled, it must have been cancelled quite a few times which then put off, because they 
kept saying ‘well we want a baseline of your Crohn’s’ – I think they thought it was Crohn’s, 
knowing it was in the family – but I think they wanted a baseline of my symptoms and how I 
was before they treated it but it kept getting cancelled and it got to the stage where I was so 
ill that they had to do something really, that’s how I understood it anyway, that was my take 
on it.          [Pamlea, 45- CD] 
 
A comparison between the management of older versus younger people was also raised by Emily. 
As there is an increased risk of colorectal cancer with older people, Emily agreed that they should 
be seen first, however she implied that her symptoms were taken less seriously due to her younger 
age, and subsequent lower risk of serious pathology: 
For example, if I was an older person, I'd be more likely to have bowel cancer than a younger 
person but say, for example, the calprotectin result was raised because they had Crohn's, 
their diagnosis would have been completely the same as mine and quicker on the basis that it 
might have been more important but it might not have been.  They've then got their Crohn's 
more under control because they're older which shouldn't really be the case.  
[Emily, 20- CD] 
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 Consequences of delay 
This final theme encompasses the impact participants felt their diagnostic delay had had on their 
subsequent illness experiences and disease course. For instance, many participants turned to 
private healthcare for advice because of delays in NHS healthcare. Additionally, the impact of 
delays in diagnosis as experienced and cited by participants is discussed. This includes the 
participants’ perceptions of how their delay has affected their symptoms and management. 
Seeking medical advice from the private healthcare sector was described by many participants, as 
they felt that they could not wait for GP referrals, NHS appointments or investigations. All 
participants had positive experiences with private healthcare and were diagnosed soon after, with 
many describing an accelerated diagnosis when compared with experiences of NHS care: 
I think I was 16, just about to turn 17.  I went for an appointment with like a private doctor at 
the Nuffield … and I was diagnosed there … And he pretty much saw me straight away and 
went, ‘Yeah, you don’t look like you’ve got IBS to me’, just looking at me.  He said how pale I 
looked and things like that.  And then he did all the usual like feeling your stomach and that 
kind of thing and said I felt very tense and felt very tender.  And then he sent me for a 
colonoscopy and it was only on the colonoscopy that the Crohn’s actually showed up, and I 
was diagnosed at that point      [Darren, 25 CD] 
 
Josie remembered feeling satisfied with her interaction with the private consultant during the 
appointment: 
So when we saw the consultant we explained what was going on, all my symptoms 
throughout the years and he was like ‘If you put all those symptoms together it sounds like 
ulcerative colitis’, so he was like ‘If you wouldn’t mind we could have a look right now in the 
office’. So he did, he had a little look and straight away he was like ‘Yeah, you’re inflamed 
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and it’s all redness and you’ve definitely got it’, like straight away within the ten minutes he 
was like ‘Yeah, I can confirm a diagnosis of ulcerative colitis’. And that was quite good 
because he didn’t waffle about and he didn’t want to just stick with bloods, he actually had a 
look, got straight to the point … He was speaking to me as well as my mother, he wasn’t just 
ignoring me he was actually paying attention and he said a little bit about what the disease 
was and he told us our options, what we could do to help me and everything. He got straight 
to the point and he didn’t just like give me a diagnosis and say goodbye or anything, he sat 
with us and explained a little bit and told me what I could do.     
          [Josie, 18- UC] 
Josie explained that, by paying privately, she had a longer appointment with the specialist and was 
positive about having received a thorough explanation for her symptoms, as well as a discussion 
about the management plan; implying that this consultant spent more time talking to her than 
previous doctors.  
 
The decision to seek private healthcare advice was influenced by financial factors. Some people 
utilised private healthcare insurance provided by their employer: 
When I finally got to see a consultant after I got diagnosed and the results came through they 
couldn't find any appointments on the NHS over summer for 3 months and then I 
remembered I had private health insurance so 2 days later saw a consultant   
[Sandra, 65- CD] 
 
There was evidence that this uncertainty of the diagnosis despite worsening symptoms negatively 
impacted on participants’ family members as well as participants. Alicia reported that her mother 
became increasingly worried, particularly as her GP displayed a lack of concern: 
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When you feel ill every single day it’s really draining and when someone is not listening to 
you and just keep sending you away it’s really very frustrating, I think my mom was just 
getting more and more worried because I’d just lose more weight, you look worse, you are 
anaemic, it wasn’t good, it wasn’t a good time    [Alicia, 22- CD] 
 
When asked about the impact of the delayed diagnosis on their IBD, participants had very different 
responses. Some participants provided evidence that a delayed diagnosis may have led to their IBD 
being more difficult to manage. Darren questioned whether he would have developed his stricture 
or adhesions, which resulted in him undergoing surgery, if he had been diagnosed quicker: 
EC- Do you think that having a delayed diagnosis has impacted on your Crohn’s at all? 
Darren- Maybe because I wonder if maybe I wouldn’t have gotten a stricture and because 
when I had my stricture removed, when I had my operation, they said there was an awful lot 
of adhesions.  And I know often they’re caused by other operations but I never had another 
operation and they said can be caused by Crohn’s symptoms, which I didn’t know.  And so, 
and it was mentioned to me that it could have been because I’d had Crohn’s symptoms for 
such a long time.  So, and that definitely does have an impact on my intestines and stomach 
and things, definitely did have, and I wonder if I may not have had a stricture if I’d gotten all 
the right medication earlier      [Darren, 25- CD] 
 
Additionally, Emily reported that she believes that the long-term management of her CD may have 
been more effective if she had been diagnosed when her first faecal calprotectin was raised: 
If it had been found by the GP, at that point, that my calprotectin was raised, I would then 
have paid to go privately to move things along because of what happened with my sister. If I 
could have then got that diagnosis within a month, I might not have had to get to that point. 
 135 
 
It took me over a year of being on Infliximab to actually not having any symptoms anymore. I 
had to try numerous other medications before that. It took over 18 months to actually get to 
the point where I hadn't got any symptoms anymore … A delayed diagnosis has an impact 
because it's more severe and so I've found that it's harder to treat. Because it's more severe
          [Emily, 20- CD] 
 
Lauren also questioned whether she would have needed to undergo surgery if her diagnosis was 
not delayed: 
EC- How has your delayed diagnosis affected you in terms of your Crohn’s? 
Lauren- I think if I’d have been treated earlier I may have avoided surgery for longer, if at all, 
perhaps, I can’t guarantee that but that does cross my mind, you know it might not have 
become fibrotic, well it probably would have but it might have been delayed, I wouldn’t have 
suffered the side effects of the weight loss, which then obviously, that has a massive impact 
on your life, and now I have a sort of bubbling resentment for the delay in diagnosis. 
          [Lauren, 45- CD] 
 
However, there was variation observed in the data, as some participants believed that their 
diagnostic delay did not impact on the management of their condition. Pamela largely associates 
her symptoms with the relapsing-remitting nature of CD as opposed to her delayed diagnosis: 
I think in the long term the delayed diagnosis hasn’t had [an impact], because I did get back 
on my feet and obviously since then you know it’s been the path of another chronic disease, 
you know, I’ve had periods when I’m fine and periods where I’m really not fine and I don’t 
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think that would be any different if I’d been diagnosed quicker I think that’s just the nature of 
the disease         [Pamela, 45- CD] 
 
Although Josie did not believe her diagnostic delay influenced the medical management of her IBD, 
she acknowledged that an earlier diagnosis may have improved her mental wellbeing as it might 
have “put [her] mind at peace” to know the cause of her symptoms: 
EC- So do you think your symptoms or the management of your condition would’ve been 
different if you were diagnosed earlier? 
Josie- I don’t know because it’s like I had symptoms and if I’d got diagnosed before I got to 
the bleeding stage and the actually like damage being done, I don’t know if they could’ve 
done anything until that point. So really I wasn’t having inflammation markers and if I wasn’t 
fully inflamed I don’t think the medications would’ve been very good or even work. So even if 
I had a diagnosis I think it would’ve put my mind at peace and know I could do something 
about it if it does get worse, but I don’t think we could’ve done anything in the early stages.
           [Josie, 18- UC] 
 
One participant, who began experiencing symptoms as a teenager but was not diagnosed until 
adulthood, implied that had she been diagnosed as a teenager, this may have had more of a 
negative impact on her life. This opinion was not expressed by other participants: 
EC- It sounds like you’ve been through so much sort of over the years though… 
Lauren- In a way I’m kind of glad that I didn’t, on reflection and you know going on social 
media which I never used to do, a lot of the young people, you see quite easily for some 
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people it becomes your life really young and I really think that if I had have known when I 
was young, it might have held me back     [Lauren, 45- CD] 
 
A consequence of one participant’s delayed diagnosis is the negative opinion they have towards 
the NHS regarding IBD: 
 I've ended up suffering more but also delayed diagnosis has meant that I just thought, 
'People don't really take Crohn's seriously.' Whenever I've spoken to someone and said, 'I'm 
not well enough to come today. I've got a bad Crohn's flare up,' I just think that people aren't 
going to take it as seriously because that was the general impression that the NHS has given 
me         [Emily, 20- CD]  
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 Qualitative results discussion 
Sixteen participants took part in research interviews, varying by age and extent of diagnostic delay; 
with participants with CD generally citing longer delays than those with UC. Key factors they 
believed contributed to their delayed diagnosis included poor proactivity from their GPs and poor 
recognition of symptoms. Whilst some patients believed their delayed diagnosis had impacted 
upon their IBD, others believed similar outcomes would have occurred even if diagnosed sooner. 
 
 Misdiagnosis 
Key misdiagnoses in both participants with UC and CD included IBS and gastroenteritis. A diagnosis 
of IBS seemed to be explained by the presence of stressors occurring in participants’ lives at the 
time of symptoms, particularly workplace stress. Qualitative research into IBS has been carried out 
from both a clinician and patient perspective, by Dixon-Woods and Critchley (2000). Although 
these patients had a correct, confirmed diagnosis of IBS, they provide an interesting insight into the 
process of being diagnosed, some of which is applicable to this study. Of the fourteen patients with 
IBS, some were concerned about the significance of symptoms, similar to participants interviewed 
in the present study. Some of the people interviewed by Dixon-Woods and Critchley also described 
a feeling that their GP was not taking their IBS symptoms seriously and they rejected the notion 
that their symptoms were psychological in origin. This was a common finding amongst IBD 
participants who had being misdiagnosed with IBS, who reported repeatedly seeking help from 
their GPs to no avail. The twelve clinicians interviewed in Dixon-Woods and Critchley study, six GPs 
and six gastroenterologists, offered mixed opinions towards IBS. When diagnosing IBS, one GP 
highlighted the importance of excluding all other diagnoses. It is surprising that only one GP in their 
study acknowledged the importance of excluding other diagnoses; however this does appear to 
reflect the patients in the present study perceived the attitude of GPs, as participants recalled 
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being left on medication for IBS even when it was ineffective. Whilst a misdiagnosis of 
gastroenteritis was discussed by many participants, there appears to be an absence of literature in 
this field. A possible reason for this is the shorter disease duration of gastroenteritis, as when 
participants experienced persisting symptoms, IBS was then considered a more appropriate 
diagnosis. 
An unexpected finding of this research was the misdiagnosis of IBD symptoms with mental health 
conditions. Whilst psychiatric conditions can cause physical symptoms, it appears more sensible to 
exclude a physical origin of symptoms before diagnosing a psychiatric condition. This was 
particularly poignant with the participant who felt that he had been ‘labelled’ with mental health 
problems and all of his symptoms were linked to this. Incorrectly attributing physical symptoms to 
psychological causes, known as diagnostic overshadowing, has been explored in literature. For 
instance, an interview study with emergency department clinicians in London about diagnostic 
overshadowing found that some clinicians may demonstrate ingrained attitudes to mental health 
patients and do not explore possible physical causes of symptoms (Shefer, Henderson, Howard, 
Murray, & Thornicroft, 2014). One psychiatric nurse in this study recalled being called to see a 
mental health patient who was deemed psychotic but in fact had fractured his foot and was in 
severe pain. Psychosis, which may include symptoms like hallucinations, delusions and changes to 
speech or behaviour can be caused by physical conditions, including sepsis, hypoglycaemia or low 
blood sugar, systemic lupus erythematosus and thyroid disease (Griswold, Del Regno, & Berger, 
2015). This demonstrates a more general need for clinicians to consider and exclude the possibility 
of a physical condition before diagnosing a psychiatric issue.  
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 Participant factors for delay 
Participants acknowledged that they may have contributed to their delay in diagnosis. Where 
participants felt they did not personally contribute to their delayed diagnosis, they explained that 
concerns about their symptoms, having a family history of IBD and lack of embarrassment to 
discuss symptoms with medical professionals prompted them to consult sooner. Participants with a 
family history seemed to demonstrate better knowledge of IBD, with many questioning whether 
they had the condition before their diagnosis. Despite this prior understanding of IBD, they still 
experienced delays to diagnosis. 
The participant-related factors for delay found in this study can be mapped onto Andersen’s Model 
of Total Patient Delay (Andersen, Cacioppo, & Roberts, 1995). This model provides an overview of 
possible decision-making factors by patients that may cause them to delay seeking medical help, 
ranging from when they detect the symptoms to when they make an appointment to seek advice 
for these symptoms. These different areas of delay include ‘Appraisal delay’, where the individual 
associates their symptoms with an illness, which may differ from the condition they actually have; 
‘Illness delay’ which is the time from the patient’s perceived sign of illness to deciding to seek 
medical advice; and ‘Behavioural delay’, which is the time taken to act on the decision to see a 
medical professional by arranging an appointment (Andersen et al., 1995). This model was utilised 
to explain participant delays in the diagnosis of cancer in a systematic review by Walter et al. 
(2012), which found that the nature of symptoms and misattribution of symptoms to benign 
conditions, like IBS in bowel cancer, were common reasons for appraisal delays. Behavioural delays 
were associated with barriers to consulting such as holidays and other life events, as well as the 
time taken to come to terms with the possible cause behind the symptoms when cancer was 
suspected (Walter, Webster, Scott, & Emery, 2012). There are similarities between the findings of 
this systematic review and the qualitative research conducted in this thesis, in that misattribution 
of symptoms to other conditions was described, as participants believed their symptoms were 
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initially caused by gastroenteritis. However, behavioural delays were not found to be a pertinent 
issue for most participants in the present study, as they persistently sought healthcare advice even 
though their symptoms were not taken seriously by their GPs. Therefore, whilst no barriers were 
identified to consulting once participants had made the decision to seek help, these findings 
suggest that there is a need to reduce IBD patients’ initial Appraisal delay. It may be that increasing 
awareness of IBD more generally, through health promotion campaigns, for example, could help to 
reduce this delay. Whilst patients can be reassured that GI symptoms are initially likely to be 
caused by an acute illness such as gastroenteritis, it is important for patients to recognise that if 
symptoms persist and are particularly severe this could indicate IBD and therefore they should not 
delay in making the decision to consult. 
 
 Healthcare factors for delay 
Primary care factors for delay were common reported by participants, and similar factors have also 
been reported by participants in qualitative studies into other long-term conditions. In research 
exploring the delays in diagnosis of endometriosis, participants similarly recalled how their GPs had 
normalised their symptoms or performed general, non-discriminatory tests (Ballard, Lowton, & 
Wright, 2006). This led many to persistently present to their GPs with problems, as was also found 
amongst the participants in the present study. Participants in the present study also described 
delays even when asking their GP whether they could have IBD due to a positive family history. This 
was also mirrored in the delayed diagnosis of endometriosis where the participants’ mothers had 
endometriosis (Ballard et al., 2006). This may suggest that there is a need for GPs to be more 
informed about conditions where there are possible genetic causes, such in the case of IBD, and as 
a result to pay more attention to the patients’ family history, particularly when this is flagged up by 
the patients themselves.  
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Key systemic factors that participants felt led to a delay in their diagnosis were missing medical 
records, miscommunication of information within medical records and delayed colonoscopy 
appointments. With the large volume of patients using the NHS, errors in communication and 
medical notes may occur. However, a mixed-methods study by Burnett, Deechland, Franklin, 
Moorthy and Vincent (2011) found that key clinical information, particularly diagnostic or 
radiologic test results, was omitted from patient records in 15% of outpatient consultations across 
three teaching hospitals in the UK, from a total of 1161 patients. According to fifteen members of 
staff involved in transporting, using or writing in clinical notes who were interviewed, missing 
information led to the cancellation of operations in fifty-five patients and put thirty-five patients at 
risk of harm. Factors associated with missing medical data included complex medical problems 
whereby patients are under the care of many specialists, merging hospitals and temporary staff 
(Burnett, Deelchand, Franklin, Moorthy, & Vincent, 2011). This study, amongst others, 
demonstrates that incomplete clinical records is an important issue and can impact patient 
healthcare, as evidenced from the participant accounts within this thesis. Similarly, a review 
investigating the delays in diagnosis of lung cancer found that poor co-ordination across medical 
services and inaccessibility of diagnostic procedures and results contributed to delay (Malalasekera 
et al., 2018). Whilst the interview findings suggest that systemic failures contribute to delays in IBD 
diagnosis, existing research in this field highlights the significance of this issue across the healthcare 
service. 
 
 Consequences of delay 
Conflicting opinions from participants arose about whether the delays in diagnosis impacted on 
their IBD in the longer term. Some participants believe they struggled to reach remission or 
required surgical intervention because of their delay. However, others accepted that the course of 
their IBD is part of having a chronic, relapsing-remitting condition, and therefore did not make a 
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link between delay and disease severity. As described in Chapter 1 section 1.2, there is evidence 
that a delay in diagnosis contributes to complications of the disease. For instance, in a study 
conducted by Szanto, et al. (2018) the rates of surgery and use of biological therapy were 
significantly increased in CD and UC patients who had been diagnosed over one year after 
symptom onset (p=0.012 and p=0.002 respectively). A more complicated disease course was found 
in a study by Li et al., where the rate of subsequent surgery was 84.7% in those with a diagnostic 
delay of over thirty-four months and 62.4% in delays below 34 months, although stenosis, fistulae 
and perianal surgery were not significantly different between the two groups. In a cross-sectional 
study by Pellino, Sciaudone, Selvaggi and Riegler (2015), a diagnostic delay of over eighteen 
months was associated with an increased risk of needing a stoma (P=0.003) and developing surgical 
complications more frequently (P=0.03). It is also important to acknowledge the participants’ 
impact of delay from their own perspectives. Many expressed negative emotions and feelings 
towards their delayed diagnosis which could have an adverse effect on the therapeutic relationship 
between the participant and healthcare professionals involved in their care. In qualitative research 
undertaken in a teaching hospital in Canada, participants who were recruited from various clinical 
sites around the hospital shared their insights regarding the need for physicians should listen to 
patients in order to improve the physician-patient relationship. They described how feeling that 
their physician listened to them led to patients taking greater ownership of their health as they felt 
the physician respected their opinions, as opposed to feeling “ridiculed” and angry (Jagosh, Donald 
Boudreau, Steinert, Macdonald, & Ingram, 2011). Findings in the present qualitative study mirrored 
some of findings in the study by Jagosh et al., as participants reported valuing the time the 
consultant spent with them during their private consultations, in contrast to feelings of resentment 
when their concerns about symptoms were incompletely addressed by GPs. However, whether 
negative experiences with healthcare professionals has impacted on IBD management or 
relationships with clinicians was not explored by participants in the study included within this 
thesis. 
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Five participants that were interviewed described some involvement of private healthcare in 
gaining a diagnosis, particularly in light of long NHS waiting times and also the unresponsiveness of 
their GP to refer them. Such findings are reflected in a recent interview study conducted with 
participants who have received a cancer diagnosis, with most patients finding that consulting the 
private sector aided their diagnosis (Parsonage, Hiscock, Law, & Neal, 2017) . As described by Doyle 
and Bull, individuals acknowledge that their medical needs are in competition with the medical 
needs of numerous others within the NHS, so private healthcare can be a useful alternative for 
them to access medical care (Doyle & Bull, 2000). In the present study, it appeared that for some 
participants, private healthcare was deemed the only way for participants to seek answers for their 
symptoms, which has an associated cost burden for the patient. The positive experiences of private 
healthcare as described by participants and the lack of progress they were making under the NHS 
demonstrates a need for the NHS to improve the care towards individuals with IBD in order to 
reduce diagnostic delays. This is particularly significant with IBD in younger people, as older people 
may receive their diagnosis of IBD by being referred under the NHS two-week wait referral system 
which is used to diagnose cancer. The absence of referral system for younger people with 
suspected IBD means they often wait longer to see an NHS consultant, in the meantime their 
symptoms may worsen and they may become unwell. 
 
 Strengths and limitations 
Adopting a semi-structured approach to interviewing as described in Chapter 5 was advantageous 
as it allowed me to explore aspects of participants’ delay which were deemed important to them, 
but which I had not originally considered. In this sense, facilitating conversation led by the 
participant provided much richer data. I also felt that the topic guide provided a comprehensive 
overview to explore participant experiences whilst allowing the flexibility to explore different 
topics as guided by the participant. 
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To ensure trustworthiness of the transcripts returned from the transcription company, the content 
was checked against the audio-recording to ensure accuracy of the data before analysis. Data 
analysis is dependent upon the accuracy of the data, therefore checking the transcripts ensured 
high quality analysis. The transparency of the data analysis offers another strength of this research, 
as the method of thematic analysis has been outlined in the thesis along with evidence of this 
process, such as the thematic maps (Appendix 11). The detail of reflexivity ensures identification of 
how my background as a medical student may have influenced this process, demonstrating rigor 
towards the analysis stage as it allows the reader insight into how I interpreted the data. 
Using thematic analysis was useful, particularly when exploring misdiagnoses or participant factors 
for delay as it allowed me to explore into the data set as a whole, whilst not losing sight of the 
individuality of each participants’ experiences. This allowed me to make comparisons and contrasts 
between the experiences of different participants and identify possible trends regarding key factors 
that contributed to, or resulted from, the diagnostic delay. 
The original intention was to conduct the qualitative research using findings from the systematic 
review, as the values for the extent of diagnostic delay extracted from the studies included in the 
systematic review would have been used to establish the criteria for inclusion in the interviews. 
However, the scale of the systematic review meant that both research approaches were 
undertaken simultaneously. Therefore, a minimum delay of three months was influenced from the 
findings from Cantoro et al. (2017), following discussion with supervisors as opposed to being 
influenced by the review findings, which may have been a misrepresentation of diagnostic delay as 
the systematic review findings demonstrated median delays ranging from two months to one or 
two years depending on the diagnosis. This meant participants with delays between 2-3 months 
were not included in the qualitative study; therefore, the qualitative sample may be less 
representative of delay presented within the systematic review studies. 
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In addition, the use of convenience sampling risks a poor spread of participant characteristics, 
including age, gender and IBD phenotype as there is no means of controlling their characteristics. 
This is apparent from the larger proportion of participants with CD who were interviewed, though 
from the findings of the systematic review, diagnostic delay of CD is more problematic that delays 
in UC diagnosis therefore exploring diagnostic delay of CD within these interviews was beneficial. 
However, the participants interviewed demonstrated variation in age, length of diagnostic delay 
and occupation (Table 5.1.1). It is worth highlighting that whilst patients with a range of diagnostic 
delay were recruited, convenience sampling may have led to the inclusion of participants with 
more protracted diagnostic delays, as they may have dissatisfaction at their diagnostic journey and 
want to involve themselves in research. In spite of this, the focus of the qualitative research was to 
establish reasons for and consequences of diagnostic delay as opposed to providing the extent of 
delay.  
Similarly, the recruitment methods used may have led to the exclusion of certain groups from 
partaking in the study, as they may not use social media. There has always been an assumption 
that older people may not use social media and a systematic review assessing the use of social 
media for recruiting research participants found an over-representation of participants of white 
ethnicity as well as young adults and those with a higher degree of education (Whitaker, Stevelink, 
& Fear, 2017). Unfortunately, details of ethnicity, geographical location or education were not 
obtained from participants interviewed in the research within this thesis. However, from my 
experience of social media recruitment, it was not a barrier to recruiting people of older ages (i.e. 
over 60 years old), and recruiting from the C&CUK meeting that that it was also possible to invite 
eligible individuals who I may not have been able to access through social media. 
A final shortcoming of this qualitative research is the absence of a second coder. The role of this 
second coder is to analyse the transcripts themselves and to discuss their interpretations of the 
data with the first coder, which deepens the understanding of the data by offering a different 
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perspective (Berends & Johnston, 2005). Due to the absence of a second reviewer, it was not 
possible to obtain different insights and interpretations of data. 
 
 Chapter summary 
This chapter outlines the findings from the interviews conducted with the sixteen participants 
recruited. The following chapter provides an overall discussion of the thesis, where the results from 
the systematic review are compared with the qualitative findings, which is typical of the 
convergent mixed method design used within the thesis. 
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6 Discussion 
This final chapter reflects on the issue of diagnostic delay in Inflammatory Bowel Disease (IBD) with 
regard to the systematic review and qualitative study, as well as reflecting on the research process 
and exploring the implications of this research on future research and clinical practice. 
 
 Summary of findings 
The aim of this research was to establish the extent of diagnostic delay of IBD together with 
possible reasons why it occurs and subsequent impacts that this delayed diagnosis may have on 
both the disease course and the patient. This was achieved by undertaking a systematic review of 
published literature which reported the extent to which IBD diagnosis can be delayed and by 
conducting semi-structured interviews with individuals who have experienced a delay in diagnosis 
of IBD. 
The findings of the systematic review demonstrate that diagnostic delay of IBD has, and continues 
to, impact negatively on patients. Whilst there has been little improvement reducing the time delay 
in receiving a diagnosis of Crohn’s Disease (CD) over time, it would appear that diagnosis of 
Ulcerative Colitis (UC) is becoming more prompt. The extent of delayed diagnosis of IBD is 
unrelated to geographical region, but greatest delays in receiving a diagnosis of CD occur due to 
factors within the healthcare systems as opposed to patients’ failure to present. 
Diagnostic delay upon entering the healthcare system may be related to key misdiagnoses 
described by participants in their interviews, such as Irritable Bowel Syndrome (IBS), mental health 
issues and haemorrhoids. Participants cited systemic failures, incorrect interpretation of symptoms 
and poor proactivity of GPs as common healthcare factors for delay. Issues surrounding perceived 
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insignificance of symptoms, embarrassment and fear were perceived to contribute to participant to 
delay. 
 
 Diagnostic delay at a population and individual level 
Combining the findings from the systematic review and qualitative research, as part of a 
convergent mixed method design, demonstrates the issue of a delayed diagnosis of IBD. They both 
highlight how diagnostic delay has been an issue over time, as the systematic review papers were 
published between 1971 and 2019 and some participants that were interviewed received their 
diagnosis between two and fifty-two years ago. In the systematic review, the diagnostic delay of CD 
was generally longer than the delay in UC diagnosis. This was mirrored in the qualitative research, 
as the median reported delay for UC diagnosis was 2 years and was 8 years for CD. A possible 
explanation of this could be the complex and varied presentation of CD, particularly as it can affect 
any part of the GI tract and so a variety of symptoms may occur meaning there can be many 
differential diagnoses (Aghazadeh et al., 2004). In contrast, UC often presents with rectal bleeding, 
an alarming symptom which may cause individuals to seek medical advice more quickly (Novacek 
et al., 2019) 
There are similarities in the findings of both research approaches. For instance, data on 
consultation and healthcare delays was present in six articles sourced in the review. The general 
conclusion from these was that though delay did occur due to actions of patients, the majority of 
delays occurred when the patient entered the healthcare system and could be linked to the 
attitude or decisions of the healthcare professional, commonly a GP. This was explored in the 
interviews, with participants providing a variety of opinions on how they influenced their delay. 
Some participants felt that their symptoms were only minor and thus did not need to see their GP. 
Others described trying to manage with their symptoms until they worsened. Worry and fear of the 
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underlying cause also dissuaded some participants from seeking help sooner. For participants who 
did not have a family history of IBD, they were largely unaware of the condition. In other medical 
conditions, patient education of certain disease has been improved with campaigns to raise 
awareness. Examples include the Headsmart campaign, which informs people of the symptoms of 
brain cancer in children through the distribution of patient information leaflets; and the act FAST 
campaign for identifying strokes which has been a national advertisement campaign on televisions 
and posters (Headsmart, The Brain Tumour Charity; Stroke.org). Many participants felt that their 
GP contributed to their delayed diagnosis through failing to arrange tests and referrals- even when 
participants were repeatedly presenting to them with their concerns. Other delays were caused by 
long waiting lists for appointments and cancelled procedures. Action has been taken to improve 
healthcare professionals’ awareness of medical conditions. For instance Crohn’s and Colits UK 
(C&CUK) have been working with the Royal College of General Practitioners on a project called IBD 
spotlight, in order to improve primary care diagnosis and support people with IBD by providing 
clinicians with information to determine whether a patient has IBD or not. Headsmart also provides 
information for clinicians for when to reassure or refer a child with worrying symptoms.  
One paper included in the systematic review explored the possible effect of a diagnosis of IBS on 
the delay in diagnosis of IBD. This study by Burgmann et al. (2006) found that a diagnosis of IBS, 
either a real diagnosis preceding IBD or a misdiagnosis, was linked to longer IBD delays. 
Misdiagnoses of IBS was a pertinent finding from interviews with eight participants. In addition, 
this misdiagnosis was cited as a healthcare factor for delay when participants felt that they were 
not further investigated despite the management for IBS being ineffective.  
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 Clinical implications 
A central finding from this body of research, from both the systematic review and qualitative 
research, is that there are significant diagnostic delays in IBD. For instance, a number of 
participants from the interviews were diagnosed with IBS for a long period of time before 
eventually being diagnosed with IBD. These delays likely occur at the level of primary care and care 
needs to be afforded to educating GPs around IBD but particularly around screening tests such as 
faecal calprotectin. Many participants described persistently asking their GP for a referral to 
secondary care services which did not happen, therefore GPs should be quicker to refer patients 
whose symptoms are challenging to manage as this could indicate an incorrect diagnosis. 
Moreover, GPs should also obtain a family history of medical conditions and, when a family history 
of IBD is present, seriously consider this diagnosis in patients presenting with chronic symptoms 
suggestive of IBD. As described above, many campaigns to raise awareness of conditions have been 
successful, and as this research highlights the issue of diagnostic delay in IBD, similar strategies 
could be used to improve awareness of IBD amongst healthcare professionals and the general 
public.  
The main issues surrounding secondary care delays were largely the long waiting times for 
appointments. This is surprising considering that NICE guidelines state that all patients with 
suspected IBD should have an appointment with a specialist within four weeks (NICE 2015). This 
timeframe has been reiterated by the 2019 IBD Standards, although patients should be seen 
sooner if clinically necessary. The 2019 IBD Standards are a list of items that represent high quality 
IBD care, including pre-diagnosis, flare management, surgical and inpatient care, which has been 
devised by healthcare professionals. In addition to the four week referral timeframe, they state 
that patients should be informed about diagnostic pathways and the timescale by which 
investigations will be completed (Kapasi et al., 2019). However, in the qualitative research many 
participants described waiting up to six months for an appointment, which highlights failures in the 
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NHS to comply with this guidance and failures in primary care where GPs did not seem to recognise 
that symptoms could possibly be caused by IBD. As such, increased awareness of the four week 
referral pathway is needed, as well as increased capacity within outpatient appointments so that 
more patients can be seen. In practice, increasing capacity with the same number of 
gastroenterologists is challenging, particularly as they diagnose and manage a range of different 
conditions. There has been minimal research recently conducted into improving referral systems 
for gastroenterological pathology. In a previous study has been conducted by Jiwa et al. in which an 
electronic pro forma was piloted and educational sessions were provided by a colorectal surgeon 
to guide primary care as to which patients required urgent referral, which proved unsuccessful and 
it threatened the established practice and protocols in primary care (Jiwa et al., 2006). This study 
demonstrates that adapting referral guidelines can be challenging to implement, however it may 
improve patient times to diagnosis and therefore further research efforts should be made to refine 
referrals for urgent GI pathology. IBD Standards acknowledges that certain NHS services may not 
meet their statements, though argue that improvements to service quality can be made as a result 
of implementing the Standards and consequently enhance patient care (Kapasi et al., 2019). 
However, applying the suggestions in the 2019 IBD Standards to clinical would improve diagnostic 
delays in patients with suspected IBD. 
The diagnosis of IBD was particularly problematic in both younger participants from the interviews, 
where delays ranged from 2 years to 26 years in participants aged under 16 years old at symptom 
onset. As paediatric patients were excluded from the systematic review, no comment can be made 
comparing age and diagnostic delay within the systematic reviews, though older people 
experienced prolonged diagnostic delays than their younger adult counterparts. There is literature 
which suggests that the diagnosis of paediatric IBD is more challenging at a younger age, leading to 
longer delays  (Nambu, Hagiwara, Kubota, & Kagimoto, 2016; Sawczenko & Sandhu, 2003; Timmer 
et al., 2011). Consequently, clinicians should consider a diagnosis of IBD in adolescents and the 
elderly. As described above, the minimum wait of four weeks for individuals may have reduced 
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diagnostic delays for some of these participants so improving awareness of this referral guidance 
should be increased. This would benefit the younger population in particular, as older patients with 
GI symptoms are more likely to be referred under the two week wait rule  (K. Patel, Doulias, Hoad, 
Lee, & Alberts, 2016). Previous research has identified that the peak onset of CD is between 20 to 
30 years old, and 30 to 40 years old for UC (Cosnes, Gower-Rousseau, Seksik, & Cortot, 2011), so a 
referral pathway for IBD is highly likely to benefit this age group, who do not fulfil the criteria for 
referral under the two week wait rule. 
 
 Avenues for further research 
The systematic review conducted in this thesis demonstrates that diagnostic delay of IBD is an 
important issue amongst adults, however this has not been explored in the paediatric population 
as these papers were excluded from the review. An important next step from this research is to 
conduct a systematic review exploring diagnostic delays in paediatric IBD. Age may contribute to 
diagnostic delay, as evidenced by the findings of this systematic review, so comparing delays in 
paediatric IBD with age of symptom onset and diagnosis may provide insight into ages more at risk 
of diagnostic delay. In addition, late adolescent years (i.e. 16 to 18 years old) can be problematic in 
healthcare when patients fall between paediatric and adult services, so exploring the impact of age 
on diagnostic delay could be achieved by subgroup analyses based on age. 
Further research into the impact of faecal calprotectin on diagnostic delay should be undertaken, 
as this investigation was not referred to in papers within the systematic review. This was because 
most of the research was conducted before the introduction of this investigation. Current research 
demonstrates that it is an effective tool to differentiate IBD from IBS, therefore it would be 
expected that an abnormal faecal calprotectin level would reduce delays (Banerjee et al., 2015). 
Undertaking research that identified a reduction in diagnostic delay following the use of faecal 
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calprotectin would strengthen the use of this test in clinical practice. This could be achieved by 
conducting a randomised control trial in which ‘usual care’, involving the absence of faecal 
calprotectin testing depending on familiarity and use of the test, is compared with strict 
implementation of the guidelines. 
Further to the novel qualitative research included within this study, factors which may increase an 
individual’s risk of a delay in diagnosis of IBD should be identified, as this can educate clinicians 
about certain factors to observe in patients which may indicate IBD. It would be beneficial to 
explore patient and healthcare factors for delay, as conducted in this thesis, in a larger population 
to look at sub-categories of reasons for delay. Reducing recall bias could be achieved by recruiting 
individuals at the point of diagnosis. Stratifying patients based on their IBD phenotype and the 
extent of diagnostic delay they experienced may identify different risk factors that contribute to 
varying degrees of delay. Purposive sampling to recruit participants from different ethnic 
backgrounds may identify additional risk factors that contribute to diagnostic delay and can ensure 
future reductions in time to diagnosis. The qualitative research within this thesis involved patient 
participants, so interviews with healthcare professionals such as GPs and gastroenterologists, for 
example, could be conducted to explore their perceptions of delays in IBD diagnosis. Combining 
these findings with the results from the patient interviews would provide a comprehensive 
overview of factors contributing to delay as well as possible consequences.  
The findings of this systematic review provide information of the extent of diagnostic delay, 
however further studies analysing clinical outcomes based on diagnostic delay could be performed. 
Various studies have already completed similar research, but a larger cohort and longer follow-up 
could demonstrate links between delayed diagnosis and worse clinical outcomes. 
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 Conclusions  
Diagnostic delay of IBD is an important issue faced by individuals worldwide. The extent of delay is 
unacceptably protracted, with patients experiencing symptoms for many months or even (in the 
most serious incidents) years without investigation or explanation. Failure of healthcare 
professionals to recognise symptoms as well as poor patient education of IBD are likely 
contributing factors. There is a propensity for clinicians to attribute symptoms of IBD to more 
prevalent conditions such as IBS and gastroenteritis, delaying both the diagnosis and treatment of 
IBD. Consequently, some individuals may experience complications of the disease such as fibrosis 
and bowel obstruction, requiring strong immunosuppressive medication or surgical intervention. 
This could be reduced if the diagnosis is established promptly. As such, improving patient and 
healthcare knowledge of IBD is important, especially in the use of the faecal calprotectin test as a 
diagnostic tool in primary care. Reducing the interval between referral and specialist appointments 
would also be an important step. 
 
 Personal reflections  
I was enthusiastic to complete an MPhil qualification in my intercalated year as I have learned 
much about medical research during previous academic years and I wanted the chance to conduct 
research of my own. My interest in gastroenterology has developed during my university studies, 
particularly in a complex disease like IBD where diagnosis and management can be challenging. 
Completing research in the diagnostic delay of IBD has been rewarding and I hope that further 
research into this important aspect of the IBD patients’ disease course is undertaken. I particularly 
enjoyed the opportunity to conduct mixed methods research as the results from both the 
systematic review and qualitative research demonstrate that diagnostic delay in IBD is an issue, 
therefore I feel I have contributed to an under-investigated area of research.  
 157 
 
Firstly, I will discuss my experiences of doing the systematic review. I have learned many new skills 
that will benefit my future career in clinical medicine, including devising a search strategy and 
appraising articles. My most challenging experience of completing this systematic review was 
managing the large volume of references and sourcing the full texts to articles, particularly as there 
were many conference abstracts. I found the review process most enjoyable, especially when I 
began to identify papers relevant to my research question. Collating the data to conduct the 
narrative synthesis was also a rewarding aspect of the process.  
Regarding the qualitative research, I enjoyed collecting data through interviewing, as each 
participant provided valuable insights into their delayed diagnosis. I believe I have captured the key 
issues discussed and presented them appropriately within each theme. As a future healthcare 
professional, I found their accounts of primary and systemic factors for delay sometimes saddening 
to hear, particularly when they felt their GPs were not listening to them. I hope that research in this 
field is published to ensure improved identification of IBD by both healthcare professionals and the 
lay population. The main challenge I faced was applying thematic analysis to my data, as I had no 
experience of analysing qualitative data before. For example, I found it difficult to aggregate codes 
together to create a theme, as initially there was extensive overlap between themes. However, 
with further refinement, I devised the three distinct themes that are discussed in detail within 
Chapter 5. 
This thesis has been a rewarding challenge and I sincerely hope that the subsequent publication of 
this work demonstrates to healthcare professionals and researchers alike that delays in IBD 
diagnosis are a significant problem, paving the way for future research that will reduce delays and 
uncertainty amongst individuals with IBD. 
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Arthritis Research UK Primary Care Centre 
Systematic Review Protocol & Support 
Template 
 
This template is primarily intended to help you plan your review in a systematic 
way. A copy of this completed form will be available via the intranet to help others 
carrying out reviews in the future and to avoid duplicating work already undertaken 
in the Centre. Keeping a record of all the reviews will also assist in planning the 
work of the Centre and ensuring adequate methodological support. Not all the 
information will be relevant to every review and items should be adapted to fit the 
type of review that is being undertaken.  
The template has been updated to include all the items from the PRISMA-P 
checklist (http://www.prisma-statement.org/Extensions/Protocols.aspx). All 
systematic reviews should be registered with PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/) unless the review is methodological. 
 
Please complete the form in as much detail as possible for your review and 
email to Opeyemi Babatunde, o.babatunde@keele.ac.uk  
 
7 Title of the 
review 
Diagnostic Delay of Inflammatory Bowel Disease: A 
Systematic Review and Meta-Analysis 
First reviewer Eleanor Cross 
Other reviewers (with 
role/contribution in 
the review) 
James Prior (2nd reviewer and co-author), Benjamin 
Sunders (2nd reviewer and co-author), Adam Farmer (co-
author) 
Clinical Portfolio 
Group 
N/A 
Funding source Conducted by funded student 
PROSPERO 
registration number 
CRD42018108886 
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Amendments to the 
protocol 
To be completed 
  
1. Background to review   
 Brief introduction to the subject of the review, including rationale for 
undertaking the review and overall aim 
 
Inflammatory Bowel Disease (IBD) includes both Crohn’s Disease and Ulcerative 
Colitis, which are chronic conditions with a relapsing-remitting clinical course. 
Abnormal immune responses in the digestive tract is the suspected pathology of 
IBD. Crohn’s disease can cause inflammation of any part of the digestive tract 
and symptoms include diarrhoea, weight loss, oral ulcers and perianal lesions. 
Ulcerative Colitis only affects the large bowel with the main symptoms being 
diarrhoea, abdominal pain and episodes of rectal bleeding. Though IBD can 
affect all ages, adolescents and young adults are most commonly affected and 
the condition has a drastic impact on the patient’s life. 
 
In order to alleviate symptoms and manage flares, quick diagnosis and prompt 
management is vital. Diagnosis is commonly confirmed by the histological 
analysis of colonoscopic biopsy. The aim of treatment is to reduce the aberrant 
immune responses in the digestive tract with steroids and other 
immunosuppressants. Surgery may be indicated in severe or stricturing disease. 
 
This systematic review and qualitative research aims to examine the extent of 
delay between the onset of IBD symptoms experienced by patients and the final 
IBD diagnosis and examine characteristics related to the extent of delay. By 
aiming to determine when IBD diagnosis typically occurs, we can hopefully justify 
the need to improve the efficiency of the pathway of IBD diagnosis and thus 
management. 
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2. Specific objectives/questions the review will address 
 
1. To explore the extent of diagnostic delay from IBD symptom onset to final 
IBD diagnosis 
2. To examine whether the extent of diagnostic delay for IBD is associated 
with specific characteristics  
 
3. a) Eligibility Criteria for including studies in the review  
If the PICOS format does not fit the research question of interest, please split up the 
question into separate concepts and put one under each heading 
i. Population, or participants 
and conditions of interest 
Adult patients with a diagnosis of 
Inflammatory Bowel Disease 
ii. Interventions/Exposure/item 
of interest 
Clinician diagnosis of Inflammatory Bowel 
Disease 
iii. Comparisons or control 
groups, if any 
N/A 
iv. Outcomes of interest 
 
Time-period of diagnostic delay, with 
information about the impact of a 
diagnostic delay on the patient’s clinical 
outcomes if such data is found from the 
search 
v. Setting Primary, secondary and tertiary care 
vi. Study designs 
All studies, including qualitative studies 
and literature reviews 
 
3. b) Criteria for excluding studies not covered in inclusion criteria  
Exclusion criteria: Systematic reviews, conference abstracts, papers that are 
unavailable in English/unable to be translated. Papers where similar conditions 
to IBD are mentioned will be included if there Is specific mention to IBD in the 
title/abstract 
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4. Search methods 
Electronic databases 
& websites 
 
Please list all 
databases that are to 
be searched and 
include the interface 
(eg NHS HDAS, 
EBSCO, OVID etc) and 
date ranges searched 
for each. 
 
NB All search 
strategies should be 
reviewed by Jo 
Jordan or Nadia Corp 
BEFORE searching 
begins 
Embase (Ovid), Medline (Ovid), CINAHL (HDAS). Search 
will not be limited by date ranges. 
Other methods 
used for identifying 
relevant research  
ie contacting experts 
and reference 
checking, citation 
tracking 
 Reference checking 
 
Journals hand 
searched 
If any are to be hand 
searched, please list 
which journals and 
date searched from, 
including a rationale.  
N/A 
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5. Methods of review 
How will search 
results be managed 
& documented? 
ie which reference 
management software, 
how duplicates dealt 
with 
Results will be exported to Mendeley. Mendeley will be 
used to exclude duplicates, close duplicates will be 
assessed further by eye. From here, any identified 
duplicates will be deleted. 
Selection process 
Number of reviewers, how 
agreements to be reached 
and disagreements dealt 
with, etc. 
Using the selection criteria, the first reviewer (EC) will 
review papers by title, removing any duplicates and 
irrelevant articles. Then, the first & second reviewer (JP) 
will screen the remaining articles by their abstract. 
 
From the identified papers, the two reviewers (EC & JP) 
will independently select papers for inclusion based on 
the title and abstract content. EC, JP, AF, BS will 
independently include based on full-text. EC and JP will 
extract the relevant information from the studies to be 
included in the systematic review. Where an agreement 
needs to be made on study inclusion or exclusion, 
reviewers 1 and 2 will discuss to decide on final inclusion 
and exclusion. 
 
Quality assessment 
Tools or checklists used 
with references or URLs, 
was this piloted? Is it to 
be carried out at same 
time as data extraction? 
Select questions from the Newcastle-Ottawa tool will be 
used as a quality assessment tool. 
How is data to be 
extracted? 
What information is to 
be collected on each 
included study? If 
databases or forms on 
Word or Excel are used, 
were these piloted and 
how is this recorded and 
by how many reviewers? 
 
 Any reported time-period of diagnostic delay 
 Method of IBD diagnosis used in the study 
 Year of study 
 Demographic characteristics (eg- age and gender)  
 Sample size 
 Time period in which participants were recruited 
 Study setting (primary care, general population, secondary 
care) 
 How “delay” was quantified (i.e. delay in diagnosis was 
classed as the period of time between initial symptoms and 
final diagnosis, delay in treatment was classed as the period 
of time between initial symptoms and initial treatment etc) 
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Outcomes to be 
extracted & 
hierarchy/priority of 
measures 
ie which measure is 
preferred and if that is 
not available which is 
next in order of 
preference? 
 
 Mean/median time period of delay in IBD diagnosis and 
related estimate range (i.e. SD, 95% CI, IQR) 
Narrative synthesis 
Details of what methods, 
how synthesis will be done 
and by whom. Is the 
Narrative Synthesis 
Framework to be used? 
 
An overview of the content of each article (study type, 
participants etc) and the diagnostic delays reported, 
including reasons for the delays and, where applicable, 
the impact on the participant. 
Meta-analysis  
Details of what and how 
analysis and testing will 
be done. If no meta-
analysis is to be 
conducted, please give 
reason. 
In the instance that sufficient papers are sourced from the 
systematic review, a random effects model will be used in 
meta-analysis. 
 
If different methods of noting diagnostic delay after 
symptom onset are used, separate meta-analyses will be 
used. 
Will the overall 
strength of evidence 
be assessed? If so, 
how?  
ie GRADE? 
N/A 
 
6. Presentation of results 
Outputs from review  
Papers and target 
journals, conference 
presentations, reports, 
etc 
Paper 
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 7. Timeline for review – when do you aim to complete each stage of the 
review 
Protocol  
 August - September 
Literature searching 
 September - October 
Quality appraisal 
 November 
Data extraction 
 November 
Synthesis 
 November - December 
Writing up 
 December - January 
 
 Support – please state if advice/training or personnel required at each 
stage 
SR overview 
 N/A 
Protocol 
development 
 Advice 
Literature searching 
 Advice 
Quality appraisal 
 N/A 
Data Extraction 
 N/A 
Synthesis 
 Advice (Statistical) 
Writing up 
 N/A 
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Please send your completed protocol to Opeyemi (see email below) as we would 
like to put examples on the Intranet.  
 
The systematic review team are available to answer any queries or give advice on 
completing your review. Systematic review workshops are run at least once a year, 
or can be arranged on an ad hoc basis if needed by a group. Presentations from 
previous workshops can be found on the Centre’s Intranet. 
 
Opeyemi Babatunde – o.babatunde@keele.ac.uk  
Jo Jordan – j.jordan@cphc.keele.ac.uk 
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Appendix 2- Search strategy used to source articles for the review 
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Exp inflammatory bowel diseases/ 
inflammatory bowel disease*.ti,ab,kw. 
inflammatory bowel disorder*.ti,ab,kw. 
ibd.ti,ab,kw. 
crohn*.ti,ab. 
ulcerative colitis*.ti,ab,kw. 
inflam* colitis*.ti,ab,kw. 
colitis/ or colitis, ulcerative/ 
 
diagnos* adj3 delay*.ti,ab,kw. 
diagnos* adj3 lag*.ti,ab,kw. 
diagnos* adj3 interval*.ti,ab,kw. 
((late* or earl*) adj3 diagnos*).ti,ab,kw. 
(health* adj3 seek*).ti,ab,kw. 
(case* adj3 seek*).ti,ab,kw. 
(case adj3 find*).ti,ab,kw. 
(delay* adj3 consult*).ti,ab,kw. 
(delay* adj3 detect*).ti,ab,kw. 
(delay* adj3 interval*).ti,ab,kw. 
(delay* adj3 refer*).ti,ab,kw. 
(delay* adj3 treat*).ti,ab,kw. 
Delayed diagnosis/ 
Early diagnosis/ 
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Appendix 3- Example table used in the data extraction of included articles 
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Appendix 4- Newcastle-Ottawa Scale used to appraise the included cohort studies   
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Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community* 
b) somewhat representative of the average ______________ in the community ¯ 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort* 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort 
 
3) Ascertainment of exposure 
a) secure record (e.g, surgical records)* 
b) structured interview* 
c) written self report 
d) no description 
 
4) Demonstration that outcome of interest was not present at start of study 
a) yes 
b) no 
 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) * 
b) study controls for any additional factor* (This criteria could be modified to indicate 
specific control for a second important factor.) 
 
Outcome 
1) Assessment of outcome 
a) independent blind assessment* 
b) record linkage* 
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c) self report 
d) no description 
 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) * 
b) no 
 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for* 
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % 
(select 
an adequate %) follow up, or description provided of those lost) * 
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
 
  
 206 
 
 
  
 207 
 
Appendix 5- Newcastle-Ottawa Scale used to appraise the included cross-sectional studies 
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Selection 
1) Representativeness of the sample: 
a) Truly representative of the average in the target population. * (all subjects or 
random sampling) 
b) Somewhat representative of the average in the target population. * (nonrandom 
sampling) 
c) Selected group of users. 
d) No description of the sampling strategy. 
 
2) Sample size: 
a) Justified and satisfactory. * 
b) Not justified. 
 
3) Non-respondents: 
a) Comparability between respondents and non-respondents characteristics is 
established, and the response rate is satisfactory. * 
b) The response rate is unsatisfactory, or the comparability between respondents 
and non-respondents is unsatisfactory. 
c) No description of the response rate or the characteristics of the responders and 
the non-responders. 
 
4) Ascertainment of the exposure (risk factor): 
a) Validated measurement tool. ** 
b) Non-validated measurement tool, but the tool is available or described.* 
c) No description of the measurement tool. 
 
Comparability 
1) The subjects in different outcome groups are comparable, based on the study design 
or analysis. Confounding factors are controlled. 
a) The study controls for the most important factor (select one). * 
b) The study control for any additional factor. * 
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Outcome 
1) Assessment of the outcome: 
a) Independent blind assessment. ** 
b) Record linkage. ** 
c) Self report. * 
d) No description. 
 
2) Statistical test: 
a) The statistical test used to analyze the data is clearly described and 
appropriate, and the measurement of the association is presented, including 
confidence intervals and the probability level (p value). * 
b) The statistical test is not appropriate, not described or incomplete. 
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Appendix 6- Poster used to advertise the qualitative study on social media 
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Appendix 7- Cover letter sent to all individuals who expressed an interest in participating in 
the study 
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Thank you for already showing an interest in taking part in a new study being undertaken by 
researchers at the Research Institute for Primary Care and Health Sciences at Keele 
University.   
 
We are trying to find out more about Inflammatory Bowel Disease (IBD), specifically why it 
can sometimes take a long time for patients to get a final diagnosis. We’d like to understand 
this problem better by interviewing you over the phone to discuss your experiences. Please 
see the enclosed Participant Information Sheet (version 5, dated 20/11/18) for further 
information regarding the research project and what it will involve you doing if you take part. 
 
We hope that you will be able to spare some time for a telephone interview with our 
researcher, it should take approximately 30 minutes. The interview will be recorded, but all 
of your answers will be dealt with in the strictest confidence.  We can also assure you 
that the answers you give, will not in any way, affect the health care you receive. 
 
If you would still like to take part, we would be very grateful if you would fill in the enclosed 
consent form and sign it at the bottom (either by written signature, electronic signature or 
typing your name in full) . Please then return this to us either by email or using the pre-paid 
envelope provided as soon as you can.  You do not need a stamp.  Once we have 
received this our Research Assistant at Keele University, Eleanor Cross will phone you to 
arrange a convenient time for your telephone interview. However, if you would like to know 
more about this study, please contact, Eleanor on 01782 734847 or email 
ibdresearchkeele@gmail.com 
 
Yours sincerely, 
 
Dr James Prior 
Research Fellow 
Research Institute for Primary Care and Health Sciences 
Keele University 
Staffordshire, ST5 5BG 
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Appendix 8- Participant information letter sent to all individuals who expressed an interest 
in participating in the study 
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PARTICIPANT INFORMATION SHEET 
 
 
Diagnostic Delay in Inflammatory Bowel Disease  
 
 
You are being invited to take part in a research study. Before you decide whether to take part 
or not, it is important for you to understand why the research is being done and what it will 
involve. Please take the time to read the following information carefully. 
 
 
What is the purpose of the study? 
Inflammatory Bowel Disease (IBD) is a condition that can cause pain, cramps, swelling of 
the gut, bloody diarrhoea and tiredness. Patients with IBD can be well for long periods, but 
flares can come back. A delay in receiving a diagnosis of IBD can result in delayed treatment, 
worse symptoms and future complications. Keele University is carrying out a new research 
study to understand the reasons why the diagnosis of IBD can be delayed. We hope that 
understanding this problem better will allow us to reduce the amount of delay experienced 
by patients.  
 
 
Why have I been invited? 
You have been invited to take part because you have been identified as someone who has 
had a diagnosis of IBD in the past. 
 
 
Do I have to take part? 
No. Whether or not you take part in this research is up to you. If you do decide to take part, 
you are free to withdraw within a month of entering the study without giving a reason. A 
decision to withdraw, or a decision not to take part, will not affect your right to access health 
services at your general practice or elsewhere. 
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What happens if I decide to take part? 
Agreeing to be in this study means that you will be asked to take part in a one-off 
telephone interview. During this interview, the researcher will ask you questions 
about your personal experience of the time between when your IBD symptoms 
started and finally receiving your IBD diagnosis, and how this final diagnosis was 
reached. The interview will last approximately 30 minutes. We just want to hear about 
your experiences, so there are no right or wrong answers. You do not need to do 
anything to prepare for the interview.  
 
The interview will be sound-recorded. Following the interview, sound recordings will 
be sent for transcription, meaning the recording will be typed out to make a paper 
copy of the interview - called a transcript. Recordings will be sent via a secure upload 
system to Keele Clinical Trials Unit’s supplier with whom there is a contract in place 
around confidentiality and security. The written copy will be returned encrypted, 
uploaded to the appropriate storage and deleted from email. All of this will be 
explained to you again at the beginning of the interview, and you will be asked to 
sign a consent form. 
 
 
What are the possible benefits of taking part? 
There will be no immediate benefits to you; however, we hope that the insight we 
gain from this research will lead to improvements in patient care, and hence help 
patients in the future. 
 
 
What are the possible risks of taking part? 
On the basis that the study involves participating in a telephone interview regarding 
your medical experiences, we do not anticipate any risks to you. Some of the 
questions asked regarding IBD may, however, invoke painful or distressing 
memories. If this is the case, the interview can be paused or stopped indefinitely. 
Please seek advice and support from your GP, NHS 111 or the Crohn’s and Colitis 
UK charity (www.crohnsandcolitis.org.uk) if you feel distressed after the interview 
has occurred, or contact ourselves if you are unsure which services to use and we 
can be of help. 
 
 
Will my taking part in this study be kept confidential? 
Yes, the answers you give in the interview will be dealt with in strictest 
confidence. Each person who is interviewed will be given a study number, so the 
data from the study will not have any identifiable information, such as names and 
addresses, and cannot be traced back to you. Handling of data will be totally 
compliant with General Data Protection Regulation (GDPR). You can find out how 
we use your information at 
https://www.keele.ac.uk/informationgovernance/informationgov
ernanceforthepublic/ 
 
The paper transcript from the interview will be anonymised, which means it will not 
contain any information that would identify you. If you mention the names of people 
or places, these will be removed from the paper transcript. This anonymised 
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information will be kept and may be used in other research studies, but researchers 
who work with this data will not have access to your personal information. Quotations 
from your transcript may be used in reports, but it will not be possible for people to 
identify you.  
 
 
How long will the answers to the study interview be stored for? 
Your identifiable contact details will be stored in a secure place only until the end of 
the study. Members of staff from regulatory departments may require access to your 
records to check that the research has been carried out to a high standard. Therefore, 
anonymised interview content will be stored securely until 5 years after the end of the 
research. After this time the transcripts will be destroyed. All identifiable personal 
information such as your name and address will be destroyed at the end of the study 
period. This will ensure that personal data will not be stored for longer than is 
necessary (General Data Protection Regulation 2018). 
 
 
What will happen if I don’t want to carry on with this study? 
You can withdraw from this study up to a month after being interviewed by contacting 
Eleanor Cross, the Research Assistant on 01782 734847 or by email 
(ibdresearchkeele@gmail.com). Withdrawing means that we would no longer contact you 
directly, but we would still keep and use the information you have provided up to the point 
of your withdrawal.  
 
 
 
 
 
 
What will happen to the results of the research study? 
The main findings from the study will be published in medical journals and will be 
used to improve understanding of diagnostic delay in IBD, which could have future 
implications for clinical care. A summary of the overall findings can be provided to 
you upon request.  
 
 
Who is funding and organising the research? 
The research is funded and organised by the Arthritis Research UK Primary Care 
Centre, at Keele University. 
 
 
Who has reviewed the study? 
Keele University Ethical Review Panel have approved this research study (Reference 
number: MH - 180002) 
 
 
Who should I contact if I would like further information? 
If you have any questions, or would like further information about this study please contact 
Eleanor Cross, the Research Assistant on 01782 734847 or on e-mail address: 
 219 
 
ibdresearchkeele@gmail.com  If you have any general questions or concerns about 
taking part in research, you can also contact the Patient Advice and Liaison Service 
(PALS). You can ask your GP surgery, hospital or phone NHS 111 for details of your 
nearest PALS; further information about PALS is also available at the NHS Choices 
website (website 
link: http://www.nhs.uk/chq/Pages/1082.aspx?CategoryID=68&SubCategoryID=153). 
You can also make a complaint using the formal complaints procedure at your GP Surgery. 
 
 
What should I do now if I want to take part? 
Please complete the consent form accompanying this information sheet and return to 
Eleanor, either via e-mail (ibdresearchkeele@gmail.com) or by the return envelope provided  
 
Upon receipt of your consent form, Eleanor will get in touch with you to ask a few simple  
questions to check if you are eligible to take part and arrange a convenient time and date to 
conduct your telephone interview. 
 
 
 
 
Thank you for taking time to read this information sheet. 
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Appendix 9- Consent form sent to all individuals who expressed an interest in participating 
in the study 
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Keele research ethics panel reference number: MH - 180002 
Centre Number:  
Study Number: 
Participant Identification Number for this study:  
 
CONSENT FORM 
 
Title of Project: Diagnostic Delay in Inflammatory Bowel Disease 
Name of Research Assistant: Eleanor Cross 
        
1. I confirm that I have read the information sheet dated 20/11/18 (version 5) for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time up  
to a month after my interview without giving any reason, without my medical care or legal  
 rights being affected. 
 
3. I understand that anonymised information collected about me may be shared 
     with other researchers. 
 
4. I agree to take part in the above study. 
 
 
             
Name of Participant   Date    Signature 
 
 
             
Name of Person taking consent  Date    Signature 
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Appendix 10- Topic guide  
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Topic Guide: Patients 
 
Diagnostic Delay in IBD Interview Topic Guide 
 
Introduction 
a. Check that participant has read and understood the patient information sheet. 
b. Explain arrangements for: consent, recording, anonymity   
c. Check patient’s recollection of the process of receiving their diagnosis of IBD (this will have 
been asked initially when arranging the interview) 
d. Confirm with patient through which service or organisation they learned of this 
study  
Experience of period between symptom onset and diagnosis 
e. How did initial symptoms present? 
f. How did you interpret these symptoms? 
g. Age at symptom onset 
h. How long after initial symptom presentation did they contact their doctor? 
i. At consultation, how were symptoms interpreted/what management 
plans/diagnoses were made? 
j. How long after original consultation did diagnosis take? 
How was final diagnosis reached 
k. Diagnosed from original/first consultation/referral? 
l. Diagnosed after worsening, or change of symptoms? 
m. What happened at the referral appointments? 
n. What investigations occurred? 
o. What management was tried (right/wrong diagnosis made)? 
p. Did patient feel they had to struggled/found it difficult to be referred/have 
symptoms taken seriously? (if mentioned by participant) 
q. How did the patient feel before and after being diagnosed? 
r. Age at diagnosis 
Key factors of diagnostic delay 
s. Main barriers to diagnosis perceived by patient (prompt patient to consider 
their own actions as barriers and barriers they experienced from healthcare 
side, specifically their GP or when in secondary care) 
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t. Personal impact of delayed diagnosis? 
u. Does patient think symptoms/management may have been different if they’d 
received an earlier diagnosis? 
v. Impact of condition on life 
w. Further details regarding complications or narrative of diagnosis and disease 
progression 
 
Clinical course of condition since diagnosis 
a. Has condition been well-managed since diagnosis? (brief overview) 
b. How many flares has patient had- potential time interval 
c. Medical and surgical management of condition 
d. General wellbeing of patient 
 
 
Close of discussion 
a. Summary of discussion: any additional remarks?  
b. Check consent is still in place. 
c. Check if participant would like to receive a summary of the interview findings.  
d. Emotional support 
  
 226 
 
  
 227 
 
Appendix 11- Thematic maps 
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Appendix 12- Ethical approval for the qualitative research 
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